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Summary 
The DNA damage response is important for maintaining genomic integrity following 
introduction of double-strand breaks (DSB) since illegitimate or incorrect repair of a 
DSB could promote malignant transformation. Mismatch-repair (MMR) deficient 
tumour cell lines are acutely sensitive to thymidine treatment and fail to activate 
homologous recombination (HR) repair following a DSB (Mohindra et al., 2002). 
Therefore, it was hypothesised that loss of HR repair may occur as a downstream 
event in tumours already deficient in MMR. The primary aim was to determine 
whether there were somatic mutations in candidate HR genes that were associated 
with colorectal cancer development and to examine the phenotypic consequences of 
such mutations. 
Analysis of the candidate HR genes, XRCC2, XRCC3 and Mus81 in a random 
collection of primary colorectal cancers and in a specific MMR-deficient tumour 
population revealed no tumour-specific mutations. 
Analysis of the MREI J, NBSI and Rad5O genes revealed a frameshift mutation in an 
intronic TlI tract of MRE11 that gave rise to alternative splicing of the gene. This 
mutation was present in >85% of MSI+ colorectal tumours suggesting that alteration of 
MRE11 occurs at a high frequency in tumours already deficient in MMR. 
The phenotypic consequences of MRE11 dysfunction were investigated by expressing 
splice variants of MRE 11 in MMR-proficient human cells. Cells expressing an MRE 11 
variant with a compromised nuclease domain, failed to activate wild-type MRE11 
following DNA damage, were dramatically more sensitive to thymidine and failed to 
activate HR repair following thymidine treatment. 
The novel results obtained here suggest that a functional MRE 11 is essential for the 
HR repair-mediated rescue of DNA replication forks impaired by thymidine. 
Furthermore, it was speculated that a functional MRE11 may be essential to resolve the 
recombinogenic substrate specifically produced by thymidine. Given that this DNA 
damage response pathway appears to be disrupted in >85% of MSI+colorectal tumours, 
these finding have important implications for treatment strategies directed against this 
subset of tumours. 
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Introduction 
1.1 Colorectal Cancer 
The colon is divided into the cecum and the ascending, transverse, descending and 
sigmoid colon. The colon and rectum are host to more primary neoplasms than any 
other organ of the body (Cotran et al., 1999). Colorectal cancers (CRC) are usually 
adenocarcinoma and the lifetime risk to the general population is 6% (McCormick et 
al., 2002). One of the risk factors for CRC is increasing age with the peak incidence of 
CRC being 60-79 years of age and less than 20% of all cases occurring before age 50 
(Cotran et al., 1999, McCormick et al., 2002). Other risk factors include family 
history, a high fat, low fibre diet, physical inactivity and long standing inflammatory 
bowel disease (Price, 2002). 
Up to 15% of all CRCs are inherited in an autosomal dominant manner (Kinzler and 
Vogelstein, 1996). The two best defined familial forms are familial adenomatous 
polyposis (FAP) and hereditary non-polyposis colorectal cancer (HNPCC). Patients 
with FAP develop multiple benign colonic adenomas at an early age and malignant 
progression of these polyps usually occurs by age 40-50 (Lynch and de la Chapelle, 
2003). FAP is caused by truncating germ-line mutations of the adenomatous polyposis 
coli (APC) gene, located on chromosome 5q21 and penetrance of FAP approaches 
100% (Lynch and de la Chapelle, 2003). HNPCC is associated with an 80% lifetime 
risk of CRC that develops at an average age of 45 years (Aaltonen et al., 1998). The 
majority of cancers in HNPCC develop on the right-side of the colon, are poorly 
differentiated, mucinous and primarily show a diploid karyotype (Cotran et al., 1999, 
Chung, 2000, Burt, 2000). HNPCC accounts for only 1-3% of all colorectal cancers 
and is also commonly associated with endometrial, gastric and ovarian cancers (Burt, 
2000, Chung and Rustgi, 2003). 
CRC can remain asymptomatic for years and diagnosis then only occurs at late stage 
where prognosis is grave. When the disease is diagnosed at an early stage the 5-year 
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survival rate is estimated to be >90% whereas CRC diagnosed at late stages when 
metastases are present has a 5-year survival rate of only 7-9% (Burt, 2000, 
McCormick et al., 2002). For this reason it is important to identify new tumour 
markers for the molecular staging and therapy of colorectal cancer. 
The accumulation of multiple mutations is necessary for colorectal cancer 
development and it was proposed that each mutation drives the malignant process 
(Vogelstein and Kinzler, 1993). However, the mutation rate in normal human cells, 
even after exposure to carcinogens, may not be sufficient to account for these multiple 
alterations. It was therefore proposed that an early step in tumour progression is one 
that induces a "mutator" phenotype (Loeb, 1991). Mechanisms that maintain genomic 
integrity, such as high fidelity DNA replication and various processes that recognise 
and repair DNA damage or eliminate damaged cells, are highly conserved in normal 
cells (Coleman and Tsongalis, 1999). A mutator phenotype could be caused by loss of 
one or more of these mechanisms that preserve genomic integrity. Evidence to support 
this hypothesis arose from studies of HNPCC where the underlying molecular defect 
was defined as a mismatch-repair (MMR) deficiency (Kinzler and Vogelstein, 1996). 
1.2 Mismatch Repair (MMR) 
Studies of the bacterial and yeast mismatch repair genes provided clues as to how the 
analogous human MMR system functions (Miller, 1998, Kolodner, 1995, Fishel and 
Kolodner, 1995). The human MMR proteins involved in mitotic processes include 
hMLHI, hMSH2, hMSH3, hMSH6, hPMSI and hPMS2. These MMR proteins 
function to repair post-replicative DNA damage and to inhibit recombination between 
divergent sequences (Toft and Arends, 1998). 
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hMSH2, in a heterodimeric complex with either hMSH6 or hMSH3, recognises and 
binds directly to mismatched DNA (Acharya et al., 1996). The hMSH2-hMSH6 
complex binds base-pair mismatches and small insertion/deletion loops created by 
primer-template slippage whereas hMSH2-hMSH3 binds only these insertion/deletion 
loops in the DNA (Raschle et al., 1999). The redundancy between hMSH3 and 
hMSH6 is reflected in yeast studies where msh3 and msh6 must both be mutated to 
demonstrate the same repair defect as an msh2 single mutant (Acharya et al., 1996). A 
second heterodimeric complex of hMLHI and hPMS2 is then thought to be recruited 
to the mismatch to coordinate the interplay between the mismatch recognition 
complex and other proteins necessary for excision of the mismatched DNA (Kolodner, 
1995, Chung and Rustgi, 2003). hMLHI can also form a complex with hMLH3 and 
hPMS 1 but the function of these heterodimers is currently unknown (Raschle et al., 
1999). 
In addition to its functions in DNA repair and recombination the MMR system may 
also have role in the DNA damage response as these proteins form part of the 
BRCA1-associated genome surveillance complex (BASC) that recognises DNA 
damage (Wang et al., 2000). 
Loss of post-replicative MMR was found to increase mutation rates 200- to 600-fold 
above normal levels and therefore induce a mutator phenotype (Bhattacharyya et al., 
1994). This mutator phenotype becomes most apparent in repetitive elements 
throughout the genome known as microsatellites. These iterative loci are normally 
relatively stable but DNA polymerase is prone to slip on these elements during 
replication. The resulting small loops in the template or nascent strand are usually 
repaired by the MMR system (Fishel and Kolodner, 1995). In MMR-deficient cells the 
loops persist and alleles of different sizes are produced in subsequent rounds of 
replication. This phenomenon is known as microsatellite instability (MSI) and is 
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defined as a change in length in a microsatellite due to the insertion or deletion of 
repeating units, within tumour DNA compared to normal DNA (Boland et al., 1998). 
The classification of tumours according to MSI status is important as it may enhance 
prognostic information since CRC prognosis is correlated with MSI (Chung and 
Rustgi, 2003) and it might also define distinct subsets of tumours that respond better 
to specific types of therapy. 
The increased genetic instability caused by loss of MMR can promote tumour 
development and mutations in the two main MMR genes, hMLHI and hMSH2, are 
present in almost 90% of HNPCC cases (Burt, 2000, Lynch and de la Chapelle, 2003). 
MMR deficiency has also been shown to be associated with sporadic colorectal, 
endometrial and gastric cancer (Liu et al., 1995, Fornasarig et al., 2000, Umar et al., 
1994, Fleisher et al., 1999). However, sporadic and hereditary MMR-deficient CRCs 
develop through different molecular pathways as the majority of sporadic MSI+ 
tumours do not have mutations in the MMR genes (Katabuchi et al., 1995, Umar et al., 
1994). Epigenetic changes primarily cause MMR-deficiency in sporadic tumours as 
over 80% of sporadic MSI+ CRC have hMLHI promoter hypermethylation which acts 
to silence the gene by decreasing transcription and ultimately reducing hMLHI 
protein expression (Leung et al., 1999, Kane et al., 1997, Chung, 2000, Veigl et al., 
1998). 
Loss of MMR alone is not sufficient for malignant transformation and is likely to be 
an early event in tumour development that is essential for the sequential mutations that 
drive the neoplastic processes (Lengauer et al., 1998). Genes that function to protect 
genomic integrity, such as the MMR genes, were collectively labelled as `caretaker 
genes' and it was proposed that mutation of such caretakers does not directly promote 
tumour initiation (Kinzler and Vogelstein, 1997). Instead, inactivation of the MMR 
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caretakers promotes microsatellite instability which means all mononucleotide runs, 
including those in coding regions, become hotspots for mutation (Jiricny, 1996, 
Baross-Francis et al., 1998, Bhattacharyya et al., 1994). 
Growth controlling genes with repetitive coding elements are known to be mutated in 
MSI+ CRC. TGFßRII has an Alo mononucleotide run that is mutated in up to 83% of 
HNPCC cases and up to 90% of sporadic MSI+ CRC (Chung, 2000). TGFß inhibits 
growth of multiple epithelial cell types and loss of this negative regulation is thought 
to contribute to tumour development (Markowitz et al., 1995). One of the mechanisms 
by which human CRC cells lose responsiveness to TGFß is by inactivation of the 
TGFßRII receptor. 
Other coding mononucleotide runs that are frequently mutated in MSI+ CRC are the 
Gg tract of the apoptosis regulator BAX, the G8 run of the IGF2R growth factor and 
the As and Cs runs of MSH3 and MSH6, respectively. Further mutation of the MMR 
genes may act as a positive feedback loop to enhance the MSI phenotype and thereby 
promote the acquisition of more traits that increase the likelihood of tumour 
progression (Chung, 2000). Mutations in repetitive elements of the DNA repair genes 
ATR, Chkl and Cdc25C have also been detected in MSI+ but not MSS endometrial 
cancers (Vassileva et al., 2002). However, whilst this analysis suggests that certain 
genes might be more susceptible to alterations in MSI+ rather than MSS cells, the 
majority of these mutations are heterozygous and it is not clear whether they 
contribute to tumour development. Further investigation is needed to establish 
whether mutations in genes involved in key cellular pathways, such as cell-cycle 
checkpoints and DNA repair, contribute to tumour progression in MMR-deficient 
cells. 
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1.3 The DNA Damage Response 
The DNA damage response includes triggering checkpoints that slow or arrest cell- 
cycle progression to allow time for repair, changing chromatin structure at the site of 
damage and the recruitment and activation of various proteins involved in DNA repair 
(Rouse and Jackson, 2002). All of these processes are essential for maintaining 
genomic stability and cellular viability following DNA damage. In humans, defects in 
many of the DNA damage responses are generally associated with cancer 
predisposition (Hoeijmakers, 2001, Jackson, 2002). 
Of the many types of DNA damage that can occur in the cell probably the most 
dangerous are DNA double-strand breaks (DSB) that occur spontaneously or are 
induced by DNA damaging agents (Khanna and Jackson, 2001). 
As few as four DSBs appear to be sufficient to activate the checkpoint signalling 
cascade and repair mechanisms (Bakkenist and Kastan, 2003), showing that DNA 
damage responses are extremely sensitive and must efficiently amplify the initial 
stimulus (D'Amours and Jackson, 2002). 
A member of the phosphatidyl-inositol-3-kinase-like protein kinase (PIKK) family, 
ATM (Ataxia-Telangiectasia Mutated) is a component of the cell signalling pathway 
that responds primarily to DSBs (Rouse and Jackson, 2002). Once a DSB has been 
sensed the signal is transduced through ATM to downstream effectors to induce cell- 
cycle arrest, DNA repair and in some cases, apoptosis (Petrini and Stracker, 2003). 
Perturbations of the DNA damage response following a DSB may lead to improperly 
or illegitimately repaired DSBs that might promote malignant transformation (Pastink 
and Lohman, 1999). 
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1.3.1 DNA Damage-Dependent Checkpoints 
The cell-cycle consists of successive rounds of DNA replication and segregation of 
replicated chromosomes into two separate daughter cells. Mitosis (M-phase) involves 
nuclear division and the first gap phase G1, where the cell prepares for DNA synthesis, 
subsequently takes place (Vermeulen et al., 2003). DNA replication occurs during the 
ensuing S-phase and this is followed by the second gap phase G2 where the cell again 
prepares for mitosis (Vermeulen et al., 2003). 
Checkpoints ensure an orderly sequence of events during the cell-cycle and DNA 
damage-dependent checkpoints, as discussed here, delay or arrest the cell-cycle after 
DNA insults to allow time for repair. Therefore, cell-cycle checkpoint control is 
critical for preventing genomic instability after DNA damage (Seo et al., 2003). 
Recent findings relating to a group of cancer predisposition syndromes suggest that 
several recombination repair proteins also have a role in DNA-damage dependent cell- 
cycle regulation (Petrini, 2000a). This implies that DNA repair processes and the 
checkpoint response are tightly coordinated. 
DNA damage sustained in Gi triggers the G1-checkpoint to delay entry to S-phase and 
therefore prevent replication of a damaged DNA template. Cells in G1 have only one 
copy of the genome available and the options for repair of specific types of DNA 
damage are limited (McGowan, 2002). DNA damage present during S-phase elicits an 
intra-S-phase checkpoint response to provide maximal inhibition of DNA synthesis 
and slow the progression through the S-phase. A third checkpoint, the G2-M 
checkpoint, allows time for repair of damaged chromatids prior to segregation in 
mitosis (Figure 1.3.1.1). 
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Figure 1.3.1.1 Schematic diagram of the phases of the cell-cycle and cell-cycle 
checkpoints. 
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Activation of cell-cycle checkpoints, by sensors that detect damaged or unreplicated 
DNA, initiates a signal transduction pathway that results in the phosphorylation of 
several proteins and transcription of a number of genes (Myung and Kolodner, 2002). 
All checkpoints require the PIKK family members ATM and ATR (ATM and Rad3 
related). ATM responds primarily to DSBs and ATR has a role in recognition of 
stalled DNA replication forks (Osborn et al., 2002). 
Different models have been proposed to describe how ATM functions in DNA 
damage-dependent checkpoints. One such model predicts that DSBs cause a change in 
some aspect of the chromatin structure in the nucleus and this change is sensed by 
ATM leading to ATM autophosphorylation on serine 1981 (Bakkenist and Kastan, 
2003). This phosphorylation event causes ATM dimer dissociation releasing an 
activated form of ATM that can induce downstream signalling cascades leading to 
checkpoint activation (Bakkenist and Kastan, 2003). An alternative hypothesis is that 
ATM is a master controller of specific cell-cycle checkpoint pathways and may be 
associated with other proteins in a large complex to allow rapid access to downstream 
targets once ATM has been activated at the site of a DSB (Shiloh, 2001). Whatever 
activation mechanism occurs following DNA damage ATM is a guardian of genomic 
stability (Shiloh, 2003) and once activated ATM phosphorylates several downstream 
target proteins such as NBS1, Chk2 and p53 that have different effects on DNA repair, 
cell-cycle progression and apoptosis. ATR phosphorylates an overlapping set of 
targets to ATM, but responds to a distinct spectrum of lesions (Jackson, 2002). 
Following induction of a DSB in S-phase ATM activates two parallel branches of the 
S-phase checkpoint response in mammalian cells to inhibit DNA replication (Falck et 
al., 2002). On one arm the protein kinase Chk2 is recruited to sites of DSBs for its 
ATM-dependent phosphorylation on Thr-68. Phospho-Chk2 then disperses throughout 
the nucleus to reach its physiological targets (Lukas et al., 2003), in this case Cdc25A 
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phosphotase. Chk2-mediated phosphorylation of Cdc25A on Ser123 targets it for 
polyubiquitination-mediated proteolysis thereby preventing the activation of both the 
S-phase promoting cyclin E/Cdk2 and the loading of Cdc45, an essential replication 
factor, onto replication origins (Falck et al., 2002). 
The second branch of the pathway involves ATM-mediated phosphorylation of NBS 1 
on Ser343 to activate the MRE11/NBS1/Rad50 complex (Figure 1.3.1.2). How this 
complex mediates S-phase arrest is not clear as its downstream targets are unknown. 
However, the importance of this complex is apparent as mutations in MRE11 or NBS 1 
can cause loss of the S-phase checkpoint and cancer predisposition (Stewart et al., 
1999, Varon et al., 1998). 
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Figure 1.3.1.2 Overview of the two parallel branches of the S-phase checkpoint 
response initiated by ATM aller a DSB [adapted from (Falck et al., 2002)]. 
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1.3.2 Homologous Recombination Repair 
In response to a DSB the cell may also activate repair mechanisms. The two main 
pathways for DSB repair in mammalian cells are homologous recombination (HR) 
and non-homologous end joining (NHEJ). DSB repair by HR requires homologous 
duplex DNA in the genome and occurs with high fidelity (Thompson and Schild, 
2001). NHEJ requires little, if any, sequence homology and is potentially mutagenic 
(Moreau et al., 1999). 
Increasing evidence suggests that HR is the predominant pathway in mitotic cells for 
repairing DSBs that form during replication, during processing of spontaneous 
damage and from exposure to DNA damaging agents (Symington, 2002, Sonoda et al., 
2001). Central to the HR pathway are genes of the Rad52 epistasis group that includes 
Rad5 l, Rad52, Rad54, Rad51 B, Rad5 l C, Rad5 l D, XRCC2, XRCC3 and the 
MREI 1/NBS1/Rad50 complex (Sonoda et al., 2001, Jeggo, 1998). 
HR requires the presence of homologous sequences such as the homologous 
chromosome or sister chromatid and is preferentially used to repair DSB in the late S- 
and G2-phases of the cell-cycle when the undamaged sister chromatid is readily 
available (Thompson and Schild, 2001). Use of the sister chromatid is preferable in 
repair as it contains identical sequences meaning there will be no loss of genetic 
information whereas use of the homologous chromosome may lead to loss of 
heterozygosity (LOH) that can contribute to malignancy (Johnson and Jasin, 2001). 
Specific factors may function in somatic cells to impede interchromosomal 
recombination and prevent LOH (Pastink and Lohman, 1999). 
Following induction of a DSB a 5'-3' exonuclease is recruited to resect the DSB ends 
and expose 3' single-strand DNA (ssDNA) tails (Thompson and Schild, 2001). The 
identity of the nuclease responsible for the 5'-3' resection of DSBs in HR is unknown. 
The MRE11/NBS1/Rad50 complex was originally proposed to be a candidate for this 
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processing because yeast mutants lacking components of the complex show a delay in 
or loss of 5'-3' resection of mitotic DSBs (Ivanov et al., 1994, Tsubouchi and Ogawa, 
1998, Lee et al., 2002). However, it is now considered unlikely that the MRE11 
complex assumes this role because MRE11 possesses only 3'-5' exonuclease activity 
and therefore the polarity of the nuclease activity is incompatible with resection (Paull 
and Gellert, 1998). A more likely role for the MRE11 complex is in recruiting or 
facilitating a 5'-3' exonuclease in vivo (Paull and Gellert, 1999, Bressan et al., 1999) 
to create 3' ssDNA tails. The ssDNA tails are then bound by RPA and Rad51 forming 
a nucleoprotein filament. Rad51 interacts with Rad52, Rad54 and the Rad51 paralogs 
(Rad51 B, Rad51 C, Rad51 D, XRCC2 and XRCC3) that assist strand transfer activity 
and the search for homologous sequences within the genome (Khanna and Jackson, 
2001). Once homologous sequences are found the nucleoprotein filament invades the 
undamaged DNA duplex displacing one strand as a D-loop (Jackson, 2002). The 3' 
terminus of the damaged DNA molecule is extended by DNA polymerase using 
sequences of the homologous chromosome/sister chromatid as a template. Ligation 
and migration of the DNA ends creates a secondary cross-over structure known as a 
Holliday junction. Resolution of the Holliday junction, possibly by Mus8 1, results in 
cross-over if both strands are cleaved in opposite senses or results in gene conversion 
with no cross-over when cleavage occurs in the same sense (Chen et al., 2001). 
Cells that are compromised for HR repair functions would have to rely on the more 
error prone NHEJ in S- and G2-phases of the cell-cycle leading to an increase in 
genomic instability and promotion of tumorigenesis (Thompson and Schild, 2001). 
Reflecting this fundamental role in maintaining chromosome stability the HR repair 
genes have been proposed to be candidate tumour suppressor genes or oncogenes 
(Thompson and Schild, 1999, Johnson and Jasin, 2001). 
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Figure 1.3.2.1 Overview of the main stages of the HR repair pathway and the genes 
predicted to have a role in various stages of HR. 
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1.4 Rad5l Paralogs 
Both mitotic and meiotic cells express the Rad51 paralogs XRCC2, XRCC3, Rad51B, 
Rad51 C and Rad5 I D. The five human paralogs have 20-30% identity with Rad51 and 
show <30% identity with each other and with the yeast paralogs Rad55 and Rad57 
(Takata et at., 2001). Multiple protein alignments of the Rad5l family members 
suggest that Rad51D and XRCC3 are closest to yeast Rad57 and yeast Rad55, 
respectively (Masson et al., 2001 a). 
Many proteins that play key roles in the DNA damage response become physically 
localised to the sites of DNA damage in nuclear foci (Rouse and Jackson, 2002). 
Rad5I foci are found in S and G2 phases of proliferating cells and ionising radiation 
(IR) exposure increases the number of foci (Masson et al., 2001b). Rad5l foci 
formation is impaired in cells with mutant Rad51 paralogs suggesting that the paralogs 
have a role in recruitment or stabilisation of Rad51 to nucleoprotein filaments 
(O'Regan et at., 2001, Bishop et al., 1998, Takata et al., 2001). 
1.4.1 Rad5l Paralog Interactions 
Analysis of the interactions of the Rad51 paralogs revealed that none of the paralogs 
interacts with itself but each paralog has a unique set of interactions with other 
paralogs suggesting they are not functionally redundant (Schild et al., 2000). 
RadSlB and Rad51D interact with each other indirectly via their interactions with 
Rad5lC (Schild et al., 2000, Liu et al., 2002). XRCC2 and Rad5lD interact to form 
nucleoprotein filaments in the presence of ssDNA (Kurumizaka et al., 2002) and 
Rad5I C also binds XRCC3 in a stable complex (Masson et al., 2001 a). 
It was initially suggested that the paralogs participate in a single multi-protein 
complex through their simultaneous interactions (Schild et al., 2000). However, it now 
seems likely that at least two distinct complexes exist in the cell, the first including 
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XRCC3-Rad5lC and the second having Rad5lB-Rad5lC-Rad5lD-XRCC2 (BCDX2) 
in a 1: 1: 1: 1 stoichiometry (Masson et al., 2001 b). Rad51 C binds Rad51 D and XRCC3 
separately not simultaneously and so Rad51 C may be partitioned between the two 
complexes in the cell (Liu et al., 2002). Interaction between the paralogs is likely to be 
dynamic and it is possible that other stable complexes are formed in a transient 
manner. 
The paralog associations do not require the presence of DNA and protein interactions 
are not affected by DNA damage, suggesting that complex formation is not induced 
by the presence of DNA DSBs (Wiese et al., 2002). No interaction between the 
complexes and Rad51 was observed suggesting that Rad51 association perhaps does 
require the presence of a DSB (Miller et al., 2002). Alternatively the interaction 
between the paralogs and Rad51 could be weak or transient (Wiese et al., 2002). 
Both the BCDX2 and XRCC3-Rad5lC complexes preferentially bind ssDNA in an 
ATP-independent manner to promote DNA aggregation (Masson et al., 2001a). This 
aggregation may facilitate DNA-DNA contacts during the search for homologous 
sequences on the sister chromatid or homologous chromosome. The specificity of the 
ssDNA binding activity of each of the complexes is potentially important for initiation 
of recombination repair as DSBs are resected to expose ssDNA tails (Masson et al., 
2001b). 
Therefore the Rad51 paralogs seemingly do not have overlapping roles but may act in 
a functional unit to promote the assembly of the Rad51 nucleoprotein filament 
(Thompson and Schild, 2001, Takata et al., 2001, Johnson and Jasin, 2001). 
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1.4.2 XRCC2 and XRCC3 
Chinese hamster ovary (CHO) cell lines irsl and irslSF cells show an extreme (60- to 
100-fold) sensitivity to DNA cross-linking agents such as mitomycin-C (MMC), a 
mild (-2-fold) sensitivity to IR and high levels of chromosome aberrations relative to 
wild type cells (Masson et at., 2001b). XRCC2 and XRCC3 were initially identified 
by their ability to complement the DNA-damage sensitivity and chromosomal 
instability of irsl and irslSF, respectively (Tebbs et at., 1995, Tambini et at., 1997). 
Xrcc2 null mutations are embryonic lethal in mice (Deans et al., 2000) suggesting that 
XRCC2 is an essential gene. The relatively mild growth defect in irsl cells may 
reflect species differences but more likely suggests that Xrcc2 is not completely 
inactive in CHO cells. 
XRCC3 was localised to chromosome 14q32.3 and found to encode a 2.5kb transcript 
(Tebbs et at., 1995). XRCC2 was mapped to chromosome 7g36.1 and found to encode 
a 1.8kb transcript that is expressed relatively abundantly in the brain and testis and at 
low levels in most other tissues (Cartwright et al., 1998). The XRCC2 and XRCC3 
proteins have conserved ATP-binding domains known as Walker boxes A and B. The 
role of these ATP-binding domains is unclear however, since substitution of highly 
conserved residues within Walker box A in XRCC2 has little effect on XRCC2 
functions (O'Regan et at., 2001). Rad5lD, a binding partner of XRCC2, is a DNA- 
stimulated ATPase (Braybrooke et at., 2000) and it may be that only one member of a 
complex is required to retain the ATP-binding requirement. 
Correct control of replication fork progression following DNA damage is crucial for 
cell viability and genomic stability. irslSF cells fail to slow replication fork 
progression after DNA damage, a response that is restored by complementation with 
XRCC3 (Henry-Mowatt et al., 2003). Similar results were obtained with mutant xrcc2 
DT40 cells suggesting that XRCC2 and XRCC3 are required for the modulation of 
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replication fork progression on damaged vertebrate chromosomes via their role in HR 
(Henry-Mowatt et al., 2003). 
The irsl and irslSF cells show a 100- and 25-fold decrease in frequency of DSB 
repair by HR respectively, that can be corrected by complementation with the wild 
type gene (Johnson et al., 1999, Pierce et al., 1999). XRCC2 deficiency results in an 
HR defect but does not affect NHEJ and XRCC3 deficiency leads to a specific defect 
in gene conversion in HR (Johnson et al., 1999, Pierce et al., 1999). The correlation 
between HR defects, decreased cell viability and chromosomal instability in XRCC2- 
and XRCC3-deficient cells implies that these genes are credible downstream targets in 
cancer development and has led to others in the field proposing that they are tumour 
suppressor genes (Thompson and Schild, 1999, Johnson and Jasin, 2001). 
CHO cells lacking Xrcc2 or Xrcc3 show chromosome segregation defects (Griffin et 
al., 2000) increasing the likelihood that these genes are guardians of the genome. 
Therefore, loss of efficient XRCC2 or XRCC3 gene function may promote malignant 
development by increasing genetic instability in the cell. 
Figure 1.4.2.1 Schematic representation of the XRCC2 or XRCC3 protein structure. 
XRCC2 is 280aa in length whereas XRCC3 is 346aa. The only known functional 
domains of these proteins are the Walker box A (putatively at residues 48-55 in 
XRCC2 and 127-134 in XRCC3) and Walker box B motifs (residues 145-150 in 
XRCC2 and 218-223 in XRCC3) [Cartwright et al., 1998, Rafii et al., 2003]. 
Walker box A Walker box B 
280 or 346 
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1.4.3 XRCC2, XRCC3 and Cancer 
A polymorphism of XRCC2, that causes an R188H amino acid substitution, has a 
subtle effect on the cells ability to repair MMC-induced DNA damage and shows a 
small but consistent association with breast cancer risk (Rafii et al., 2002, Kuschel et 
al., 2002). However, the role of amino acid 188 in functioning of XRCC2 is not 
known as it does not appear to be necessary for XRCC2-Rad51D interaction (Rafii et 
al., 2002) and integrity of XRCC2 Walker box A is not essential for protein function 
(O'Regan et al., 2001) but amino acid 188 is a conserved residue between mouse and 
human (Cartwright et at., 1998). 
A MMR-deficient uterine cancer cell line was also found to carry a heterozygous 
frameshift mutation of XRCC2 that is expected to disrupt the Walker box B 
(Mohindra et al., 2002). A screen of primary uterine sarcomas associated this 
polymorphism with hyperplastic tissue suggesting that it may play a role in a rare 
subset of uterine cancers (Mohindra et al., 2003). 
A C/T polymorphism of XRCC3 is present in the healthy, cancer-free population 
(Shen et at., 2002). This polymorphism leads to a non-conservative amino acid 
substitution, 7'241M, the functional consequences of which are not known. The 
T241 M variant was reported to be associated with an increased risk of malignant 
melanoma, bladder cancer and breast cancer (Winsey et al., 2000, Matullo et al., 2001, 
Kuschel et al., 2002). However, cells expressing the T241M variant show no defect in 
HR repair and are no more sensitive to MMC than wild type cells (Araujo et al., 
2002). In addition, further studies to confirm the relationship between this 
polymorphic variant and bladder cancer or malignant melanoma failed to observe the 
originally reported association (Stem et al., 2002, Duan et al., 2002). 
A rare heterozygote variant of XRCC3 that potentially gives rise to a non-synonymous 
D213N substitution in the conserved Walker box B was found to abrogate the function 
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of XRCC3 (Rafii et al., 2003). However, this heterozygote variant was not associated 
with breast cancer and was only observed in three non-cancer controls (Rafii et al., 
2003) further suggesting that this gene is not a tumour suppressor. 
Therefore, it remains to be determined whether there are mutations or polymorphisms 
of XRCC2 and XRCC3 that have subtle effects on DNA repair capacity and thereby 
increase the risk of colorectal cancer. 
1.5 Mus8l 
A Holliday junction (HJ) is a symmetrical branched DNA structure that needs to be 
resolved to re-establish duplex DNA. Holliday junctions can occur during 
recombination when newly synthesised DNA becomes associated with the displaced 
strand. These are typically resolved by an enzyme that cuts either pair of similarly 
oriented strands (Chen et al., 2001). 
Holliday junctions can also be created at stalled replication forks when the Y- 
branched stalled fork regresses by annealing two newly synthesised strands together to 
form an X-shaped HJ (Haber and Heyer, 2001, Osborn et al., 2002). This can be 
resolved by introducing nicks into non-complementary strands of the HJ to leave one 
intact duplex along with unprotected DNA ends that can invade the template to re- 
initiate replication (Osborn et al., 2002). 
Mus8l is a putative component of the endonuclease that resolves Holliday junctions to 
linear duplex products (Chen et al., 2001, Boddy et al., 2000). Mus8l was initially 
identified in S. pombe through its ability to interact with the forkhead associated 
(FHA) domain of checkpoint kinase cdsl (human homologue is Chk2) (Boddy et al., 
2000). The human Mus81 protein was subsequently isolated through its interaction 
with the FHA domain of hChk2 (Chen et al., 2001). Human Mus8l is located on 
chromosome 11g13 and codes for a 551 amino acid protein. 
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Mus8l is a member of the XPF family of endonucleases with a highly conserved 
VERKX, D motif that is proposed to form the catalytic site (Boddy et al., 2000). Other 
conserved motifs include a C-terminal helix-hairpin-helix signature that is found in 
other XPF proteins and proteins involved in DNA metabolism. A second helix- 
hairpin-helix motif is present in the N-terminus that is predicted to allow non-specific 
DNA binding via the phosphate backbone (Boddy et al., 2000). Mus81 possesses one 
of the defining features of a HJ resolvase in that it is able to introduce nicks into 
strands of like polarity across a 4-way helical branch point (Boddy et al., 2001). 
Cells exposed to agents that damage DNA or block DNA replication have increased 
levels of hMusS l and hMus8l has an associated endonuclease activity against 
synthetic His (Chen et al., 2001). These observations led to the suggestion that Mus8l 
has a role in resolution of His that arise when DNA replication is blocked by damage 
or nucleotide depletion (Chen et al., 2001, Haber and Heyer, 2001). 
Improper resolution of the HJ may lead to chromosome segregation defects and 
increased genomic instability, therefore it is possible that mutations in Mus8l promote 
malignant transformation. 
Figure 1.5.1 Diagrammatic representation of the putative domains of Mus8l as 
predicted by protein alignments (Chen et al., 2001). 
Putative Helix-hairpin-helix 
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1.6 The 111RE11 Complex 
The MRE11 complex consists of MRE11, NBS1 and Rad50 and the MRE11-Rad50 
proteins appear to form the core of the complex since these are well conserved from 
archaea to humans (Anderson et al., 2001). The Xrs2 protein of Saccharomyces 
cerevisiae shares little homology with the human NBSI protein except in the N- 
terminus and there is no corresponding prokaryotic protein (Anderson et al., 2001). It 
appears as though the MRE11-Rad50 core proteins are ancient proteins that have 
acquired recent binding partners in evolutionary history (Petrini, 2000b). 
The MRE11 complex is hypothesised to have several roles in the cell including DNA 
damage recognition (Petrini and Stracker, 2003), prevention of DSB formation during 
DNA replication (Costanzo et al., 2001), cell-cycle checkpoint activation (Grenon et 
al., 2001), participation in some aspects of NHEJ (Paull and Gellert, 2000) and 
telomere maintenance (Zhu et al., 2000). A number of these suggested roles for the 
complex come from studies of the conserved yeast MRE11 complex, as discussed later 
in this chapter. The biochemical or biological basis for many of these proposed 
functions of the MRE11 complex is unknown and remains an area of controversy. 
Moreover, investigations into the precise function of the MRE11 complex have been 
hampered by the fact that null mutations of these genes are lethal to vertebrate cells 
(Yamaguchi-Iwai et al., 1999, Luo et al., 1999, Zhu et al., 2001). 
a) NBSI 
NBS1 was mapped to chromosome 8g21 and encodes a 95kDa, 754 amino acid 
protein. Two transcripts of NBS1,2.6kb and 4.4kb, that differ in the amount of 3' 
untranslated sequence they contain are expressed in most tissues with the highest 
expression seen in the spleen, ovary and testis (Varon et al., 1998). 
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The NBS1 protein (also known as p95 and nibrin) contains a 150 amino acid FHA 
domain in its N-terminus that may be associated with phospho-specific protein-protein 
interactions (Zhao et al., 2002). Adjacent to the FHA domain is a 70-80 amino acid 
BRCA1 carboxy-terminal (BRCT) motif (D'Amours and Jackson, 2002). BRCT 
domains are generally required to mediate protein-protein interactions and are often 
found in DNA damage responsive cell-cycle checkpoint proteins (Zhao et al., 2002, 
Varon et al., 1998). 
b) RadSO 
Rad5O resides on chromosome 5q31 and codes for a 1312 amino acid protein that 
forms a stable complex with MRE11 (Dolganov et al., 1996). At least two transcripts 
of Rad50,4.6kb and 5.9kb, are produced by alternative splicing of the gene (Kim et 
al., 1999). 
Rad50 belongs to the structural maintenance of chromosomes (SMC) family of 
proteins whose features include a Walker box A at the N-terminus and a Walker box 
B at the C-terminus (Dolganov et al., 1996). These ATP-binding domains are 
separated by a coiled-coil motif that is interrupted by a putative globular domain 
(Dolganov et al., 1996). Examination of the S. cerevisiae Rad50 suggested that the 
protein forms an anti-parallel homodimer through a flexible hinge region to bring the 
catalytic domains together and create a functional ATP-binding domain (Anderson et 
al., 2001). This homodimer appears to bind ScMrell at or close to the catalytic 
domains so that the ScMrel1 nuclease activity is closely associated with ScRad50 
ATPase activity (Anderson et al., 2001). 
Human Rad50 recognises dsDNA and may have a role in tethering or bridging DNA 
ends to assist repair (Connelly and Leach, 2002, de Jager et al., 2001b). 
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c) MREJ I 
MRE11 lies on chromosome 11g21 and codes for a 708 amino acid protein (Petrini et 
al., 1995). Two MRE11 mRNA species, one of 2.4kb and a second of 6.6kb, exist in 
all tissues with the expression pattern of the smaller transcript directly correlating with 
the level of tissue proliferation and being most abundant in the testis (Petrini et al., 
1995, Carney et al., 1998). MRE11 shares a promoter with the foetal globin-inducing 
factor gene and the two genes are transcribed divergently (Pitts et al., 2001). This type 
of promoter organisation is seen in other genes involved in the DNA damage response 
such as ATM and BRCA1. 
It has been proposed that S. cerevisiae Mre I1 forms a homodimer and that regions in 
both the N- and C-terminus of the protein are required for this self-interaction 
(Chamankhah and Xiao, 1999). It has further been suggested that NBS 1 binding 
requires hMREI 1 dimerisation (D'Amours and Jackson, 2002). 
The N-terminal nuclease domain of hMRE11 consists of four phosphoesterase motifs, 
the first three of which are common to many phosphoesterases and the fourth has 
homology to nuclease motifs found in E. coli SbcD and bacteriophage T4 gp47 
(D'Amours and Jackson, 2002). The C-terminus of MRE11 is more divergent and has 
charged clusters of amino acids required for DNA binding (D'Amours and Jackson, 
2002). Rad50 binding to MRE11 requires several sites in the N-terminus of MRE11 
and may stabilise the MRE11 protein and/or facilitate NBS1 binding (Desai-Mehta et 
al., 2001). MRE11-NBS1 binding requires the last 101 amino acids of NBS1 and 
amino acids 1-319 of MRE11 (Desai-Mehta et al., 2001). 
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Figure 1.6.1 Diagrammatic representation of the human NBS1, Rad50 and MRE11 
protein structures. 
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Figure 1.6.2 Model depicting the putative architecture of the MRE 11 complex as 
proposed by D'Amours and Jackson, 2002 and supported by analysis of the yeast 
complex (Anderson et al., 2001). Rad50 is predicted to dimerise and adopt a flexible 
conformation. The MREI I dimer binds close to the Rad50 ATPase domains and 
MRE II interacts with NBS 1 independently of Rad50 (Paull and Gellert, 1999). 
Rul ME ME R 
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1.6.1 Catalytic Activities of the MRE11 Complex 
MRE11 has single-strand annealing activities that may facilitate joining of non- 
homologous ends or might be important for the rescue of collapsed replication forks 
(Paull and Gellert, 1998, de Jager et al., 2001a). MRE11 by itself also has 3'-5' 
dsDNA exonuclease activities and endonuclease activities that are enhanced 3-4 fold 
in the presence of Rad5O (Paull and Gellert, 1998). Binding of NBS1 can alter the 
specificity of the nuclease activities by stabilising MRE11-Rad50 protein-DNA 
complexes and allowing partial unwinding of DNA duplexes (Paull and Gellert, 
1999). The DNA-damage dependent phosphorylation of NBS1 and MRE11 may also 
modify the nuclease activity of the complex (D'Amours and Jackson, 2002). 
Together the MRE11 complex possesses Mn2+-dependent 3'-5' exonuclease activity 
on 3' recessed ends or blunt dsDNA ends (Paull and Gellert, 1998, Trujillo et al., 
1998) and endonuclease activity on 3' ssDNA branches and hairpin structures (Paull 
and Gellert, 1999). It is likely that MRE11 is the only nuclease in the MRE11 
complex and NBS1 and Rad50 modify and regulate its activities. 
1.6.2 Links between DNA Repair and Cell-Cycle Checkpoint Functions 
Mutations in the ATM gene lead to ataxia telangiectasia (A-T), an inherited disorder 
characterised by cerebellar ataxia, oculocutaneous telangiectasia and an increased 
incidence of cancer, especially lymphoid tumours (Kraakman-van der Zwet et al., 
1999). Cells from A-T patients show increased sensitivity to IR, genomic instability 
and a failure to suppress replication fork firing after DNA damage, a phenomenon 
known as radio-resistant DNA synthesis (RDS) (Kraakman-van der Zwet et al., 1999). 
Nijmegen breakage syndrome (NBS), caused by mutations in NBS1, is characterised 
by microcephaly, developmental defects, immune deficiency and a high incidence of 
lymphoma. NBS cells display increased IR sensitivity, increased chromosomal 
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aberrations, decreased survival and RDS indicating a loss of S-phase checkpoint 
activation (Franchitto and Pichierri, 2002, Varon et al., 1998). The founder mutation 
657de15 is seen in 90-95% of NBS patients and this mutation leads to premature 
truncation of NBSI downstream of the FHA and BRCT domains (Desai-Mehta et al., 
2001, Varon et al., 1998). The striking cellular and clinical similarities between A-T 
and NBS indicated that ATM and NBS1 function in the same checkpoint pathway. 
This idea was further supported by evidence that ATM phosphorylates NBS 1 after IR 
and this event is required for S-phase checkpoint activation (Petrini, 2000a, Wu et al., 
2000). 
MRE11 and Rad5O accumulate in nuclear foci after IR-induced damage in a dose- 
dependent manner (Maser et al., 1997). These irradiation-induced foci (IRIF) are 
thought to represent sites of ongoing repair and therefore these proteins were predicted 
to have some role in DNA DSB repair (Carney et al., 1998). In NBS cells the MRE11- 
Rad50 interaction remains intact but these proteins are not restricted to the nucleus 
and do not form IRIF, suggesting that NSB 1 is required for the nuclear localisation of 
MRE11-Rad50 (Desai-Mehta et al., 2001). This fact, together with the discovery that 
NBS1 was a member of the MRE11 complex, highlighted a link between proteins 
involved in DSB repair and those implicated in the checkpoint response. 
Mutations in MRE11 cause A-TLD (A-T like disorder) whose phenotype is almost 
indistinguishable from A-T (Stewart et al., 1999). A-TLD cells share similar features 
with A-T and NBS cells, such as chromosomal instability, IR sensitivity and RDS 
(Stewart et al., 1999), thereby strengthening the connection between DSB repair by 
the MRE1 I complex and cell-cycle checkpoint responses controlled by ATM. 
The fact that A-TLD, NBS and A-T cells display RDS, together with the observation 
of impaired IRIF formation in these cells suggests that the MRE11 complex, together 
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with ATM, plays a significant role in both S-phase checkpoint activation and DNA 
damage recognition (Stewart et al., 1999, Carney et al., 1998). 
1.6.3 Potential Functions of the MRE11 Complex 
A role for the MRE11 complex in NHEJ is tentative. Some reports suggest that yeast 
rad5O, mrell and xrs2 mutants are deficient in both HR and NHEJ (Wilson, 2002) 
whereas others report that these mutants solely display decreased efficiency of some 
aspects of NHEJ (Moore and Haber, 1996). However, it is hypothesised that the single- 
strand annealing activities of human MREI 1 could be important in certain elements of 
NHEJ (Paull and Gellert, 2000, Paull and Gellert, 1999). 
Another putative function of the hMRE11 complex is in the maintenance of telomeres 
as a small fraction of the hMRE11 complex was found to be located at telomeres and 
associated with TRF2, a telomere repeat binding factor (Zhu et al., 2000). Experiments 
using a temperature sensitive mutant form of ScMrell that carried a Prol62Ser 
mutation showed defects in telomere maintenance even at permissive temperatures 
suggesting that the 162 residue is important for telomere function of the ScMrell 
complex (Chamankhah et al., 2000). This residue may be important for secondary or 
tertiary structure of ScMrel1 and was suggested to be important for interaction with 
other proteins (Chamankhah et at., 2000). Residues in the C-terminal region of 
ScMrel l also appear to be critical for telomere preservation (Chamankhah and Xiao, 
1999). The nuclease activity of the MRE11 complex may not be required for its role at 
telomeres, however, as nuclease-deficient mrel1 yeast mutants have a normal telomere 
length (Moreau et al., 1999). 
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The MREI1 complex may also have roles in meiotic recombination events. Deletion 
of Mrel 1 in yeast leads to severe defects in processing and formation of DSB during 
meiosis (Usui et al., 1998). The ScMrelI DNA binding site B was shown to be 
required for formation of meiotic DSBs (Moreau et al., 1999) whereas both the 
nuclease activity and the DNA binding site A were found to be essential for meiotic 
DSB processing (Usui et al., 1998). 
Although it is now thought unlikely that the hMRE11 complex is involved in DSB 
end-resection during mitotic recombination a role for the complex in HR has not been 
ruled out. A deficiency in S. cerevisiae Mre11 leads to a decrease in IR-induced sister 
chromatid recombination suggesting a primary role for the Mrell-Rad50-Xrs2 
complex in DNA damage-induced HR (Bressan et al., 1999). Using chicken DT40 
NBS1 knockout cells it was also shown that NBS1 was essential for HR in vertebrates 
(Tauchi et at., 2002) supporting the hypothesis that this complex functions in 
recombination repair. The exact nature of this role is still of some controversy 
however, especially since cells from A-TLD and NBS patients do not show gross DSB 
repair defects (Stewart et al., 1999, Varon et al., 1998). A likely role for the MRE11 
complex is as a key organiser of DSB repair that determines the type of processing to 
be used depending on the nature of ends at the break (Paull and Gellert, 1999). 
A role for the hMRE11 complex in replication is supported by the observation that the 
complex co-localises with PCNA throughout the S-phase and it has been proposed 
that the hMREI l complex is loaded onto chromatin in a replication-dependent manner 
(Mirzoeva and Petrini, 2003). The N-terminal FHA and BRCT domains of NBS1 
associate with the E2F1 transcription factor under normal unstressed conditions and 
this interaction may direct the MRE11 complex to origins of replication (Maser et al., 
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2001). The failure of NBS and A-TLD cells to repress firing of DNA replication 
origins in response to IR also suggests the MRE11 complex is a negative regulator of 
DNA replication following DNA damage (Maser et al., 2001). Putative replication 
functions of the MRE11 complex are further supported by the fact that mammalian 
cells that lack a functional MRE11 show increased chromosomal breaks and 
accumulation of DSBs during DNA replication (Yamaguchi-Iwai, 1999, Costanzo, 
2001). By analogy with the homologous E. coli SbcCD functions, the MRE11 complex 
may act at the replication fork by associating with or resolving unusual DNA 
structures that are formed during replication (Xiao and Weaver, 1997, Petrini, 2000b). 
Checkpoint functions for the MreI l complex were proposed as it was found that yeast 
lacking functional Xrs2 or Mrel1 were defective in S-phase checkpoint activation 
(D'Amours and Jackson, 2001, Grenon et al., 2001, Myung and Kolodner, 2002). 
Cells from A-TLD and NBS patients also fail to activate the S-phase checkpoint 
following IR-induced damage (Stewart et al., 1999, Varon et al., 1998, Carney et al., 
1998) further supporting a role for this complex in control of cell-cycle checkpoints. 
Upon induction of a DSB, recruitment of the hMREII complex to sites of DNA 
damage occurs independently of ATM, suggesting that with respect to DNA damage 
recognition the complex is upstream of ATM (Mirzoeva and Petrini, 2003). However, 
activation of the S-phase checkpoint responses requires chromatin binding, NBS1 
phosphorylation and possibly other interactions such as the E2F1 association 
(Mirzoeva and Petrini, 2001, Maser et al., 2001). The FHA and BRCT domains of 
NBS I direct chromatin association and E2F binding in the nucleus and the ATM- 
dependent phosphorylation of NBS1 might only occur when the MREI1 complex is 
chromatin-bound (Zhao et al., 2002). 
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Recently it was suggested that changes in chromatin structure arising from DNA 
damage may well be the initiating event in the DNA damage response (Petrini and 
Stracker, 2003, Bakkenist and Kastan, 2003). One hypothesis proposed that these 
chromatin changes are recognised by a sensor that was chromatin-bound prior to the 
induction of the DSB and the sensor itself may then become a target for the 
transducing kinase (Petrini and Stracker, 2003). It is entirely possible that the MRE11 
complex is a sensor of DNA damage as it is chromatin bound in an S-phase-specific 
manner and associates with DNA damage soon after its induction suggesting that the 
MRE II complex functions at the earliest time points after DNA damage (Petrini, 
2000b, Petrini and Stracker, 2003). It was further suggested that the DNA damage- 
dependent phosphorylation of NBS1 and MRE11 may then alter the activity of the 
complex from a sensor of DNA damage to a mediator of the checkpoint response 
(Petrini and Stracker, 2003). However, since MRE11 chromatin binding is cell-cycle 
specific the DNA damage response may vary according to cell-cycle phase and 
therefore the MRE 1I complex may not be the sole sensor of DNA damage. 
The MRE11 complex is undoubtedly important in maintaining genomic integrity. 
Inactivation of the S. cerevisiae Mrel1, Rad50 or Xrs2 proteins increases the rate of 
gross chromosomal rearrangements by 500- to 600-fold in yeast cells (Chen and 
Kolodner, 1999). The human MRE11 complex is chromatin bound in a cell-cycle 
regulated, ATM-independent manner consistent with its role in surveillance of 
chromosome integrity (Zhao et al., 2002). In addition, an essential role for the MREI 1 
complex in maintaining chromosomal DNA during the normal cell-cycle is supported 
by the fact that null alleles of MRE11, Rad50 and NBS1 cause embryonic lethality in 
vertebrates (Yamaguchi-Iwai et al., 1999, Luo et al., 1999, Zhu et al., 2001). In 
contrast, chicken DT40 NBS 1 knockouts display HR defects but not a lethal phenotype 
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(Tauchi et al., 2002) and NBS does not confer an extremely acute phenotype, probably 
due to the fact that truncated forms of NBS1 are expressed in these cells. Creation of a 
mouse model that reflected many of the characteristics of NBS suggested that NBSI 
function retained by the truncated NBS1 protein (70kDa protein in human NBS) is 
sufficient to prevent embryonic lethality (Kang et al., 2002). 
1.6.4 The MRE11 Complex and Cancer 
The discovery that mutations of MRE11 and NBS1 cause syndromes that are 
associated with an increased cancer predisposition links alterations of the MRE11 
complex genes with tumour development. Further mutations and polymorphisms of 
these genes are in fact seen in the cancer population. 
A subset of breast and lymphoid primary tumours were found to have mutations of 
MREI1 at conserved positions (Fukuda et al., 2001) while polymorphisms and 
mutations of NBS1 are known to be present in some breast, ovarian and colon cancer 
cell lines (Tessitore et al., 2003) suggesting that alterations of MRE11 and NBS1 exist 
in at least a subset of cancers. 
A mutation in a poly(T) tract in intron 4 of MRE11, leading to alternative splicing and 
generation of truncated MRE11 products, was found to be present in >90% of MSI+ 
colorectal tumours (Giannini et al., 2002). This mutation was also seen in 12% of 
cases of MSI+ therapy-related acute leukaemia (Casorelli et al., 2003). Heterozygous 
frameshift mutations of an A9 tract in Rad50 were observed in 33% of MSI+ CRCs and 
28% of MSI+ gastric cancers (Kim et al., 2001). This implies that MRE11 and Rad50 
are major targets for inactivation in MMR-deficient cells. 
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1.7 Aims for this Study 
Guarding the genome against unwanted genetic alterations is paramount in preventing 
malignant transformation. To protect genomic integrity a number of mechanisms have 
evolved to recognise and repair DNA damage. The supposition that loss of any of 
these pathways is sufficient to increase genetic instability and promote tumorigenesis 
is corroborated by evidence from HNPCC. These cancers develop through a multi- 
step process that is likely to involve a cascade of primary and secondary mutator 
genes that accelerate genomic instability (Kim et al., 2001). The primary mutator 
genes in this cascade are known to be the MMR genes that are inactivated in the 
majority of hereditary and sporadic MSI+ colorectal tumours. It is now important to 
determine which genes are downstream mutational targets in these tumours. Likely 
candidates include genes involved in DNA repair and cell-cycle checkpoints, as 
mutations that compromise the functions of these genes would further increase genetic 
instability and might elevate the risk of malignant transformation. 
This study aims to clarify whether the XRCC2, XRCC3, Mus81 and MRE11 complex 
genes are mutated in colorectal cancer or whether polymorphisms of these genes act 
as low-penetrance risk factors for cancer. This research will also investigate the 
phenotypic consequences of common mutations occurring in MSI+ colorectal cancer 
cells. 
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2.1 Materials 
2.1.1 General Laboratory Equipment 
a) Laboratory equipment and instruments 
Micro Centaur centrifuge Sanyo Scientific 
Eppendorf 5414D centrifuge Eppendorf 
Swing-out Bench Top Centra MP4 rotor International Equipment 
Company 
Heated Hybridisation Shaker Stuart Scientific 
Water-jacketed Incubator 3250 for Tissue culture Thermo Forma Scientific 
Class II A/B3 Biological Safety Cabinet Thermo Forma Scientific 
Water Bath Sanyo Gallenkamp 
Boekel BBA Heating block Grant Instruments 
Primus 96 Plus PCR Thermal Cycler MWG Biotech AG 
Eppendorf Mastercylcer Gradient Eppendorf 
ABI04-S Balance Mettler-Toledo 
Scott II Ohaus Balance for >mg weights Scaleman 
Vortex Genie 2 Scientific Industries 
12xl5cm Agarose H5 Gel Electrophoresis System Invitrogen 
20x2lcm Agarose Gel Electrophoresis Tank Anachem 
Polvacrylamide Gel Protean II xi cell Bio-Rad 
Kodak Analysis System 120 and 1D software Scientific Imaging Systems 
CHEF DR III Pulse-field Gel electrophoresis Bio-Rad 
System 
UV Transilluminator UVP Incorporated 
Light Box Bennet Scientific 
P2, P10, P20, P200 and P1000 Pipettes Gilson Medical Electronics 
1-10µl and 1-50µl Multi-channel Pipettes Philip Harris Scientific 
Electronic Pipette Aid Hirshmann Laborgerate 
12000-14000 Dalton Dialysis Membranes MediCell 
pH Meter Denver Instrument Company 
Standard Power-Pack Biometra Savant 
LI-COR Long Read Sequencer MWG Biotech AG 
Spectrophotometer Eppendorf 
lee Machine Scotsman Ice Systems Ltd 
Semi-Dry Transfer Cell Bio-Rad 
Western Gel Mini Protean II Cell Bio-Rad 
Unitemp Microbiological Incubator Harvard Apparatus 
IBL 437 Cs-137 Irradiator CIS Biointernational 
Denley Anthos 2001 Plate Reader Eppendorf 
Sequencher Software Gene Code 
TE 200 Fluorescence Microscope Nikon 
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b) Glassware, plastics and disposables 
Item Supplier 
Pyrex Glassware SLS or VWR 
Pasteur Pipettes Volac 
250m1,500ml, 11 glass bottles SLS 
Sterile Filter Gilson Pipette Tips Continental Laboratory Products 
Refill Tips for Gilson P10, P200 and P1000 Continental Laboratory Products 
Pipettes 
Plastic 15m1 and 50ml polypropylene centrifuge Coming 
tubes 
35mm, 60mm, 100mm Tissue Culture Dishes Sarstedt or Greiner 
6-well Culture Plates Greiner 
Bacterial Culture Dishes Bibby Sterilin 
1.2m1 Cryovial Nalgene 
5ml Bijoux Sarstedt 
150x25mm Tissue Culture Plates Corning 
0.5ml, 1.5m1 and 2m1 microcentrifuge Tubes Sarstedt 
50m1 Plastipak Syringes Becton Dickinson 
8.5mm Cuvette 220-1600nm Eppendorf 
Universal Tubes Bibby Sterilin 
5m1 and 10ml Stripettes Bibby Sterilin 
25m1 and 50m1 Stripettes Continental Laboratory Products 
0.2ml 96-well PCR Plates ABgene 
0.2ml Strips of 8 Tubes for PCR SLS 
6x 26 x 1.0-1.2mm Microscope Slides VWR 
0.4cm Electrode Gap Gene Pulsar Cuvettes Bio-Rad 
96-well Lidded Plates Corning 
Cell Scraper Sarstedt 
(, ) tliscellanc'ous I)ishosahle Luhorutoii Equipment 
I 
Item Supplier 
Swann Morton Disposable Sterile Scalpels SLS 
Aluchef Aluminium Foil VWR 
Bodyguards Low Protein Latex Examination VWR 
Gloves 
Autoclave Tape VWR 
Kimberley Clark Paper Tissue SLS 
39 
Materials and Methods 
d) Sterilisation 
Plastic ware and glassware were washed in RBS detergents and rinsed several times in 
tap water followed by a final rinse in deionised water. Plastic and glassware was dried 
at 80°C in a hot air oven. Any items requiring sterilisation were autoclaved in a 
Rodwell MP24 autoclave, supplied by SLS, at 15p. s. i pressure, 120°C for 15 minutes. 
Filter sterilisation of solutions for tissue culture was carried out using sterile syringe 
filters. 
e) Purified Water 
Tap water was passed through a still to produce glass-distilled water. The water was 
sterilised by autoclaving for 15 minutes at 15 p. s. i. Ultra-pure deionised water was 
obtained from an installed Purite Prestige Labwater 250 purification system. A Purite 
Neptune Labwater system provided >18MS2 water for use in molecular biology 
experiments. 
2.1.2 Chemicals, Biochemicals and Molecular Biology Reagents 
a) Chemicals 
Chemicals were always at least AnaiR-grade or equivalent and were stored according 
to the supplier's instructions. 
Unless otherwise stated all chemicals, acids, ethanol and methanol were supplied by 
VWR. Agarose was supplied by Cambrex Bioscience and pulse-field grade agarose 
was supplied by Bio-Rad. Thymidine, mitomycin C, hydroxyurea, camptothecin, 
puromycin and ampicillin were supplied by Sigma-Aldrich. Sigma-Aldrich also 
provided PMSF, leupeptin, pepstain, BSA and N-laurosarcosyl. 
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Coomasie brilliant blue, SDS and 30% acrylamide/bis acrylamide solution (37.5: 1) 
were supplied by Bio-Rad. Microcystin phosphotase inhibitor was a kind gift from 
Professor Carl Smythe (Centre for Developmental Genetics). Hoechst 33342 stain was 
purchased from Sigma-Aldrich. 
h) Biochonicals 
LiofectAMINE Invitrogen 
T4 DNA Ligase NEB 
Proteinase K Sigma-Aldrich 
Hygromycin B CalBiochem 
Restriction Enzymes Promega or NEB 
c) RT-PCR. PCR Master Affix 
2X PCR master mix, purchased from ABgene, was used for the majority of PCR 
reactions. This master mix contained 75mM Tris-HCl pH 8.8,20mM (NH4)2SO4, 
1.5mM MgCI2,0.2mM of each dNTP, 0.01% Tween 20 and 1.25U Tay DNA 
polymerase. 
The AccuPrime Tay DNA polymerase system, used for high fidelity amplifications, 
was purchased from Invitrogen. AccuPrime Tay DNA polymerase was provided in a 
storage buffer of 20mM Tris-HCI (pH 8.0), 0.1mM EDTA, ImM DTT, stabilizers and 
50% (v/v) glycerol. lOX AccuPnme PCR Buffer I and II contained 200mM Tris-HC1 
(pH 8.4), 500mM KCI, 15mM MgC12,2mM dGTP, 2mM dATP, 2mM dTTP, 2mM 
dCTP, thermostable AccuPrime protein and 10% glycerol. 
Native P/u DNA polymerase, purchased from Stratagene, was supplied in 50mM Tris- 
I1('l (pH S-2), 1 mM DTT. 0.1 mM EDTA, 0.1% Tween 20,0.1% Igepal CA-630 and 
50% (v/v) glycerol. 
One-step RT-PCR experiments were carried out using a Reverse-iT One Step RT-PCR 
kit purchased from ABgene. This kit included a 2X RT-PCR master mix and 
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50units/pl Reverse-iT RTase blend containing RNase inhibitor. The 2X RT-PCR mix 
contained optimised reaction buffer, 1.25U Thermoprime Plus DNA polymerase, 
0.2mM each dNTP and 1.5mM MgC12. All master mixes and polymerases were stored 
at -20°C. 
d) Molecular Biology Kits 
QIAGEN supplied molecular biology kits for DNA extraction from human tissues 
(QIAamp DNA Mini Kit), RNA extraction from animal cells or tissues (RNeasy Mini 
Kit), RNA homogenisation (QlAshredder), extraction of DNA from bacterial cell 
cultures (QlAprep Miniprep Kit) and clean-up of PCR products (QlAquick Gel 
Extraction Kit or QIAquick PCR Purification Kit). 
cDNA synthesis was carried out using the SuperScript II RNase if Reverse 
Transcriptase kit purchased from Invitrogen. This contained 200U/µ1 Superscript II, 
5X first strand buffer and 0.1M DTT. SuperScript II was supplied in 20mM Tris-HC1 
(pH 7.5), 100mM NaCl, 0.1mM EDTA, 1mM DTT, 0.01% (v/v) NP-40,50% (v/v) 
glycerol storage buffer. The 5X first strand buffer was supplied in 250mM Tris-HCI, 
375mM KCI, 15mM MgClz. Oligo-(dT)12.18 primer was supplied by Invitrogen. 
In the main, sequencing reactions were carried out using a SequiTherm Excel II DNA 
Sequencing Kit-LC for 25-41 cm gels. This kit, supplied by Epicentre Technologies, 
was designed specifically for use with a LI-COR automated DNA sequencer. Some 
sequencing reactions, especially those for sequencing mononucleotide runs, were 
carried out using the Thermo Sequenase Primer Cycle Sequencing Kit from 
Amersham Pharmacia Biotech. All reagents for the above kits were stored according 
to the manufacturer's instructions. 
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e) DNA molecular weight markers 
A 100bp DNA ladder (0.5µg/µ1), supplied by Invitrogen, was used to estimate size of 
PCR products on agarose gels. Hyperladder I supplied by Bioline was used for size 
estimation and quantification of PCR products on agarose gel. 
J) Oligonucleotide primers 
Unmodified oligonucleotide primers for PCR amplification were ordered from MWG 
Biotech AG or EurogenTech. Modified infrared dye (IRD) labelled oligonucleotides 
for sequencing were supplied by MWG Biotech AG. 
2.1.3 Preparation of Standard Solutions 
Solutions were prepared and stored at room temperature unless otherwise stated. 
a) TBE buffer (10X, pH 8.0) 
lOX TBE was made up using 108g Tris-base, 55g boric acid, 40m1 0.5M EDTA and 
ddH2O. The pH was adjusted to 8.0 such that the final volume was 1 litre. 
b) TAE buffer (1 OX, pH 8.0) 
lOX TAE was made up using 48.4g Tris-base, l lml acetic acid, 20m1 0.5M EDTA 
and ddH2O. The pH was adjusted to 8.0 and the final volume was 1 litre. 
c) TE buffer (10X, pH 7.4) 
IOX TE buffer was made up of 10mM Tris-Cl (pH 7.4) and 1mM EDTA (pH 8.0) and 
the final pH was adjusted to 7.4. 
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d) ED TA (0. SM, pH 8.0) 
0.5M EDTA (ethylene diamine tetra-acetic acid) was made by dissolving 186. l g of 
disodium ethylene diamine tetra-acetate into 1 litre of water. The pH was adjusted to 
8.0 with NaOH. 
e) Phosphate Buffered Saline (PBS) 
1X PBS was made with lOg/1 NaCl, 0.25g/1 KCI, 0.25g/1 KH2PO49 1.43g/1 Na2HPO4 
and distilled water. This solution was autoclaved for sterility. 
ß Ethidium Bromide (5mg/ml) 
One tablet of ethidium bromide, purchased from Sigma-Aldrich, was dissolved in 
20m1 of distilled water to prepare a 5mg/ml stock solution. Ethidium bromide was 
used at a working concentration of 0.5µg/ml. Ethidium bromide stocks were kept 
protected from light. 
g) Bromophenol Blue Loading Buffer 
0.5g of bromophenol blue was dissolved in 50m1 ddH2O. 50m1 of glycerol was then 
added and this was mixed well. 20X Gibco blue (TBS), purchased from Invitrogen, 
was then added drop-wise until the colour stayed blue. 
h) Formamide Loading Buffer 
Loading buffer for single strand conformation polymorphism (SSCP) gels was made 
up of 0.1% xylene cyanol, 0.1% bromophenol blue, 2mM EDTA, OA M NaOH and 
95% formamide. This was stored at -20°C. 
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i) SSCP Fixer 
Fixer for SSCP gels was made up of 10% absolute ethanol, 0.5% acetic acid and 
ddH2O. 
j) SSCP Developer 
Developer for SSCP gels was made up of 1.5% NaOH, 0.15% formaldehyde and 
ddH2O. 
k) Sodium Carbonate 
0.75% Na2CO3 and ddH2O were mixed to produce sodium carbonate solution used in 
SSCP gel developing. 
1) Silver Nitrate (0.1 %) 
Ig of silver nitrate was dissolved in 1 litre of water to make 0.1% silver nitrate 
solution that was kept protected from light. 
m) DNA Lysis Buffer 
DNA lysis buffer was made from 100mM Tris. HCl (pH 8.5), 5mM EDTA, 0.2% SDS, 
200mM NaCl and 100µg/m1 Proteinase K. 
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2.1.4 Tissue Culture Materials 
a) Tissue Culture Medium 
All tissue culture medium was stored at 4°C and sterility checked before use. 
Dulbeccos Modified Eagles Medium (DMEM) containing 4.5g/1 glucose with L- 
glutamine was purchased from BioWhittaker or Invitrogen. 1X non-essential amino 
acids, supplied by BioWhittaker, were added to the medium before it was used for 
tissue culture. OptiMEM serum free medium was purchased from Invitrogen. 
b) Foetal Calf Serum 
Virus, endotoxin and mycoplasma screened foetal calf serum (FCS) was bought from 
Perbio. This was sterile filtered before use. 
c) Antibiotics 
Initial experiments were carried out with penicillin and streptomycin in tissue culture 
medium to inhibit the growth of bacterial species that may be harmful to cell yield. 
Penicillin was purchased from Britannia Pharmaceuticals and streptomycin supplied 
by Sigma-Aldrich. Penicillin was used at a final concentration of 100U/ml and 
streptomycin at IOOpg/m1 in culture medium. Stock solutions of antibiotics were 
stored at -20°C. 
Fungizone, purchased Invitrogen, was used in tissue culture plates when needed to 
prevent the growth of fungus. This was used at a final concentration of 2µg/m1 in 
growth medium. Fungizone was stored at 4°C. 
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d) Trypsin 
Trypsin was purchased as a sterile 2.5% stock solution from Invitrogen. Trypsin was 
used at a concentration of 0.025% and stored at 4°C for up to a week. 
e) Versene/EDTA 
Versene/EDTA was purchased from VWR. 0.2g EDTA was dissolved in 1 litre of 
PBS (for use at 0.02%), distributed into l Oml aliquots and stored at 4°C until use. 
ß Mycoplasma Testing 
Mrs. Janet White (Institute for Cancer Studies) tested all cell lines for the presence of 
mycoplasma. A PCR-based mycoplasma ELSIA kit purchased from Roche was used 
for testing. All cells tested for this study were found to be free of contamination. 
2.1.5 Western Blotting Materials 
2.1.5.1 Preparation of Standard Western Blotting Solutions 
a)1. SM Tris (pH 8.8) 
1.5M Tris was made by dissolving 187g of Tris-base into 1 litre of ddH2O and the 
final pH was adjusted to 8.8 using HCI. 
b) IM Tris (pH 6.8) 
Dissolving 121g of Tris-base into 1 litre of ddH2O made IM Tris. The final pH was 
adjusted to 6.8 using HCI. 
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c) Lower Stacking Buffer 
Lower buffer for 7.5% western gels was made by dissolving 187g of Tris-base (1.5M) 
and 4g SDS into 1 litre of water. The final pH was adjusted to 8.8 using HCI. 
d) Upper Stacking Buffer 
Upper buffer for 7.5% western gels was made by dissolving 60.5g of Tris-base (0.5M) 
and 4g SDS into 1 litre of water. The final pH was adjusted to 6.8 using HCI. 
e) Protein Lysis Buffer 
IX lysis buffer was made up of 20mM Tris/Acetate pH 7.5,0.27M sucrose, 1mM 
EDTA, 1mM EGTA, 1mM sodium orthovanadate, 10mM sodium beta- 
glycerophosphate, 50mM NaF, 5mM sodium pyrophosphate and 1% (w/v) Triton X- 
100. Just before use the following components were added: 0.1% (v/v) beta- 
Mercaptoethanol, 1µM Microcystin, 0.2mM PMSF and 1X protease cocktail. 
,n 
100X Protease Cocktail 
100X protease cocktail was made up of 5µg/µl leupeptin, 10µg/µ1 pepstain, 5mg/ml 
BSA and ddH2O. This was stored at -20°C. 
g) Phenylmethylsulphonyl Fluoride (PMSF) 
A 10mg/ml solution was prepared by dissolving 100mg PMSF in 10ml isopropanol. 
Aliquots of PMSF were stored at -20°C. 
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h) Protein Loading Buffer 
Protein loading buffer was made up using 2% SDS, 62.5mM Tris, 50% glycerol and 
0.25mg/ml bromophenol blue. Aliquots of buffer were stored at room temperature and 
just prior to use 5% ß-mercaptoethanol was added. 
i) IOX TGS Running Buffer 
lOX TGS was made up of 30g Tris-base, 144g glycine, lOg SDS and the volume 
adjusted to 1 litre with ddH2O. This buffer was stored at room temperature. 
j) IOX TBS and TBS-T 
One litre of lOX TBS was prepared with 24.2g Tris-base, 80g NaCl and ddH2O. The 
pH was adjusted to 7.6 with HCI. This buffer was then diluted to a 1X concentration 
and 0.1 % Tween-20 added before using as a wash buffer. 
k) Transfer Buffer 
Transfer buffer was made of 3.03g Tris-base, 14.4g glycine, 200m1 methanol and the 
volume adjusted to 1 litre with ddH2O. This was stored at 4 °C. 
1) Coomasie Blue Protein Stain and Destain 
0.25% Coomasie brilliant blue was combined with 50% methanol, 10% acetic acid 
and ddH2O for the protein stain. Destain was made from 10% methanol, 10% acetic 
acid and ddH2O. 
m) Isobutanol Saturated Water 
50m1 isobutanol was combined with 200m1 distilled water and stored at room 
temperature. 
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2.1.5.2 Western Blotting Equipment 
a) Coomasie Plus 200 Protein Assay Reagent 
Coomasie Plus reagent for use in protein quantification assays was purchased from 
Perbio. 
b) Protein Marker 
Pre-stained precision plus protein marker was purchased from Bio-Rad. This marker 
was supplied in 30% (v/v) glycerol, 2% SDS, 62.5mM Tris, pH 6.8,50mM DTT, 
5mM EDTA, 0.02% NaN3 and 0.01% bromophenol blue. Marker was stored at -20°C. 
c) Nitrocellulose Membrane 
Hybond ECL nitrocellulose membranes were purchased from Amersham Pharmacia 
Biotech. This is a 100% pure, unsupported nitrocellulose membrane. 
d) Filter Paper 
Extra think 7.5 xl Ocm filter paper for use in transfer was purchased from Bio-Rad. 
e) ECL Detection Kit 
ECL Western blotting detection reagents were purchased from Amersham Pharmacia 
Biotech. This system is a light emitting non-radioactive method for detection of 
immobilised specific antigens, conjugated with horseradish peroxidase-labelled 
antibodies. 
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J) Filin, Developer and Fixer 
13 x 18cm medical X-ray Fujifilm was supplied by GRI. Universal paper developer 
and fixer stocks, supplied by Ilford, were diluted 1 in 10 and 1 in 3, respectively, prior 
to use. 
g) Antibodies 
h , N1 RE II Oncogene 1: 800 86 Rabbit 
hNIRE11 Bethyl Labs Inc. 1: 1000 86 Rabbit 
NBSI Oncogene 1: 800 95 Rabbit 
Phospho-NBSI Cell Signalling 1: 1000 95 Rabbit 
(Ser343) Technology 
Phospho-Chk2 Cell Signalling 1: 800 62 Rabbit 
(Thr68) Technology 
Phospho-Chkl Cell Signalling 1: 1000 58 Rabbit 
(Ser345) Technology 
Actin Sigma-Aldrich 1: 2500 37 Rabbit 
2.1.6 ? Microbiological Materials 
a) LB Broth 
LB broth was made up by suspending 25g LB broth in one litre of deionised water. 
This suspension was autoclaved as described. The LB broth has a pH of 7.0±0.2 at 
25°C. Before use in cultures 100µg/ml of ampicillin was added to LB broth. 
h) Agar Plates 
For solid culture media that could be inoculated on the surface 12-15g of agar and 25g 
of LB broth were suspended in one litre of deionised water. The suspension was 
autoclaved as described. 
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c) Frozen Storage Buffer 
Initially a solution of 10mM potassium acetate (pH 7.5) and 10% glycerol was made. 
To this solution was added 100mM KCI, 45mM MnC12.4H20,10mM CaC12.2H20 and 
3mM HACoCI3. The pH was adjusted to 6.4 using HCI. This buffer was stored at 4°C. 
d) SOB and SOC Medium 
SOB medium was made up from 2% Bacto tryptone, 0.5% Bacto yeast extract, 
10mM NaCl, 2.5mM KCI, 10mM MgC12 and 10mM MgSO4. SOC medium is 
identical to SOB but contains 20mM glucose. 
e) E. coli Strains 
0 RT M- ,11 11 11 TME 
D115a A(lacZYA-argF) U169 deoR Invitrogen 
recA 1 endA 1 hsdR 17 (rk-, Mk) phoA supE44 
X- thi-1 gyrA96 re1A1 
TOPIO F mcrA 0(mrr-hsdRMS-mcrBC) ý 80 Invitrogen 
1acZAM15 AlacX74 recA1 deoR araD139 
A(ara-leu)7697 ga/U ga1K rpsL (StrR) endAI 
nupG 
EZ Competent [F':: TnlO(Tc') proA+B+Iac11ZAM15] recAl QIAGEN 
Cells endAI hsdR17 (rk12 , Mk 12+) 
lacg/nV44 thi-l 
gyrA96 re/A I 
J) Vectors 
The expression vector pcDNA3. IN5-His TOPO TA was supplied by Invitrogen. This 
vector was supplied as IOng/µl plasmid DNA in 50% glycerol, 50mM Tris-HCI (pH 
7.4 at 25°C). ImM EDTA, 2mM DTT, 0.1% Triton X-100,100. tg/ml BSA and 30µM 
phenol red. 
The pDrive cloning vector was supplied by QIAGEN, in a linear form ready for use in 
direct ligation of PCR products. This vector was supplied as 50ng/µl plasmid DNA. 
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ClonTech supplied the pIRESI ro3 expression vector, a circular vector with ampicillin 
and puromycin selective markers. Maps of all the vectors used can be found in 
Appendix I. 
2.1.7 Biological Materials 
a) Human Colorectal Cancer Samples 
Anonymous archival tissue samples from 106 patients with histologically confirmed 
sporadic colorectal cancer were obtained from the tumour bank at the Department of 
Pathology at Sheffield University Medical School. A further collection of 27 right- 
sided colorectal tumours was made from the same resource. For each tumour sample 
obtained the adjacent normal tissue was also provided. This was either normal colon 
tissue or lymph node material. Data provided with samples included a case number 
and information of either `tumour' (T) or `normal' (N), sex and age of the patient and 
staging information (Appendix VI). The samples were available as formalin-fixed 
paraffin-embedded blocks. Blood donor control DNA was acquired from a resource 
obtained by Saeed Rafii (Institute for Cancer Studies). Ethical approval for the use of 
these samples in this study was provided by the South Sheffield Research Ethics 
Committee. 
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h/ Human ('ei! lines 
All cell lines used were of human origin and were adherent cells. Details are provided 
hclo\%: 
II (I -I l t, Colon, carcinoma hMLHI-'-, hPMS2 
(reduced expression) 
SK-UT-I ATCC Uterine, Ieiomyosarcoma hMSH2-/- 
SWW'480 ATCC Colon, adenocarcinoma None 
DL. D-I ATCC Colon, adenocarcinoma hMSH6-/- 
IIEC-I-: k ATCC Endometrial, adenocarcinoma hPMS2-/-, hMLHI 
(reduced expression) 
2774 ATCC Ovarian, adenocarcinoma hMSH2+/- 
S\' 48 . \TCC Colon, adenocarcinoma hMSH6-'-, hMLH- 
methylation silenced 
expression 
ýI R('5V A CRC Cell Lung, fibroblasts None 
Repository 
LS 1741' A CC Colon, adenocarcinoma hMSH6-1- 
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2.2 METHODS 
2.2.1 Tissue Sample Preparation and microdissection 
Microdissection was needed for tumour (and normal) tissue when less than 80% of the 
sample originated from the tumour (or normal) population. Sections of 5µm were 
provided on uncoated slides. The paraffin wax was removed from the slides in two 
washes of xylene. The sample was then re-hydrated using consecutive washes in 
100% ethanol, 95% ethanol, 70% ethanol and distilled water. The required tissue was 
identified using an H&E stained slide and then microdissected out using a scalpel. The 
tissue was transferred to a 1.5m1 microcentrifuge tube along with 25µ1 Tris-EDTA 
buffer. Before DNA extraction, these microdissected samples were centrifuged at full 
speed for 10 minutes to pellet the tissue and the Tris-EDTA buffer was removed. 
Those samples that did not undergo microdissection had to be xylene treated to 
remove the paraffin wax. Sections cut into microcentrifuge tubes were treated with 
12001il xylene and vortexed vigorously. The sample was centrifuged for five minutes 
on full speed at room temperature and the supernatant discarded. The pellet was 
washed with 1200µ1 100% ethanol and vortexed. The sample was again centrifuged at 
room temperature at full speed for five minutes and supernatant discarded. The 
ethanol wash was repeated once and the pellet was then air-dried at 37°C for 10-15 
minutes. 
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2.2.2 DNA Extraction 
a) DNA Extraction from Human Tissue 
DNA was extracted from tissue samples using a QIAamp DNA mini-kit. Following 
xylene treatment or microdissection the tissues were lysed in 360µl tissue lysis buffer 
and 400µg proteinase K and incubated at 56°C overnight in an orbital shaker. 
Following this, 400µ1 lysis buffer was added; samples were vortexed for 15 seconds 
and then incubated at 70°C for 10 minutes. The tubes were then briefly centrifuged 
and 40011 ethanol was added. Samples were again vortexed for 15 seconds and briefly 
centrifuged to remove drops from the lid of the tube. The samples were then applied to 
QIAamp spin columns and the DNA was adsorbed onto the silica-gel membrane 
during a centrifuge step of 8000rpm for one minute. After disposal of the filtrate the 
column was then washed with 500µ1 wash buffer to improve the purity of the eluted 
DNA and centrifuged at 8000rpm for one minute. The filtrate was again discarded, the 
column washed with 500µ1 of a second wash buffer to remove residual contaminants 
and then centrifuged at full speed for three minutes. The column was placed in a clean 
1.5m1 micro-centrifuge tube and 200µ1 elution buffer (10mM Tris-Cl, 0.5mM EDTA; 
pH 9.0) was added to the column. The column was incubated at room temperature for 
five minutes and then centrifuged at 8000rpm for one minute. This elution step was 
repeated twice to increase yield of the DNA so that DNA was eluted in a final volume 
of 600pl elution buffer. 
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b) DNA Extraction from Human Cell Lines 
DNA was extracted from adherent cell lines after removing the medium and washing 
cells twice with PBS. To each 10cm tissue culture dish 800µ1 DNA lysis buffer was 
added, the plate was rocked and left for 2 minutes. A cell scraper was used to scrape 
off the cells, which were then collected with a pipette and placed in a 15ml centrifuge 
tube. 200µg proteinase K was added to the tube, mixed and tubes were incubated in a 
37°C water bath overnight. An equal volume of isopropanol was then added to the 
tube and mixed by inverting. DNA was recovered by lifting the aggregated precipitate 
from the solution using a pipette. This was placed in a 1.5ml microcentrifuge tube and 
the DNA pellet was allowed to air-dry. The pellet was re-suspended in ddH2O. 
2.2.3 Microsatellite Analysis 
Matched normal and tumour DNA were analysed with the Bethesda Consensus panel 
of microsatellites (Boland et al., 1998). These markers included three mononucleotide 
(BAT25, BAT26, BAT40), six (CA) dinucleotide (MFD15, APC, D2S123, D18S69, 
D18S58 and D10S197) and one tetranucleotide (MYCL1) microsatellites. 
Forward primers were labelled with infrared dye (IRD-700 or IRD-800). PCR 
amplification was performed with 40ng purified genomic DNA, 2X PCR master mix 
and 1-2pmoles of each primer. PCR reactions were carried out in a final volume of 
l0µ1 and subjected to 40 cycles of amplification in a Primus 96+ thermocycler. PCR 
products were analysed on a LI-COR 4200 automated sequencer. PCR profiles and 
primer sequences for each microsatellite marker are summarised in Appendix II. 
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2.2.4 PCR Amplification 
Normally PCR amplifications were carried out in a total volume of 20µ1 containing at 
least 40ng of extracted genomic DNA or 20ng cDNA, 10µ1 2X PCR master mix and 
6-10pmol of each primer. PCR reactions were subject to the following cycling 
programme: 1 cycle of 95°C, 3 minutes; 35-40 cycles of 94°C for 30 seconds, 25-40 
seconds at the optimally determined annealing temperature for each primer pair (see 
Appendix II), 72°C for 1 minute per 600bp and 1 cycle of 72°C, 5 minutes. Reactions 
were maintained at 4°C after cycling and then stored at -20°C until use. Primer 
sequences and annealing temperatures used in PCR are reported in Appendix II. 
For PCR reactions where a more accurate Taq polymerase was required the 
AccuPrime Taq DNA polymerase system was used. This system improves PCR 
specificity and improves the fidelity of Taq by 2-fold. PCR amplifications with this 
system were carried out in a total volume of 25µ1 containing at least 40ng of genomic 
DNA or 20ng cDNA, 2.5pl lOX AccuPrime buffer I (for small genomic DNA 
<200bp, plasmid or cDNA) or buffer II (for genomic DNA 200bp-4kb), 5pmol each 
primer and O. 5µ1 AccuPrime Taq DNA polymerase. PCR reactions were subject to the 
following cycling programme: 1 cycle 94°C, 2 minutes; 30-35 cycles of 94°C for 30 
seconds, 30 seconds at 55-60°C, 68°C for 1 minute per kb. Reactions were maintained 
at 4°C after cycling and then stored at -20°C until use. 
To create blunt-ended PCR products (i. e. with no A-overhang) 2.5U of Pfu was added 
to PCR products amplified as above. The PCR reaction was then run for 10 more 
cycles to fill in the DNA ends. 
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2.2.5 Agarose Gel Electrophoresis 
Electrophoresis is the movement of charged molecules through a matrix by an electric 
field. The mobility of the molecule is dependent on the strength of the electric field, 
the size and shape of the molecule and the net charge of the molecule. 
Agarose electrophoresis gels, stained with ethidium bromide, were used to separate 
and visualise DNA and RNA products. 0.8-2% agarose gels were used to analyse PCR 
or RT-PCR products. 
For a 1% agarose gel Ig of agarose was weighed out and 100ml of IX TAE was 
added. The solution was melted in a microwave in order to dissolve the agarose and 
the solution was then left to cool to -60°C. At this point 0.5pg/ml ethidium bromide 
was added and the gel was poured into the gel tray. After the gel had solidified, IX 
TAE running buffer was poured into the gel box, 0.5µg/ml ethidium bromide was 
added to the running buffer, and the comb was removed. Amplified products were 
mixed with bromophenol blue loading dye and then loaded, alongside a DNA size 
ladder, into the wells. Gels were run at 100V for 30-60 minutes, depending on 
separation needed. The gels were visualised on an UV transilluminator. 
2.2.6 Clean-up of PCR Products 
A QlAquick PCR purification kit was used for direct purification of PCR products 
from amplification reactions. A QlAquick gel extraction kit was used for extraction of 
DNA fragments from standard agarose gels. 
In PCR purification, to allow efficient binding of PCR products to the column 5 
volumes of binding buffer were added to one volume of PCR reaction. The sample 
was then applied to a silica-membrane spin column and centrifuged at full speed for 
one minute to allow adsorption of DNA to the membrane. The flow-through, 
containing contaminants such as unwanted primers, enzymes and unincorporated 
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nucleotides, was discarded and salts were removed from the column by adding 750µl 
wash buffer and centrifuging the column for one minute at full speed. The flow- 
through was discarded and residual ethanol was removed in an additional one minute 
centrifugation step. The column was then placed in a clean microcentrifuge tube and 
DNA was eluted with 50µ1 elution buffer (10mM Tris-Cl, pH 8.5) in a one minute 
centrifugation. 
During gel extraction, the required DNA fragment was excised from the agarose gel 
with a clean, sharp scalpel. The gel slice was weighed and 3 volumes of solubilisation 
buffer were added to one volume of gel. The mixture was incubated at 50°C for 10 
minutes to release the DNA from the agarose and one gel volume of isopropanol was 
added to the tube. The sample was then applied to a spin column and centrifuged at 
full speed for one minute to allow adsorption of the DNA to the membrane. 
The column flow-through was discarded and a further 5001i1 solubilisation buffer was 
added to the column. The column was centrifuged at full speed for one minute to 
remove any traces of agarose. The column was washed with 750µ1 wash buffer in a 
one minute centrifugation step to remove contaminating salts. The flow-through was 
discarded and residual ethanol from the wash buffer was removed by placing the 
column in a clean microcentrifuge tube and centrifuging at full speed for a further 
minute. DNA was eluted from the column in 50µ1 elution buffer (10mM Tris-Cl, pH 
8.5). 
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2.2.7 Single strand conformation polymorphism (SSCP) gels 
The principle of the SSCP method is based on the fact that the electrophoretic 
mobility of nucleic acids in non-denaturing gels is sensitive to both size and shape. 
Unlike double-stranded DNA, single-stranded DNA is flexible and will adopt a 
conformation determined by intramolecular interactions and base stacking that is 
uniquely dependent on composition (Orita et al., 1989). This conformation can be 
affected when even a single base is changed. Conformational changes can be detected 
as alterations in the electrophoretic mobility of the single-stranded DNA on a non- 
denaturing polyacrylamide gel. SSCP is a simple and sensitive method but it does not 
reveal the nature or position of sequence changes. 
a) Casting and Running of SSCP Gels 
10% and 12% SSCP gels were made up according to Table 2.2.7.1 below. The gels 
were poured between vertical glass plates and left to set for -1 hour. Prior to loading 
of samples, gels were placed at 4°C to cool for 15 minutes. 
Table 2.2.7.1. Composition of SSCP gels 
30%º Acrylogel 20ml 24ml 
IX TBE 6m1 6ml 
ddH2O 34ml 30ml 
25% APS 160µl 160µl 
TEMED 12µ1 12µl 
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1-2µl of amplified DNA was mixed with denaturing formamide loading dye to a final 
volume of 10µl. The samples were denatured to single-stranded DNA for 5 minutes at 
95°C and then placed on ice for one minute before being loaded onto a 10-12% 
polyacrylamide gel. Samples were electrophoresed at 17°C in 1X TBE running buffer. 
Appendix III shows the SSCP running profiles for each of the exons analysed. 
b) Silver Staining of SSCP Gels 
After electrophoresis SSCP gels were placed in a plastic container for staining. Fixer 
solution was added and the gel shaken for 10 minutes. The fixer solution was then 
discarded and the gel was washed with ddH2O. Gels were then covered with 0.1% 
silver nitrate and shaken for 20 minutes. Silver nitrate solution was then removed and 
the gel was washed twice with ddH2O. SSCP gels were developed in 500ml fresh 
developer shaking for 25-30 minutes. Once clear bands were apparent on the gel the 
developer was discarded and 0.75% sodium carbonate solution was added to cover the 
gel. The gel was shaken for a further 2-3 minutes then the sodium carbonate solution 
was discarded. The gel was then sealed in a plastic bag and analysed on a light box. 
2.2.8 Sequencing 
Samples were usually subject to cycle sequencing using a SequiTherm EXCEL II 
DNA Sequencing Kit-LC for 25-41 cm gels. All reagents were thawed on ice and 
vortexed before use to ensure uniform distribution of components. The following 
components were added to a microcentrifuge tube to make the premix: 7.2µl 3.5X 
sequencing buffer, 2pmoles each IRD-labelled primer, 2-3µl amplified DNA template, 
5U DNA polymerase and deionised water to 17µl. Four lanes of a 96-well plate were 
labelled A, C, G and T and 2µ1 of the termination mixes for A, C, G or T containing 
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45µM each of dATP, dCTP, dTTP and 7-deaza-dGTP along with the specific ddNTP, 
were placed in the appropriate well. On ice, 4µl of the premix was added to each of 
the four wells of termination mix and mixed by pipetting. Each reaction was overlaid 
with wax and the reactions then underwent the following cycling: 1 cycle of 95°C, 5 
minutes; 30-40 cycles of 95°C for 30 seconds, annealing temperature (see Appendix 
II) for 15 seconds, 70°C for 1 minute. Once cycling was complete, 3. t1 of formamide 
loading buffer (95% (v/v) formamide, 10mM EDTA, 0.1% basic fuchsin, 0.01% 
bromophenol blue, pH 9.0) was added to each reaction ready for gel electrophoresis. 
A second technique for sequencing of difficult templates, especially long templates 
(>750bp) and templates with mononucleotide runs in them, was carried out using the 
Amersham Thermo Sequenase Primer Cycle Sequencing kit. For each template to be 
sequenced the following master mix was prepared: 2-3µl amplified template DNA, 
2pmoles each IRD-labelled primer and distilled water to 13µl. The components of the 
master mix were mixed by gentle vortexing. Four wells of a 96-well plate were 
labelled A, C, G and T for each termination reagent. The A, C, G and T reagents 
contained 40mM Tris-HCI pH 9.5,6mM MgC12,0.04% Tween-20,0.04% Triton X- 
100,0.08mM 2-mercaptoethanol, 1.67 units/µl DNA polymerase with 0.00028 
units/µl Thermoplasma acidophilum inorganic pyrophosphatase, 0.4mM dATP, 
0.4mM dCTP, 0.4mM 7-deaza-dGTP, 0.4mM dTTP and 1.33µM of the specific 
dideoxynucleotide terminator. Into each A well 2µl of the A reagent was added and 
this was repeated for C, G and T. Into each of the four labelled wells 2µl of the master 
mix was added and mixed by pipetting. Each reaction was overlaid with wax and the 
reactions underwent the following cycling: 1 cycle of 95°C, 2 minutes; 30-35 cycles 
of 95°C 30 seconds, annealing temperature (see Appendix II) 30 seconds, 72°C for 1 
minute. Once cycling was complete, 4µl of formamide loading buffer was added to 
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each reaction ready for gel electrophoresis. 
Prior to loading samples onto the gel each sample was heated to 95°C for 3 minutes. 
Dr. Ian Brock (Institute for Cancer Studies) loaded 1µl of each sample into separate 
lanes of the sequencing gel and reactions were run in a LI-COR automated long-read 
sequencer. Sequence data was analysed using the Sequencher computer software. 
2.2.9 RNA Extraction 
RNA was extracted from cells using an RNeasy mini kit. Media was removed from 
the plates of cells and cells were washed with 10ml PBS. The PBS was discarded and 
samples were lysed in the presence of a highly denaturing guanidine isothiocyanate- 
containing buffer which inactivated RNases and ensured isolation of intact RNA. 
Using a cell scraper cells were gathered together and collected into a 1.5m1 
microcentrifuge tube. The lysate was vortexed until no clumps of cells were visible. 
The lysate was pipetted onto a QlAshredder column sitting in a 2ml collection tube, 
which was centrifuged at full speed for 2 minutes to homogenise the lysate. The flow- 
through was collected and one volume of 70% ethanol was added to this to provide 
the appropriate binding conditions for RNA. 
Up to 700µ1 of the sample was then loaded onto the silica-gel membrane of a mini- 
spin column sitting in a 2m1 collection tube. The column was centrifuged for 15 
seconds at 10000rpm to allow binding of the RNA and flow-through was discarded. 
Successive aliquots of the sample were added to the column and centrifuged as above, 
until all sample had been through the column. Contaminants were removed from the 
column in three consecutive steps with wash buffers and centrifugation at 10000rpm 
for 15 seconds. To eliminate any wash buffer carryover the column was placed in a 
new collection tube and this was centrifuged at full speed for 2 minutes. The column 
was then placed in a new 1.5m1 collection tube and 50µl RNase-free water was 
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pipetted directly onto the membrane. The column was centrifuged for one minute at 
10000rpm to elute RNA. Samples were stored at -20°C. 
2.2.10 RT-PCR 
RNA is prone to degradation and so RNase-free plastics, RNase-free water and filter 
tips were used and gloves were worn at all times during RT-PCR set-up. 
RT-PCR amplifications were carried out in a total volume of 25µl containing 500ng of 
extracted RNA, O. 5µ1 reverse transcriptase blend (includes RNase inhibitor), 12.5µl 
2X RT-PCR master mix and 1 Opmol of each primer. RT-PCRs were carried out using 
the following profile: 1 cycle of 47°C for 30 minutes for first strand synthesis; 1 cycle 
of 94°C for 2 minutes for RTase inactivation and initial denaturation; 40 cycles of 
94°C 20 seconds, 54-60°C 30 seconds, 72°C 1 minute. RT-PCRs finished with a final 
extension of 72°C for 5 minutes. 
2.2.11 cDNA Synthesis from Total Cellular RNA 
When cDNA copies of the total RNA were required Superscript RT was used to 
reverse transcribe the RNA. RNA was prepared at 2µg in ddH2O to a total volume of 
9.5µl in a reaction tube. In a second tube, a master mix was made up containing lµl 
0.5µg/µ1 oligo-(dT)12.18 primer, 0.5µl RNA guard (31600 units/ml), 4p1 5X buffer 
containing 250mM Tris-HCI, 375mM KCI and 15mM MgC12,2µl O. 1M DTT, 2µl 
dNTP mix (10mM each) and lpl Superscript-RT (200U/µ1). The master mix was 
vortexed and to this 10.5µ1 volume the 9.591 RNA was added and mixed. The tube 
was incubated at room temperature for 10 minutes then at 44°C for 2 hours. 
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2.2.12 Tissue Culture 
Tissue culture was carried out in sterile conditions in a containment 2 laboratory 
cabinet. All cell lines were sustained in a 37°C, 5% CO2 humidified incubator. 
2.2.12.1 Passage 
Cells were passaged when 80-100% confluent. This was determined by visualising 
cells using a light microscope or indicated by a colour change of medium from red to 
yellow. This colour change was caused by a decrease in pH in the growth medium. 
Cells were washed once with PBS to remove proteins and divalent cations that may 
inhibit the action of the trypsin. Cells were harvested using trypsin/versene. Plates of 
cells were placed in an incubator for 5 minutes and then cells were dislodged by 
gently tapping the side of the plate. Cells were re-suspended in a small amount of 
medium by pipetting with a 5ml or 10ml pipette. Cells were split and re-seeded by 
adding the desired amount of re-suspended cells to fresh medium in a plate and 
returning the plate to a 37°C incubator. 
2.2.12.2 Cryopreservation 
Excess cell stocks could be frozen for storage. Medium was removed from plates that 
were 60-80% confluent and the cells were washed with PBS. Cells were harvested in 
medium following trypsin/versene treatment and centrifuged at 1300rpm for 3 
minutes. A mixture of 10% DMSO in medium was prepared and the cell pellet was re- 
suspended in 2m1 of this mixture. The cell suspension was aliquoted into 1.2m1 
cryovials and these were placed at -80°C for storage. 
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2.2.12.3 Thawing of Cells 
Cryovials were removed from the -80°C freezer and placed in 37°C water to thaw the 
cells rapidly. Rapid thawing minimises the toxic effect of DMSO on cells. 
2.2.12.4. Preparation of Dialysed Serum 
Small molecules and ions present in foetal calf serum might interfere with dose 
response experiments and so they need to be removed. This can be done by placing 
foetal calf serum in dialysis membranes and surrounding the membranes with 1X 
PBS. The dialysis membranes are semi-permeable and allow molecules under 12- 
14000 Daltons to pass out into the surrounding buffer. This surrounding PBS buffer 
was changed five times to achieve a dilution factor of 105. The resulting dialysed 
foetal calf serum was filter sterilised before use. 
2.2.13 Microbiological Methods 
2.2.13.1 Preparation of Competent Cells 
New stocks of competent E. coli could be prepared by streaking an agar plate with 
DH5a and leaving to grow in a 37°C incubator overnight. Twenty 2-3mm diameter 
colonies were picked from the agar plate and inoculated into a2 litre flask containing 
200m1 SOB medium (1 colony per 10ml culture medium; culture volume to flask 
volume ratio of 1: 10). The inoculated medium was incubated in a 37°C shaking 
incubator until the cell density was 6-9 x 107 viable cells/ml (-3-4 hours). The culture 
was aliquoted into 50ml centrifuge tubes and chilled on ice for 10-15 minutes. Cells 
were then pelleted by centrifugation at 2000-3000rpm for 15 minutes at 4°C. The cell 
pellet was thoroughly drained and cells were re-suspended in 66m1(1/3 of the culture 
volume) of frozen storage buffer (FSB) by gently vortexing. Cells were incubated on 
ice for 10-15 minutes and again pelleted by centrifugation at 2000-3000rpm for 15 
67 
Materials and Methods 
minutes at 4°C. The cell pellet was drained and cells re-suspended in 16ml (1/12.5 of 
the culture volume) FSB. A 3.5% aliquot of DMSO was added to the centre of the cell 
suspension and tubes were swirled for 5-10 seconds. Tubes were incubated on ice for 
5 minutes. A second 3.5% aliquot of DMSO was added as above and tubes were 
incubated on ice for 10-15 minutes. 210µ1 aliquots were placed in chilled 1.5m1 
microcentrifuge tubes and cells were flash frozen by placing the tubes in dry ice for 
several minutes. Competent cells were stored at -80°C. 
2.2.13.2 Preparation of Agar Plates 
Before pouring, solid agar stocks were melted in a microwave and 100µg/ml of 
ampicillin was added after cooling. About 10ml of agar was then poured onto bacterial 
culture dishes. The lids of the dishes were replaced while the agar set, then the lids 
were removed and plates were placed in a containment hood with airflow to allow the 
plates to dry. 
2.2.13.3 Preparation of SOB and SOC Medium 
During preparation of SOB or SOC, 2% Bacto-tryptone, 0.5% Bacto-yeast extract, 
10mM NaCl and 2.5mM KCl were combined in 18Mfl water. This was autoclaved for 
15 minutes at 121°C. Just prior to use 10mM MgCI2,10mM MgSO4 and 20mM 
glucose (for SOC only) were filter sterilised through a O. 22µ membrane and combined 
with the medium. The final pH of the SOC medium was 6.8-7.0 
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2.2.13.4 PCR Cloning 
The amount of PCR product used in the ligation reaction depends on the size of the 
PCR product and molar ratio of PCR product DNA to vector DNA. The amount 
required can be calculated using the following equation: 
ng PCR product required = ng of vector used x PCR product size (bp) x molar ratio 
Vector size (bp) 
The QIAGEN and TOPO TA cloning kits take advantage of the 3' A-overhang 
generated at the end of each PCR product by non-proof-reading Taq polymerase. The 
cloning vectors are supplied in linear form with a single 3' T overhang so that they 
specifically and efficiently hybridise with the PCR inserts. The TOPO vector also has 
topoisomerase-I covalently bound to the vector to prevent recircularisation and to 
provide the enzymatic activity for ligation. 
The pIRESpuro3 vector was supplied in circular form and therefore had to be cut within 
the multiple cloning site with a suitable restriction enzyme, usually EcoR V, to create a 
site for insertion of PCR product. PCR products were ligated to the digested 
pIRESparo3 vector in a blunt-end ligation reaction containing PCR product, 5ng vector, 
I unit of T4 DNA ligase and 1X T4 DNA ligase buffer (50mM Tris-HCI, 10mM 
MgC12,10mM DTT, 1mM ATP, 25µg/ml BSA pH 7.5). Ligation reactions were 
carried out at room temperature overnight. DH5oc chemically competent cells then 
were transformed with 3-5µl of this ligation mixture. 
PCR products to be cloned for sequencing were cloned using the QIAGEN PCR 
cloning kit. For each cloning reaction the subsequent components were combined in 
the following order in a 10µl reaction: 50ng pDrive cloning vector, 13-26ng PCR 
product, 5µl 2X ligation master mix containing all reagents and cofactors required for 
ligation and ddH2O. The ligation reaction was briefly mixed and incubated for 1 hour 
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at 4°C. 3-5µl of the ligation mixture was taken for transforming into EZ or DH5a 
chemically competent cells. 
The TOPO cloning kit was used to clone PCR products into the pcDNA3.1/V5-His- 
TOPO expression vector. The following components were combined in each 5 t1 
cloning reaction: 1 t1 salt solution (200mM NaCl, 10mM MgC12), 5ng pcDNA3.1/V5- 
His-TOPO and 5-lOng PCR product. The reaction mixture was mixed gently and 
incubated for 5 minutes at room temperature. 3-5 t1 of the reaction mixture was taken 
for transformation of TOP 10 or DH5a chemically competent cells. 
2.2.13.5 Transforming Chemically Competent Cells 
Chemically competent cells were removed from their -80°C store and thawed on ice. 
3-5µl of the ligation-reaction mixture was added to a 50µl vial of cells and mixed by 
gently flicking the tube. The vials were incubated on ice for 15-30 minutes and cells 
were then heat-shocked in a 37°C (TOPO or EZ) or 42°C (DH5(x) water bath for 90 
seconds. Tubes were returned to ice for 2 minutes and 950µl SOC medium was added. 
Since SOC is such a rich medium this step of the protocol was carried out near a flame 
to minimise contamination. Vials were then incubated in a shaking incubator at 37°C, 
225rpm for 30-60 minutes to allow expression of the ampicillin resistance marker. 
100-15011 transformation mixture was spread onto LB-agar plates containing 
100µg/ml ampicillin. These agar plates were incubated overnight in a 37°C incubator 
to allow colony formation. 
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2.2.13.6 Preparation of Overnight Cultures 
Clones were picked from agar plates following overnight incubation. To reduce the 
risk of contamination this procedure was carried out near a flame. Aliquots of 5ml LB 
medium plus 100µg/ml ampicillin were placed in universal tubes. A pipette tip was 
used to pick a clone from the agar plate and the tip was dropped in the LB medium. 
The cap of the universal tube was replaced but left loose to ensure enough air was 
present for bacterial culture growth. Universal tubes were incubated overnight in a 
shaking incubator at 37°C, 225rpm. 
2.2.13.7 Purification ofPlasmid DNA 
The QlAprep miniprep kit was used for purification of high-copy plasmid DNA from 
overnight cultures of E. coli in LB medium. The overnight culture was centrifuged at 
3000rpm for 10 minutes to pellet the bacterial cells and the LB medium was removed. 
The pellet was re-suspended in 250µ1 a buffer containing RNase A and transferred to 
a 1.5ml microcentrifuge tube. To lyse the bacterial cell wall and release the plasmid 
DNA 250µl of an alkaline lysis buffer was added and samples were mixed by 
inverting the tube 4-6 times. To neutralise the lysate and adjust to high-salt binding 
conditions 350µl neutralisation buffer was added and mixed by immediately inverting 
the tube 4-6 times. The tubes were then centrifuged for 10 minutes at maximum speed 
to pellet the unwanted components of the reaction. The supernatant was applied to a 
QlAprep silica-membrane column by decanting and plasmid DNA was selectively 
adsorbed to the membrane in high-salt conditions by centrifuging for 1 minute at 
maximum speed. The flow-through, containing RNA, cellular proteins and 
metabolites, was then discarded. 
When endA+ strains of E. coli were being used the column was washed with 500µ1 of 
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a wash buffer that removed any trace nuclease activity that may degrade the plasmid. 
The flow-through was discarded and salts were removed from the column by washing 
with 750µ1 of a second wash buffer and centrifuging for 1 minute at maximum speed. 
The flow-through was again discarded and the columns were centrifuged for a further 
minute at maximum speed to remove any residual wash buffer. The QlAprep column 
was placed in a clean 1.5m1 microcentrifuge tube and 50µ1 elution buffer (10mM Tris- 
Cl, pH 8.5) was added to the centre of the column. After standing at room temperature 
for 1 minute the column was centrifuged for 1 minute at full speed to elute the plasmid 
DNA in low salt. The DNA was stored at 4°C until use. 
2.2.14 Restriction Digestion 
Restriction digests were carried out by combining the following in a 0.5m1 
microcentrifuge tube: 1X restriction buffer specific for the enzyme, 1-2U restriction 
enzyme, 0.1 µg/µ1 Bovine Serum Albumin (BSA) and 0.5-1.5µg DNA. The tubes were 
then placed at a temperature specific to the restriction enzyme (usually 37°C) for 1-2 
hours. The restriction digestion products were analysed on an agarose electrophoresis 
gel. 
2.2.15 Stable Transfection of Adherent Cells 
Cultured cukaryotic cells were transfected with plasmid DNA containing the gene of 
interest for functional studies. Table 2.2.15.1 below shows new cell lines that were 
produced and the constructs that were transfected in. Further details of mutant MRE11 
constructs are provided in Chapter 4 and details of the SCneo recombination reporter 
are shown in Appendix IV. 
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2.2.15.1 Transfection with Lipofectamine 
The day before transfection, 105 cells were seeded in 6 well dishes with 2ml of 
complete growth medium (DMEM) with serum. The cells were incubated for 18-24 
hours at 37°C in a CO2 incubator to become 50-80% confluent. The transfection 
efficiency is sensitive to culture confluence therefore the seeding protocol was exactly 
the same from experiment to experiment. 
For each well in the transfection 2µg DNA was diluted into 100µl of medium without 
serum (Opti-MEM). For each well of the transfection 5µg LipofectAMINE reagent 
was diluted into 100µl Opti-MEM medium. The diluted DNA and diluted 
LipofectAMINE reagent were combined, mixed gently and incubated at room 
temperature for 30-45 minutes to allow DNA-liposome complexes to form. 
Cells were taken from the incubator, medium was removed, the cells were rinsed with 
PBS and 450µ1 Opti-MEM medium was added. For each transfection 150µl Opti- 
MEM was added to the tube containing the complexes. Tubes were mixed gently and 
the diluted complex solution was placed on cells so that the transfection volume was 
800µl. The cells were incubated for 18-24 hours at 37°C in a CO2 incubator. 
Following incubation, 800µ1 of DMEM growth medium with 20% serum was added 
to cells without removing the transfection mixture. The cells were incubated at 37°C 
in a CO2 incubator for a further 18-24 hours. 
For continued cell growth following this incubation the medium was replaced with 
DMEM medium with 10% serum and cells were incubated at 37°C in a C02 incubator 
for 48 hours. 
To select for stable expression of the transfected DNA, cells were plated in medium 
containing the selective agent expressed by the vector. Cells were then incubated at 
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37°C in a CO2 incubator until colonies formed. Single colonies were isolated and 
grown out in selective agent on 10cm tissue culture dishes. 
2.2.15.2 Electroporation 
2-3x106 cells were plated on 10cm tissue culture plates and allowed to grow for 2-3 
days. Cells were trypsinised, counted and 1.5x106 cells/ml were re-suspended in PBS. 
To 0.75m1 of the cell suspension 15ng SCneo plasmid was added and this mixture was 
placed in a 0.4cm cuvette on ice for 10 minutes. Cell suspensions were electroporated 
at 1kV/cm, 960µF then placed on ice for 10 minutes before being plated out on 
several 10cm dishes in complete medium. To select for cells carrying the SCneo 
plasmid hygromycin was added to the medium after 48 hours, to a final concentration 
of 0.1 mM. Hygromycin resistant (hygR) colonies were isolated and expanded from 
each cell line. 
To identify strains containing a single copy of SCneo, Southern blotting was carried 
out on 10µg genomic DNA isolated from each clone. The 1.1kb XhoI-HindIII 
fragment radio-labelled with [a 32P]dCTP was used as a probe, and detection was 
performed by autoradiography. Southern blotting work was carried out by Mr. A. 
Mohindra (Institute for Cancer Studies). 
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Table 2.2.15.1. Cell lines created by stable transfection of new constructs. 
SVV 480/ 
SN3 
SMIh 
SW480 
S W480/ 
SN3 
SCneoa SCneo Reporter 0.1 mM Hygromycin 
SCneo + SCneo Reporter 
MRE 11 + pIRESp°r°3 
314de1345` 
0.1 mM Hygromycin 
+ 1. tg/ml puromycin 
HCTI 16/ HCTI 16 SCneo SCneo Reporter 0.1mM Hygromycin 
HN5 
'Details of the SCneo construct are provided in Appendix IV. 
'Two independent SM I clones (SM 1.3 and SM 1.6) were created. 
`For more information of mutant MRE II constructs see Chapter 4. 
2.2.16 Growth Assay 
To estimate the growth rate of cell lines 10 plates of 5x 104 cells were plated on 10cm 
dishes. One plate of cells was trypsinised and counted every 1-2 days and cell 
numbers were plotted against time. 
2.2.17 Toxicit assay 
Cytotoxic responses to various agents were measured to determine differences 
between transfected and parental cell lines. Unless otherwise stated, toxicity assays 
were carried out in medium supplemented with dialysed serum (to remove exogenous 
sources of deoxynucleosides). The cytotoxic agents were prepared by dissolving them 
in dialysed medium. Plating efficiency of each cell line was calculated by dividing the 
number of colonies at dose zero by the number of cells plated. Table 2.2.17.1 shows 
the effect of each toxic agent on the cell. 
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Table 2.2.17.1. Mode of action of each cytotoxic agent used. 
cells accumulate in S-phase 
N MC Creates DNA interstrand cross links 
Hvdroxyurea Inhibits ribonucleotide reductase resulting in replication 
fork stall and S-phase arrest 
Camptothecin Creates replication-specific double strand breaks 
Ionising Radiation Creates global single and double strand breaks 
2.2.17.1 Thvmidine Toxicity Assay 
Duplicate plates of 500 cells were plated in 10cm tissue culture dishes and treated 
with varying concentrations of thymidine (0 - 4mM). Plates were incubated at 37°C, 
5% CO2 for 14 days to allow for colony formation. Cells were then stained with 0.4% 
methylene blue/50% methanol and colonies containing >50 cells were scored. The 
surviving fraction was determined by dividing the average number of colonies at each 
dose by the average number of colonies on the control plates (dose 0mM). This 
number was then divided by the plating efficiency to correct for inter-experiment 
differences. 
2.2.17 .2 
Mitomvcin C (MMC) Toxicity Assay 
For doses of less than or equal to 30nM MMC, 200 cells were plated in duplicate in 
each well of 6-well dishes. For doses >30nM MMC, 200 and 2000 cells were plated in 
each well of 6-well dishes. Cells were treated with varying doses of MMC from 0- 
100nM and plates were incubated at 37°C, 5% CO2 for 10-12 days to allow for colony 
formation. Cells were stained, scored and the surviving fraction calculated as 
described above. 
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2.2.17.3 Hydroxyurea (HU) Toxicity Assay 
Duplicate plates of 500 cells were plated in 10cm tissue culture dishes and treated 
with varying concentrations of HU (0 - 500µM). Plates were incubated at 37°C, 5% 
CO2 for 14 days to allow for colony formation. Cells were stained, scored and the 
surviving fraction calculated as described above. 
2.2.17.4 Camptothecin (CPT) Toxicity Assay 
For zero doses duplicate plates of 200 cells were plated on 6cm tissue culture dishes. 
For all other doses 200 and 2000 cells were plated on 6cm dishes. Cells were treated 
with varying doses of CPT from 0- 40nM and plates were incubated at 37°C, 5% CO2 
for 12-14 days to allow for colony formation. Cells were stained, scored and the 
surviving fraction calculated as described above. 
2.2.17.5 Ionising Radiation (IR) Toxicity Assay 
Cells were grown up on 10cm tissue culture dishes before being trypsinised and re- 
suspended at 5x 105 cells/ml. Seven 2m1 aliquots of these cells were placed in 15ml 
tubes and put on ice. The seven aliquots represented seven doses: 0,1,2,5,6,8 and 
10 gray gamma radiation. Cells were irradiated on ice in suspension and then diluted 
so that 500 cells were plated out on 10cm dishes in medium supplemented with 10% 
(non-dialysed) foetal calf serum. Plates were incubated at 37°C, 5% CO2 for 14 days 
to allow for colony formation. Cells were stained, scored and the surviving fraction 
calculated as described above. 
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2.2.18 Recombination Assays 
The I-SceI system was developed for estimating the frequency of homologous 
recombination repair events in cells (Johnson et al., 1999). The system utilises the 
SCneo recombination substrate (see Appendix IV) that contains two non-functional 
copies of the neomycin-phosphotransferase (neo) gene. One copy (3' neo) is a 5' 
truncation of the neo gene so that it lacks the 5' region but retains the 3' region. The 
second copy (S2neo) is the full neo gene, having promoter and full open reading- 
frame, disrupted by an 18bp I-SceI endonuclease site. Both copies of the neo gene are 
on a construct that is stably integrated into the mammalian genome. The two neo 
genes are in direct orientation and separated by a functional hygromycin gene to allow 
for selection of cells containing the construct. 
I-SceI is a yeast mitochondrial intron-encoded endonuclease with an 18bp recognition 
sequence. pCMV3n1s-I-SceI is an expression vector that contains a triplicated nuclear 
localisation signal fused to I-SceI (see Appendix IV). This expression vector is 
transiently transfected into cells to induce a double-strand break. Double-strand break 
repair can occur by non-homologous end joining that utilises little or no homology 
and so does not result in a functional neo gene. Or repair can occur by homologous 
recombination, resulting in a functional neo+ gene that can be scored by resistance of 
cells to G418. The SCneo recombination substrate and the pCMV3nls-I-SceI 
expression vector used for these experiments were kind gifts from Dr Maria Jasin, 
Memorial Sloan Kettering Cancer Centre. 
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2.2.18.1 Double Strand Break Induced Recombination Assay 
Cell lines were plated in selective medium containing hygromycin for 3-5 days prior 
to the recombination assays. 
On day one, 3x 106 cells for each cell line were plated in duplicate on 10cm tissue 
culture dishes. These plates were incubated overnight at 37°C, 5% C02. 
On day 2, for each cell line 2µg of pCMV3nls-I-Scel expression vector was diluted 
into 200µl Opti-MEM and 20µg LipofectAMINE reagent was diluted into 200µl Opti- 
MEM. The diluted DNA and diluted LipofectAMINE reagent were combined and 
mixed gently to form the test solution for each cell line. A control solution of 20µg 
LipofectAMINE in a final volume of 400µ1 Opti-MEM was also made for each cell 
line. The test and control solutions were incubated at room temperature for 30-45 
minutes to allow DNA-liposome complexes to form. Following this, medium was 
removed from the cell lines, cells rinsed with PBS and serum-free medium and 
overlain with 1.6m1 Opti-MEM. Control solution was added to one of the two plates 
for each cell line, and test solution was added to the second plate. The cells were 
incubated for 5 hours at 37°C in a CO2 incubator. Transfection mixture was then 
removed and replaced with IOml DMEM supplemented with 10% serum. Plates were 
incubated overnight at 37°C, 5% CO2. 
On day 3 of the recombination assay, cells were trypsinised and counted. For each 
`test' 10 plates of 105 cells, 5 plates of 5x 104 cells and 5 plates of 2x 104 cells were 
plated on 10cm dishes. For each `control' 20 plates of 2x 105 cells were plated on 
10cm dishes. 500 cells from each `test' and `control' were also plated to measure 
plating efficiency. Plates were incubated at 37°C, 5% C02 overnight to allow cells to 
attach. 
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Recombination frequencies were determined by selection in media containing 1mg/ml 
G418 on day 4. Plates of 500 cells for plating efficiency were not placed under any 
selection. Cells were incubated for 10-14 days before staining and scoring colonies (as 
for toxicity assays). All recombination assays were repeated independently three to 
four times. 
2.2.18.2 Cytotoxic Agent Induced Recombination Assays 
The SCneo system can also be used to score homologous recombination repair events 
induced by exposure to cytotoxic agents. 
3x 6-well dishes per cell line were inoculated with 1000 cells and these cells were left 
to grow out until all 18 wells were confluent. Cells were then trypsinised, plated on 
10cm plates and left to grow for a further 3-4 days. Plating relatively small numbers 
of cells and growing them out to a large number in this way, eliminates pre-existing 
neo+ cells. All 18 plates were trypsinised, counted and re-seeded at 106 cells per 10cm 
dish. Cells were left to attach for 5 hours prior to treatment. Three doses of toxic agent 
were used on cells and 6 plates were treated with each dose for 24 hours. Following 
the 24-hour treatment the agent was removed and cells were left to recover in 
complete medium for 2 days. For each of the 18 cell lines 15 plates of 2x 105 cells 
were re-plated on 10cm dishes and 500 cells were also plated to estimate plating 
efficiency. Cells were left to attach overnight at 37°C, 5% CO2 before adding lmg/ml 
G418. Plates of 500 cells for plating efficiency were not placed under any selection. 
Cells were incubated for 10-14 days before staining and scoring colonies (as for 
toxicity assays). All recombination assays were repeated independently two to three 
times. Recombination frequency was calculated by dividing the average number of 
colonies on the test plates by the average number of colonies on the control plates 
(dose 0mM). 
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2.2.19 Western Blotting 
Protein samples were separated on the basis of size using sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE). A discontinuous system was used to 
allow fine resolution of the individual proteins. This type of discontinuous system 
uses different buffers in the gel and electrode solutions and uses a stacking gel on top 
of a resolving gel to compress the samples to a thin starting band allowing better 
resolution. 
2.2.19.1 Protein Extraction 
Cells were plated at a density of 2x 106 on 10cm tissue culture dishes and left to grow 
for 24 hours. Some cells were treated with a cytotoxic agent prior to protein extraction 
so that signalling events caused by the treatment could later be assessed. 10mM 
thymidine and 2mM hydroxyurea treatments were added to cells and cells were left to 
grow for a further 24 hours. For cells to be treated with IR, all medium was removed, 
cells washed with PBS and the plate of cells exposed to 10 gray IR. Medium was then 
replaced and cells were incubated for a further 2 hours. Protein from untreated control 
cells and treated cells was extracted 48 hours after initial plating. 
Medium was removed from cells, cells were washed four times with PBS to remove 
serum proteins and the plates were placed on ice to prevent denaturation of proteins. 
3O0µ1 of protein lysis buffer was added to each plate and cells were removed using a 
cell scraper and pipetted into a 1.5m1 microcentrifuge on ice. 
Tubes were centrifuged at full speed for 5 minutes and the supernatant removed and 
aliquoted. Aliquots of protein were stored at -85°C. 
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2.2.19.2 Protein Quantification 
PBS was used to make 1 in 50,1 in 100 and 1 in 200 serial dilutions of protein 
samples. Equal volumes of the protein dilution and Coomasie Plus 200 Protein Assay 
Reagent were mixed together and 80µ1 of each dilution was loaded in triplicate to a 
lidded 96-well plate. Known concentrations of BSA (25µg/ml, 20µg/ml, 15pg/ml, 
lOpg/ml, 5µg/ml and lµg/ml) were used as protein standards. Equal volumes of each 
BSA standard and Coomasie Plus 200 Protein Assay Reagent were mixed together 
and 801l of each concentration loaded in triplicate to the 96-well plate. A plate reader 
then read the absorbance of each solution at 595nm wavelength. By plotting the BSA 
standard absorbance readings against its known concentration a linear graph could be 
produced and concentration of the protein samples then estimated from the graph. 
This method was a variation of the Bradford assay (Bradford, 1976). 
2.2.19.3 Casting Discontinuous Polyacrylamide Gels 
Western gels were prepared according to the tables below. A 7.5-12% resolving gel 
was poured between vertical glass plates and overlaid with isobutanol saturated water. 
The gel was left to set for 30-60 minutes at room temperature. The isobutanol- 
saturated water was removed and the top of the gel was rinsed with distilled water 
before the 5% stacking gel was poured on top around the gel comb. The stacking layer 
was left for 20-30 minutes to set before samples were loaded into the wells. The 7.5% 
resolving gels were used specifically for obtaining resolution of phosphorylation 
induced mobility shifts. 
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Table 2.2.19.3.1. Composition of 8-12% Western resolving gels and 5% stacking gels. 
5% 8% 10% 12% 
Acrvlamide/Bis 37.5: 1 0.83m1 2.6m1 3.2m1 3.8m1 
IM Tris pH 8.8 Nil 3.75m1 3.75m1 3.75m1 
I NI Tris pH 6.8 0.63m1 Nil Nil Nil 
Distilled H2O 3.45m1 3.45m1 2.85ml 2.25m1 
10% SDS 501.11 l00µ1 l00µ1 100µl 
10% APS 50µl l00µ1 100µl l00µ1 
TEMMED 10µl l0µ1 10µl 10µl 
Table 2.2.19.3.2. Composition of 7.5% Western gels and the corresponding stacking 
gel. 
Acrv lamide/Bis 37.5: 1 1 nil 5ml 
Lower Buffer Nil 5ml 
Upper Buffer 2.5m1 Nil 
Distilled H2O 6.5m1 lOml 
10% APS 50µl l00µ1 
TEMED IOµ1 l0µ1 
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2.2.19.4 SDS PAGE and Western Blotting 
50µg protein was added to 1X SDS sample buffer and boiled for 3 minutes at 100°C. 
Heating a protein sample in the presence of a thiol reagent in this way fully dissociates 
the protein to its subunits. SDS can then associate with the subunits giving them all 
the same net negative charge so that separation is achieved strictly according to size. 
Samples were loaded onto the gel alongside 15µl Precision Protein Standards Marker 
used to estimate molecular weights of protein samples. The protein samples were run 
at 20mA through the stacking gel and 40mA through the resolving gel until the 
desired resolution had been obtained. The gel was removed from the glass plates and a 
clean scalpel was used to remove the stacking gel layer and any dye front still left on 
the gel. Gels were placed in Towbin transfer buffer for 10 minutes along with one 
nitrocellulose membrane per gel. Protein bands were transferred from the gel to the 
membrane in a semi-dry transfer cell at 10V for 30-45 minutes. The membrane was 
then placed in 5% milk for 1 hour to block non-specific protein binding sites. The 
primary antibody was diluted into 5% milk according to the manufacturer's 
instructions (see materials) and poured over the membrane. Membranes were left 
shaking at 4°C overnight. Unreacted primary antibody was washed off the membrane 
with four 10-minute washes in 1X TBS-T. The membrane was incubated for 1 hour at 
room temperature with the secondary antibody diluted 1: 1000 in 5% milk, and 
membranes were then washed 4-5 times for 10 minutes with 1X TBS-T. Detection of 
the secondary antibody was achieved using the ECL system. An equal volume of 
detection solution 1 was mixed with detection solution 2 to give a final volume of 
0.125m! cm2 membrane. Excess buffer was drained from the membrane and 
membranes were placed on cling-film, protein side up. The ECL detection solutions 
were pipetted over membranes and incubated for 1 minute at room temperature. 
Excess detection reagent was drained off and blots were placed in plastic in a film 
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cassette. In the dark, autoradiography films were placed on top of the membrane and 
exposed for 30-120 minutes in the closed cassette. Films were developed in the dark 
by placing them in developing solution for 3 minutes, washing the film in water, then 
placing in fixing solution for 2 minutes. Films were finally washed in water and then 
dried. 
2.2.19.5 Gel Preservation 
Western gels could be preserved following transfer of proteins to the nitrocellulose 
membrane. The gel was stained in Coomasie Blue protein stain for 1 hour and 
destained in 3-4 10-minute washes. Gels were then enclosed in cellophane and dried 
in a gel drier for 2 hours. 
2.2.20 Pulse-field gel electrophoresis 
10cm tissue culture plates were inoculated with 2-3x106 cells 24 hours prior to 
treatment. Cells were left untreated or treated with 2mM HU, 1-2mM thymidine 
(TdR), 5-10mM TdR or IOnM CPT for 24 hours. Cells were then trypsinised from the 
plates and 1x106 cells were melted into 0.8% agarose inserts. For the IR treatment, 
1x106 cells were melted into 0.8% agarose inserts and inserts were placed in tubes in 
2m1 medium. Tubes were then placed on ice and exposed to 10gy IR. All agarose 
inserts were then incubated at 50°C in 0.5M EDTA, 1% N-laurylsarcosyl and lmg/ml 
proteinase K for 48 hours. Inserts were washed four times for 2 hours in 1X TE buffer 
before being loaded onto a 0.8% agarose gel (made with pulsed-field grade agarose 
and 0.5X TBE). Pulsed field gel electrophoresis was carried out at 120° angle, 60-240 
seconds switch time at 4V/cm for 24 hours. Gels were subsequently stained in a 
solution of 0.5X TBE and lmg/ml ethidium bromide for 12 hours before being 
visualised on a UV illuminator. 
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2.2.21 Apoptosis Measurements 
Cells were co-transfected with a GFP-plasmid and a pIRESparo3 plasmid in a standard 
5hr transfection with Lipofectamine (see above). For transient transfection, DMEM 
containing 20% serum was added to cells without removing the transfection mixture 
and 22 hours after the start of transfection cells were given fresh DMEM 
supplemented with 10% serum for 2 hours. 0.01mg/ml Hoechst 33342 stain was added 
to medium to assess apoptosis based on nuclear morphology. After 30 minutes, cells 
were observed by fluorescence microscopy and a minimum of 500 nuclei expressing 
GFP were counted. Cells were counted as apoptotic if their nuclei were obviously 
bright blue and condensed. 
2.2.22 Statistical Tests 
Chi-squared, Student t-test, regression analysis and p values were calculated using 
Microsoft Excel or by using the Stata statistics and data analysis package. Haplotype 
analysis was performed by Dr. Angie Cox (Institute for Cancer Studies) using the 
PMplus programme (Zhao et al., 2000). 
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3.1 Introduction 
Homologous recombination (HR) repair is an important pathway because it 
mediates faithful repair of DNA damage and prevents increased levels of 
illegitimate repair that may contribute to genetic instability. In addition to the role in 
maintaining genomic integrity, other work in the laboratory indicated that the HR 
repair pathway is defective in some mismatch repair (MMR)-deficient tumour cells 
(Mohindra et al., 2002), suggesting that HR genes are mutational targets in tumour 
development. Therefore, this study examined whether genes involved in the HR 
pathway were altered in colorectal cancers. 
The XRCC2 and XRCC3 genes, along with Rad51 B, Rad51 C and Rad51 D, are 
Rad5l paralogs that may assist Rad5l during HR. Cells that lack XRCC2 or XRCC3 
are highly sensitive to DNA cross-linking agents such as mitomycin C (MMC), 
show genetic instability and possess HR defects (Brenneman et al., 2000, Johnson 
et al., 1999, Pierce et al., 1999). Severe homozygous mutations of XRCC2 and 
XRCC3 are embryonic lethal (Liu et at., 1998). However, mutations or 
polymorphisms of these genes giving more subtle effects on DNA repair capacity 
may have implications for cancer susceptibility in the population. 
Mus81 was recently identified as a putative Holliday junction resolvase with a 
potential role in cleavage of a class of DNA structures that form at stalled or 
collapsed replication forks (Boddy et al., 2000, Chen et at., 2001). Cells with a 
defective Mus8l show a checkpoint-dependent delay in the cell-cycle and do not 
display timely completion of DNA replication (Boddy et at., 2001). Loss of Mus81 
function may lead to accumulation and persistence of anomalous DNA structures in 
the cell that, potentially, could contribute to a malignant phenotype. 
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3.2 Aims and Objectives 
Given that the HR pathway is defective in certain MMR-deficient cells (Mohindra et 
al., 2002) the hypothesis for this study was that the HR repair pathway is modified as 
a downstream event in the development of colorectal cancers, especially in those 
colorectal tumours already deficient in MMR. The primary objective in investigating 
this hypothesis was to determine whether there were any mutations of the candidate 
HR repair genes, XRCC2, XRCC3 and Mus8l, in a random collection of colorectal 
cancer samples and in a set of right-sided MSI+ colorectal tumours using SSCP-PCR 
and sequencing. Polymorphisms that were detected during this study would be 
analysed to establish whether they were in Hardy-Weinberg equilibrium and evaluated 
to determine whether they were significantly associated with colorectal cancer. Any 
alterations of the candidate genes that appeared to contribute to colorectal cancer 
development or progression would be further investigated. 
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3.3 Characterisation of Colorectal Tumours 
Human colorectal tumours were collected in two separate series. The first consisted of 
106 tumours with histologically confirmed sporadic colorectal cancer diagnosed 
between 1997 and 1998. This was a random collection to reduce bias and attempt to 
eliminate confounding variables. The second collection included twenty-seven right- 
sided tumours, which are known to be predominantly microsatellite unstable (Cotran 
et al., 1999), to try to enrich the sample for unstable tumours. Since no molecular data 
were available for these tumours they were classified according to their microsatellite 
instability (MSI) status. 
Tumour and corresponding normal DNA pairs were tested using the Bethesda panel of 
microsatellite markers. MSI was defined by the presence of novel bands following 
PCR amplification of tumour DNA that were not present in PCR products of the 
corresponding normal DNA. For the first collection of 106 tumours five mono- and di- 
nucleotide runs (BAT25, BAT26, MFD15, D2S 123 and APC) were tested initially and 
a further five markers (BAT40, D18S58, D18S69, D10S197 and MYCL1) were used 
to distinguish between microsatellite stable and low microsatellite unstable tumours. 
The MSI status of the right-sided tumour collection was determined by testing all ten 
markers in all 27 tumours. 
Colorectal tumours were scored as MSI-H (high MSI) when > 40% of the tested 
markers were unstable. A score of MSI-L (low MSI) was given when <40% of 
markers tested were unstable and samples were considered stable when none of the 
tested markers showed instability (Figure 3.3.1). Results of the MSI classification are 
shown in Table 3.3.1. 
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Table 3.3.1. \ISI status of samples fron the first collection which was randomly 
chosen, the second right-sided collection and the combined collection. 
Initial randmnlý ')') 10-1.4) 3 (2.8) 4 (3.8) 106 (100) 
chosen tumours 
Right-sided 14 (51.9) 3 (11.1) 10 (37.0) 27(100) 
tumours 
Total collection 1 13 (85. O) 6(4.5) 14 (10.5) 133 (100) 
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Figure 3.3.1. Examples of banding patterns seen for the Bethesda microsatellite 
markers. (A) Normal (N) and tumour (T) DNA samples from the same patient show 
different banding patterns in these markers indicating microsatellite instability. (B) 
Normal and tumour DNA from the same patient shows the same amplification 
products indicating these samples are microsatellite stable (MSS). 
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3.4 SSCP Analysis of Colorectal Tumours 
The full coding sequence of each of the candidate genes was amplified by PCR in 106 
colorectal tumours. PCR products were visualised on agarose gels and once it had 
been established that the correct fragment had been amplified, products were run on 
single-strand conformation polymorphism (SSCP) polyacrylamide gels to screen for 
base changes. A product size of 200-250bp is optimum for screening on SSCP (Orita 
et at.. 1989) and therefore some exons were amplified as overlapping fragments to 
reduce the product size. Several samples showed altered banding patterns when run on 
SSCP gels but when these samples were sequenced no base change was apparent 
(Table 3.4.1). 
Table 3.4.1. False positives can occur with SSCP. Samples that appear to have an 
altered SSCP pattern often have no sequence change. 
Mus81 16 235 194 41 (17.4) 
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3.5 XRCC2 Mutation Screening 
Sequencing of the XRCC2 gene in tumour DNA from several individuals revealed a 
previously reported heterozygous G-A transition resulting in the alteration of amino 
acid arginine 188 to histidine (Figure 3.5.1). The functional consequences of this 
polymorphism are slight and previous investigations reported the allele frequency of 
the variant G allele of XRCC2 R188H in blood donor controls as 0.06 (Rafii et al., 
2002). Using this published control allele frequency it was possible to compare 
unmatched controls with case data (Table 3.5.1). This comparison showed that there 
was no significant difference in genotype frequencies between cases and controls for 
XRCC2 R188H (x2 = 0.91, p=0.6). 
It was observed in this study that the allele frequency of the G allele in colorectal 
cancer cases was 0.08. Using this information it could be shown that the genotype 
frequencies presented in colorectal cancer cases were consistent with those expected 
under Hardy-Weinberg equilibrium (x2 = 0.7, p=0.7) (Table 3.5.1). 
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3.6 XRCC3 Mutation Screening 
Screening of the XRCC3 gene in tumour DNA revealed several previously reported 
polymorphisms. During screening of XRCC3 exon 4a C-T polymorphism in intron 4 
at position 8995 was detected (Figure 3.6.1). PCR primers that had been designed to 
amplify the full coding sequence of XRCC3 also included some overlapping intronic 
sequence which allowed this sequence variant to be seen. 
SSCP analysis of exon 7 revealed six different patterns (Figure 3.6.2, A-F) and 
sequencing of these samples showed the presence of two polymorphisms. The first 
was a C-T polymorphism in exon 7 at 18067 resulting in an alteration of amino acid 
threonine 241 to methionine (T241M) and the second an A-G polymorphism in intron 
6 at position 17893 (Figure 3.6.3). 
The allele frequencies observed in the cancer population were used to test whether the 
genotype distributions for each polymorphism were in Hardy-Weinberg equilibrium 
(Table 3.6.1). The genotype frequencies in the tumour population for all 
polymorphisms were consistent with those expected under Hardy-Weinberg (intron 4 
x2=0.0055, p=0.97, intron6 x2= 0.39, p= 0.82 andexon7x2=1.95, p=0.38). 
All three polymorphisms in XRCC3 had been previously reported in healthy 
individuals (Shen et al., 1998). The reported control allele frequencies were used to 
estimate genotype distributions for a control population (Table 3.6.1). This analysis 
showed that none of the polymorphisms detected were significantly different between 
cases and controls (intron 4x2 = 0.5, p=0.78, intron 6 x2 = 1.59, p=0.45 and exon 7 
x2 = 2.4, p=0.3). 
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However, the control genotype distributions had been estimated using allele 
frequencies from an unmatched normal population. To attempt to match the case and 
control data more closely, XRCC3 exon 7 genotype frequencies from the colorectal 
cancer population were compared to those obtained from a South Yorkshire collection 
of mammography screening controls (J. Shorto and S. Rafli, Institute for Cancer 
Studies) (Table 3.6.2). This showed that there was no statistically significant 
difference between cases and controls for T241M (x2 = 3.03, p=0.22). 
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Figure 3.6.1 (A) During SSCP screening of XRCC3 exon 4 11/106 samples showed an 
cxtra band (shown by blue arrow) and were sequenced to check for base changes. 
(B) Sequencing revealed a C-T heterozygous polymorphism in the intronic region 
surrounding exon 4 at position 8995 that was indicated by the presence of aC and T 
peak at the same position. (C) Samples with the more common SSCP pattern were 
sequenced and found to have a wild type C/C homozygote genotype at position 8995. 
The rare TT genotype was not seen. 
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Figure 3.6.2. SSCP gel analysing XRCC3 exon 7. Six different patterns (A-F) were 
seen suggesting that more than one polymorphism was being detected. Sequence 
analysis revealed two polymorphic loci, one in exon 7 and one in intron 6. The table 
shows which SSCP pattern corresponds to which genotype at each of the polymorphic 
loci. 
Genotype at XRCC3 Genotype at XRCC3 
Pattern Intron 6 17893 Exon 7 18067 
Polymorphic Site Polymorphic Site 
A A/A C/T 
B A/G C/C 
C G/G C/C 
D A/G C/T 
E A/A T/T 
F (wild type) A/A C/C 
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Figure 3.6.3. Sequence chromatograms for the polymorphisms in XRCC3 intron 6 and 
exon 7. (A) Chromatograms show the C/C homozygous wild type, C/T heterozygote 
and the T/T homozygote genotypes for the exon 7 polymorphic site. (B) Sequence 
analysis showed examples of the A/A wild type homozygote, A/G heterozygote and 
the variant G/G homozygote genotypes for the intron 6 polymorphic site. 
A 
Exon 7 C/C 
ýýý 
tiý 
B 
Intron 6 A/A 
GACAGCT0 T 
TaTJa fl 3A 
A 
kVXk 
Intron 6 A/G 
Exon 7 T/T 
GGCCATGCTG 
GGCCATGCTG 
1ý 
1 
GGCCACGCTG 
6GCCACGCTG 
Intron 6 G/G 
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Table 3.6.1. Genotype frequency distributions of each polymorphism in a cancer and 
calculated control population. 
'Reported control allele frequencies: intron 4 (T) = 0.04, intron 6 (G) = 0.38, exon 7 (T) = 0.38 
hAllrle frequencies in cases: intron 4 (T) = 0.05, intron 6 (G) = 0.33, exon 7 (T) = 0.34 
XRCC3 Intron 4 C/C - 95/106 (89.6) 98/106 (92.2) 96/106 (90.2) 
XRCC3 Intron 4 C/T - 11/106 (10.4) 8/106 (7.8) 10/106 (9.5) 
XRCC3 Intron 4 T/T - 0/106 (0.0) 0/106 (0.0) 0/106 (0.3) 
XRCC3 Intron 6 A/A - 50/106 (47.2) 41/106 (38.4) 48/106 (44.9) 
XRCC3 Intron 6 A/G - 43/106 (40.5) 50/106 (47.2) 47/106 (44.2) 
XRCC3 Intron 6 G/G - 13/106 (12.3) 15/106 (14.4) 11/106 (10.9) 
XRCC3 Exon 7 C/C Thr/Thr 50/106 (47.2) 41/106 (38.4) 46/106 (43.4) 
XRCC3 Exon 7 C/T Thr/Met 39/106 (36.8) 50/106 (47.2) 48/106 (45.3) 
XRCC3 Exon 7 T/T Met/Met 17/106 (16.0) 15/106 (14.4) 12/106 (11.3) 
Table 3.6.2. Summary of XRCC3 exon 7 genotype frequencies for colorectal cancer 
cases and mammography screening controls. 
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C/C Thr/Thr 376/957 (39.3) 50/106 (47.2) 
C/T Thr/Met 433/957 (45.2) 39/106 (36.8) 
T/T Met/Met 148/957 (15.5) 17/106 (16.0) 
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Linkage analysis of the exon 7 and intron 6 loci in 106 samples suggests that these 
two polymorphisms are strongly linked (x2 = 38.97, p=7.07x10-8) (Table 3.6.3). 
Haplotype analysis of all three polymorphisms of XRCC3 showed that the intron 4 
8995, intron 6 17893 and exon 7 18067 sites are in linkage disequilibrium (x2 = 55.36, 
p=2.7x 10-11) and there are four common haplotypes (Table 3.6.4). The 17893 and 
18067 polymorphisms were considered alone and haplotype frequencies compared to 
previously reported data that suggested an association between these two polymorphic 
sites (Kuschel et al., 2002). This analysis showed that the haplotype frequencies 
obtained in this study were consistent with those previously reported (x2 = 0.006, p= 
0.97) (Table 3.6.5). 
Table 3.6.3. The polymorphisms at exon 7 and intron 6 of XRCC3 are in linkage 
disequiiibriunn. 
C/C 12/106 (11.3) 25/106 (23.6) 13/106 (12.3) 
C/T 21/106 (19.8) 18/106 (17.0) 0/106 (0.0) 
T/T 17'106 (16.0) 0/106 (0.0) 0/106 (0.0) 
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Table 3.6.4. Haplotype analysis for XRCC3 polymorphisms. 
C A C 0.417228 0.282185 
C A T 0.219120 0.344247 
C G C 0.201320 0.316965 
C G T 0.105729 0.000000 
T A C 0.025034 0.048004 
T A T 0.013147 0.000093 
T G C 0.012079 0.008507 
T G T 0.006344 0.000000 
Table 3.0.5. Comparison of haplotype frequencies observed for XRCC3 intron 6 and 
exon 7 polymorphisms in colorectal cases and previously reported breast cancer cases 
(Kuschel et al., 2002). 
AC 0.3302 0.3056 
AT 0.3443 0.3869 
GC 0.3250 0.3023 
GT 0.0000 0.0053 
°Polvniorphic bases listed in 5' to 3' order 
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3.7 Mus81 Mutation Screening 
SSCP screening of the Mus81 gene in DNA from colorectal cancer patients detected 
altered banding patterns in exon 6, exon 9, exon 11 and exon 12. Subsequent 
sequencing revealed six previously unreported and two reported polymorphisms 
(Figures 3.7.1-3.7.5). To determine whether the polymorphisms were tumour specific 
and whether there was any loss of heterozygosity (LOH) in the tumour samples, 
normal and corresponding tumour DNA was analysed side-by-side on SSCP to detect 
differences (Figure 3.7.6). 
Six of the detected polymorphisms did not give rise to amino acid changes but two, 
C314G in exon 6 and C617T in exon 9, led to non-synonymous amino acid changes 
(Table 3.7.1). These polymorphisms were further analysed in a population of 85 
normal blood donor controls to determine the frequency of each genotype in a normal 
population. These genotype frequencies were compared to those observed in the 
tumour collection to determine whether there was any difference between the cases 
and controls and therefore whether the polymorphisms were tumour-associated (Table 
3.7.2). Statistical analysis showed that the genotype frequencies for exon 6 C314G did 
not differ significantly between cases and controls (x2 = 3.18, p=0.204). Similarly, 
the genotype frequency distributions for exon 9 C617T were not statistically 
significantly different between colorectal cancer cases and blood donor controls (X 
2- 
0.18, p=0.91). 
The frequency of the variant alleles in the tumour population was used to estimate 
genotype frequency distributions as predicted by Hardy-Weinberg (Table 3.7.2). This 
analysis showed that both C314G and C617T non-synonymous polymorphisms were 
in Hardy-Weinberg equilibrium in the colorectal cancer cases (x2 = 0.01, p=0.99 and 
x2 = 0.0, p=1, respectively). 
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Frequencies of the variant alleles observed in the colorectal cancer population were 
also used to estimate the Hardy-Weinberg genotype distributions for each of the 
synonymous polymorphisms (Table 3.7.3). This analysis showed that genotype 
distributions for all polymorphisms, except A840G, were consistent with those 
expected under Hardy-Weinberg equilibrium. To determine if this A840G difference 
was due to an association between loci, haplotype analysis was carried out on all the 
polymorphisms detected in Mus8l. This analysis showed that there were three 
common haplotypes that occurred in >5% of cases, three haplotypes that were seen in 
1-5% of cases and seven haplotypes seen in <1% of cases (Table 3.7.4). The other 243 
possible haplotypes were not seen in any of the cases and the 8 loci examined were 
strongly associated (x2 = 423.29, p= 2x10"11). 
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Table 3.7.1. Synonymous and non-synonymous amino acid changes seen in Mus8l 
during analysis of colorectal cancer samples. 
Mus8l Exon 6 C312T 104 Ala Yes 
Mus81 Exon 6 C314G 105 Pro-Arg Yes 
Mus81 Exon 9 C671 T 224 Thr-Met No 
Mus81 Exon 9 T711 C 237 Ala No 
Mus8l Intron 9 G-A - - No 
Mus81 Exon 11 A840G 280 Arg No 
Mus81 Exon 11 T852C 284 Cys No 
Mus8l Exon 12 T1023G 341 Thr No 
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Figure 3.7.1. SSCP and sequencing analysis of Mus8l exon 6 detected two 
polymorphic sites; C312T (blue boxes) and C314G (pink boxes). (A) Analysis of exon 
6 revealed three different SSCP patterns. (B) Sequencing chromatogram showing the 
variant 312 T'T and 314 G/G homozygous genotype. (C) Chromatogram showing 
sample with a wild type sequence. (D) Sequence data showing double heterozygote 
C/T and C/G for Mus81 exon 6. 
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Figure 3.7.2. SSCP analysis of Mus81 exon 9 showed several different banding 
patterns suggesting the presence of several polymorphisms. Sequencing revealed two 
polymorphic sites in exon 9 (positions 617 and 711) and one in intron 9. The genotype 
corresponding to each SSCP pattern is shown in the table below. 
Pattern Genotype at Genotype at Genotype at 
Intron 9 Exon 9 C617T Exon 9 T711C 
A G/G C/C T/T 
B G/A C/C T/C 
C G/G C/T T/T 
D G/A C/C T/C 
I GA C/T T/C 
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Figure 3.7.3. Sequence chromatograms showing the three polymorphisms in Mus8l 
exon 9. (A) Chromatograms showing the detected G/G and G/A genotype for the 
intron 9 polymorphic site. The rare A/A genotype was not seen for this locus. (B) 
Sequence analysis showing the C/C and C/T genotypes for the C617T exon 9 
polymorphic site. The rare T/T genotype was not seen. (C) Chromatograms showing 
the T/T and T/C genotypes for the T71 1C exon 9 polymorphic site. No samples were 
observ cd that were CC homozygote at this locus. 
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Figure 3.7.3. Two polymorphisms were detected in Mus81 Exll. (A) Analysis of 
MusS'I exon II on SSCP revealed extra bands (blue arrows) in some samples. (B) 
Sequencing of samples with the most common SSCP pattern showed wild type 
sequence at both sites. (C) Some samples were A/G heterozygous at polymorphic site 
A840G but remained wild type for T852. (D) Chromatograms showing a sample 
heterozygous at the T852C polymorphic site and wild type for A840. 
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Figure 3.7.5. Analysis of a1us81 exon 12 revealed a synonymous T1023G 
polymorphism. (L) SSCP analysis shows three different banding patterns on the gel. 
(B) Sequence analysis shows the T/T homozygote. (C) Chromatogram showing a T/G 
heterozygous sample. AG and T peak can be seen in the same position at 1023. (D) 
Sequence chromatogram showing the G/G rare homozygote for the Mus8l exon 12 
polymorphic site. 
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Figure 3.7.6. SSCP gel analysis of normal (N) and corresponding tumour (T) DNA 
suggests that the AIus81 polymorphisms are not tumour specific and provides no 
evidence for LOH. (A) Samples showing variation in Mus8l exon 6 have the same 
banding pattern in normal and tumour DNA. (B) Comparison of normal and tumour 
DNA for 2%fus8l exon 9. (C) Tumour DNA shows variation in Mus8l exon 11 on 
SSCP but corresponding normal DNA has same variant pattern. (D) Normal and 
tumour DNA frone same patient showed the same SSCP pattern for Mus8l exon 12. 
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Table 3.7.2. Genotype frequencies of non-synonymous Mus8l polymorphisms in a 
colorectal cancer and a normal blood donor control (BDC) population. Genotype 
frequencies expected by Hardy-Weinberg (H-W) are also shown. 
C/G Pro/Arg 45/85 (52.9) 42/105 (40.0) 43/105 (41.2) 
G/G Arg/Arg 6/85 (7.1) 9/105 (8.6) 9/105 (8.4) 
Mus81 C671T C'C Thr/Thr 88/89 (98.9) 103/105 (98.0) 103/105 (98.0) 
C/T Thr/Met 1/89 (1.1) 2/105 (2.0) 2/105 (2.0) 
TT Met/Met 0/89 (0.0) 0/105 (0.0) 0/105 (0.0) 
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Table 3.7.3. Comparison of the frequency of synonymous Mus8l polymorphisms in 
the colorectal tumour population with the frequency expected by Hardy-Weinberg. 
Mus8l C312T CC 54/105 (51.4) 53/105 (50.4) 
C/T 42/105 (40.0) 43/105 (41.2) x2= 0.03 
T/T 9/105(8.6) 9/105 (8.4) p= 0.99 
i1us81 T71IC T/T 102/106 (96.2) 102/106 (96.0) 
T/C 4/106 (3.8) 4/106 (4.0) x2= 0.0 
T/T 0/106 (0.0) 0/106 (0.0) P =l 
. %fus8l 
G-A Intron 9 G/G 103/106 (97.1) 104/106 (98.0) 
G/A 3/106 (2.9) 2/106 (2.0) x2= 0.2 
A/A 0/106 (0.0) 0/106 (0.0) p= 0.90 
Mus81 A840G A/A 60/106 (56.6) 65/106 (60.8) 
A/G 46/106 (43.4) 36/106 (34.4) x2= 6.3 
G/G 0/106 (0.0) 5/106 (4.8) p= 0.04 
Mus81 T852C T/T 104/106 (98.1) 104/106 (98.0) 
T/C 2/106(l. 9) 2/106(2.0) x2= 0.0 
C/C 0/106(0.0) 0/106(0.0) p =1 
31us81 T1023G T/T 53/106 (50.0) 55/106 (51.9) 
G/T 47/106 (44.3) 43/106 (40.3) x2= 0.49 
G/G 6/106 (5.7) 8/106 (7.8) p= 0.78 
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Table 3.7.4. Haplotype analysis of the 8 Mus81 polymorphic loci detected in 
colorectal cancers showed 13 common haplotypes. The most common haplotypes 
(>5%) are listed first. 
(HF Haplotype Frequency, Indep = Frequency if loci are independent, Assn = Frequency with 
association) 
T 
T 
T 
T 
C 
C 
C 
1 
T 
T 
G 
G 
G 
A 
G 
A 
T 
T 
T 
T 
G 
G 
0.2701 
0.0049 
0.0169 
0.6625 
0.1675 
0.0799 
C C C T G G T T 0.0779 0.0278 
T T C T G A T T 0.0432 0.0142 
C C C T G A T G 0.1055 0.0101 
T T C C A G T G 0.0000 0.0095 
T T C T G G T T 0.0125 0.0050 
C C C T G A C T 0.0026 0.0048 
C C T T G A C T 0.0000 0.0048 
T T C C G G T G 0.0000 0.0048 
T T T C A G T G 0.0000 0.0044 
(' C C T G G T G 0.0304 0.0044 
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3.8 Analysis of XRCC2 Mononucleotide Runs 
A frameshift mutation of a coding T8 run of XRCC2 was detected in a MMR-deficient 
uterine cell line (Mohindra et al., 2002) and therefore it was proposed that mutations 
of the coding mononucleotide runs of the candidate genes may be more common in 
MSI+ tumours. No mutations of XRCC2 were detected in 106 colorectal tumours 
during this study and SSCP screening did not reveal the frameshift mutation in 
XRCC2 T8, therefore 20 MS1+ and 4 MSS. colorectal tumours were analysed by 
sequencing. The T8 run of XRCC2 exon 3 along with the A7 and T7 mononucleotide 
runs of XRCC2 exon 3 were examined (Figure 3.8.1). No coding mononucleotide 
tracts longer than six nucleotides were present in the other candidate genes. Samples 
were amplified and PCR products were subject to direct sequencing to determine the 
frequency of mutation in these runs in colorectal cancer samples. All colorectal 
samples analysed had wild type sequence in the XRCC2 mononucleotide runs after 
direct sequencing (Figures 3.8.2-3.8.3). 
Heterozygous mutations of mononucleotide runs are difficult to detect and the 
mutation in the T8 run had been seen previously in the heterozygous form (Mohindra 
et al., 2002). Therefore the T8 run was amplified in a selection of MST' samples using 
the more accurate AccuPrime Taq system and PCR products were cloned into the 
pDrive cloning vector. Six independent clones per sample were chosen for sequencing 
using the Thermo-sequenase system. Samples where z 50% (but <100%) of clones 
carried a mutant allele were classified as heterozygous and samples where no clones 
carried a mutant allele were classified as wild type. This extensive cloning analysis 
confirmed that none of the MSI+ samples had a mutation in XRCC2 Tg (Figure 3.8.4). 
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Figure 3.8.1. Diagram showing relative position of the T8, A7 and T7 mononucleotide 
runs in. tRC(''. 
tttttttt, aaaaaaacatttttlt 
Exon IIi Exon 2 Exon 3 
Figure 3.8 2. Sequencing of XRCC? TK in colorectal cancer samples reveals no 
mutations. (A) Sequencing gel for three different MSI+ samples shows each have wild 
type TK runs. (B) Sequencing chromatogram showing the 8 thymines. 
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Figure 3.8.3. Sequencing chromatograms showing the wild type A7 and T7 
mononucleotide runs in XRCC2 exon 3 as seen for all MSI+ CRC samples. 
Figure 3.8.4. Six independent clones for an MSI+ sample all carry a wild type T8 allele 
suggesting this sample is truly wild type for XRCC2 T8. 
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3.9 Discussion 
There is now a large body of evidence suggesting that acquisition of genomic 
instability may represent an early step in malignant development (Kinzler and 
Vogelstein, 1997, Claij and Riele, 1999, Stoler et al., 1999). There is also evidence 
that mutations in homologous recombination (HR) repair genes may contribute to 
tumour development in genetically unstable cells (Mohindra et al., 2002). The 
primary goal of this study was to establish whether there were somatic mutations in 
candidate HR genes that could contribute to colorectal cancer development. 
Although no such mutations were detected, this analysis revealed several 
polymorphisms in the candidate HR genes and so it was determined whether these 
polymorphisms were likely to contribute to tumorigenesis. 
The form of genomic instability associated with MMR-deficiency is known as 
microsatellite instability (MSI) and therefore this collection of tumours was 
classified according to MSI status. MSI is caused by a failure of the MMR system 
to repair errors that occur during DNA replication and is characterised by an 
increase in single nucleotide mutations and variation in length of simple repetitive 
sequences that occur throughout the genome. Cells with a deficient MMR system 
accumulate mutations more rapidly than normal cells and therefore mutations in 
critical genes become more likely (Coleman and Tsongalis, 1999, Bhattacharyya et 
al., 1994). 
A panel of five markers to detect MSI have been validated for use in colorectal 
cancers and are recognised as the Bethesda reference panel (Boland et al., 1998). A 
further five microsatellite markers were recommended for use in a second panel to 
distinguish between low MSI (MSI-L) and microsatellite stable (MSS) samples 
(Dietmaier et al., 1997). Using these markers the level of MSI in sporadic colorectal 
tumours has previously been estimated to be 10-15% (Kim et al., 1994, Wheeler et 
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al., 2000). The frequency of MSI in the initial collection of sporadic colorectal 
tumours obtained for this study was 6.6%. This collection of tumours alone was 
used to determine the frequency of mutations in the candidate HR genes. It is 
therefore possible that the low level of MSI in this original tumour population 
limited our ability to detect DNA repair gene alterations that might be more 
common in tumours already deficient in MMR. 
A second right-sided tumour collection was obtained to increase the number of 
MSI+ tumours as it has been reported that tumours in the proximal colon are more 
likely to be MSI+ (Chung, 2000, Burt, 2000). The level of MSI in the right-sided 
tumours was found to be 48.1% and so by combining the two collections the MSI 
frequency rose to 15%, which was closer to previously reported values. The MSI+ 
tumours were later screened specifically for mutations in coding mononucleotide 
runs of candidate HR genes. 
The methods chosen for screening the candidate genes were SSCP-PCR and 
sequencing. The results presented here show that, although SSCP is accurate and 
sensitive, it can introduce false positive data into the study. However, sequencing 
easily eliminates these false positives and all samples were sequenced in the 
forward and the reverse directions to confirm the results. When amplified products 
of 200-250bp are being screened SSCP can expect to detect 70-90% of all single 
base substitutions (Humphries et al., 1997). 
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The candidate genes chosen for SSCP-PCR analysis have a role in HR repair. These 
genes are potential targets for mutation since loss of any repair pathway destabilises 
the genome, making malignancy more likely and it has also been shown that certain 
MSI+ tumour cell lines have HR repair defects (Mohindra et al., 2002, Mohindra et 
al., 2003). 
XRCC2 is highly conserved in mammalian species and is essential for efficient 
repair of DNA double-strand breaks by HR between two sister chromatids (Deans et 
al., 2000). It interacts with Rad51 D and has two potential Walker box ATP-binding 
domains. Analysis of XRCC2 in the DNA of several colorectal cancer patients 
revealed a G-A polymorphism that led to an alteration of arginine 188 to histidine 
(R188H). This polymorphism has been reported to be associated with breast cancer 
(Rafii et al., 2002) but the results obtained here indicate that it may not be similarly 
associated with colorectal cancer. Analysis of genotype frequencies for the R188H 
polymorphism in the cancer and control populations showed no statistically 
significant difference between the two, suggesting that this polymorphism is not 
associated with colorectal cancer. However, the control values were estimated using 
allele frequencies from a previously reported unmatched blood donor control 
population. The blood donor control and colorectal cancer populations were both 
collected from the South Yorkshire area, but they are not sex-matched and are 
unlikely to be age-matched. To fully confirm that this polymorphism is not 
associated with colorectal cancer, screening data from a larger population of cancer 
patients would need to be compared to data from a matched normal population. 
Although alignments of human, mouse and hamster XRCC2 proteins show that 
arginine 188 is an invariant residue (Rafii et al., 2002, Cartwright et al., 1998) the 
RI 88H polymorphism seems to have a subtle effect on protein function. Expression 
of the R188H variant has a slight effect on the cells ability to repair MMC-induced 
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damage (Rafli et al., 2002). The 188 site does not overlap with the region that is 
required for XRCC2 interaction with Rad5 1D (Rafii et al., 2002) and the integrity 
of the ATP-binding domain is not necessary for XRCC2 function (O'Regan et al., 
2001). XRCC2 R188H is a conservative amino acid change that does not appear to 
lie in a functional domain and it seems unlikely that this polymorphism has a role in 
colorectal cancer development or progression. No other polymorphisms or 
mutations of XRCC2 were seen in the SSCP-PCR screening of colorectal cancer 
samples. 
XRCC3 is required for correct chromosome segregation and for the efficient repair 
of DNA damage by the HR repair pathway making it a potential tumour suppressor 
gene (Griffin et al., 2000). Little is known, at present, about the specific functional 
domains of XRCC3. The protein has two putative ATP-binding domains, Walker 
boxes A and B, and interacts with Rad5lC during HR (Masson et al., 2001a), 
although the residues critical for this interaction are unknown. Screening of XRCC3 
in a collection of colorectal cancer samples revealed several polymorphic sites 
within the gene and it is known that variants of XRCC3 are common within the 
healthy population (Shen et al., 1998). 
A C-T polymorphism in XRCC3 intron 4 at position 8995 was detected in DNA 
from colorectal cancer patients. The genotype frequencies for this polymorphism 
were in Hardy-Weinberg equilibrium and did not differ from control data that had 
been estimated using allele frequencies reported for healthy individuals (Shen et al., 
1998). This polymorphism is intronic and does not affect any of the important 
signal sequences directing intron removal and so is unlikely to affect XRCC3 
function. However, haplotype analysis suggested that this locus is linked to other 
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polymorphic loci in XRCC3 and it may be that there is a linked dysfunctional 
variant that affects cancer susceptibility. 
SSCP screening and sequencing of XRCC3 exon 7 revealed that two 
polymorphisms had been detected, one A-G polymorphism in intron 6 at position 
17893 and one C-T polymorphism in exon 7 at position 18067. The exon 7 change 
led to alteration of amino acid threonine 241 to methionine (T241 M). 
The presence of the T allele at position 18067 has been found to be significantly 
associated with increased risk of malignant melanoma development, bladder cancer 
and breast cancer (Winsey et al., 2000, Matullo et al., 2001, Kuschel et al., 2002) 
and has been associated with a non-statistically significant increased risk of 
squamous cell carcinoma of the head and neck (Shen et al., 2002). However, other 
studies have found no association between the T241 M variant and lung cancer or 
non-small cell lung cancer (David-Beabes et al., 2001, Butkiewicz et al., 2001). 
The A-G intronic polymorphism was also found to be associated with breast cancer 
cases and it seems that 17893G may have a dominant protective effect as the 
presence of the rare G allele was associated with a decreased risk of developing 
breast cancer (Kuschel et al., 2002). 
Analysis using allele frequencies reported for healthy individuals (Shen et al., 1998) 
revealed that the intron 6 and exon 7 polymorphisms were not statistically 
significantly associated with colorectal cancer. Once again, however, there was no 
matching between normal and tumour populations and the allele frequency of 
18067T in a normal population had been taken to be 0.38 whereas others have 
reported the allele frequency in healthy individuals to be 0.3-0.38 (Winsey et al., 
2000, David-Beabes et al., 2001, Shen et al., 1998). The T241M polymorphic data 
was further investigated by comparing the genotype frequencies in colorectal cancer 
cases to those obtained from a large mammography screening control population. 
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These controls were more closely matched to the cases as they had a median age 
range of 50-65 years, and had all been collected from the South Yorkshire area. 
However, they were not sex matched as all the controls were female. This analysis 
further suggested that there was no significant association between colorectal cancer 
and the T241M polymorphism. A larger colorectal cancer sample and matched 
normal controls would need to be studied to establish whether there truly is an 
association between colorectal cancer and T241 M. Indeed, attempts to verify the 
association of 18067 T with malignant melanoma and bladder cancer in other 
populations have been unsuccessful in confirming the original result (Duan et al., 
2002, Stern et al., 2002). 
The A-G intron polymorphism is non-coding and therefore unlikely to affect 
XRCC3 function. There is also little evidence that the T241M polymorphism affects 
the XRCC3 protein as the amino acid change does not alter either of the two ATP- 
binding domains, which are the only functional domains identified to date. 
The T241M polymorphism changes a neutral hydrophilic amino acid with a 
hydroxyl group to a hydrophobic one with a methyl sulphur group. This may result 
in a change in protein structure or function (Kuschel et al., 2002) that may alter its 
ability to interact with Rad51C. However, the T241M variant is still capable of 
promoting homology directed repair of chromosomal double-strand breaks and cells 
expressing the variant protein are no more sensitive to MMC than those expressing 
wild type protein (Araujo et al., 2002). 
The fact that the T241 M variant appears to have no detrimental effect on XRCC3 
function could be explained by evidence suggesting that 7241M itself is not disease 
causing but is in linkage disequilibrium with a closely linked dysfunctional variant 
(Rafii et al., 2003). In fact, a rare haplotype containing T241M was more strongly 
associated with breast cancer than T241M itself (Kuschel et al., 2002). A haplotype 
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containing 17893G and 18067C was associated with a decreased risk of breast 
cancer whereas a haplotype containing 17893A and 18067T was associated with a 
significantly increased risk of breast cancer (Kuschel et al., 2002). 
Haplotype analysis of the three XRCC3 polymorphisms studied here (intron 4, 
intron 6 and exon 7) showed four frequent haplotypes and all other haplotypes were 
seen in less than 1% of cases. Haplotype analysis of the 17893 and 18067 
polymorphisms alone provided haplotype frequencies that were in close agreement 
with previously reported data (Kuschel et al., 2002) and the analysis also showed a 
strong association between the intron 6 and exon 7 loci. 
Some evidence indicates that the 17893G allele is protective whereas the 18067T 
allele increases risk of breast cancer (Kuschel et al., 2002) and indeed these two 
alleles did not appear together in a haplotype in any of the colorectal cancer cases. It 
seems that neither variant has an extensive effect on protein function lending 
support to the theory that the T241M allele is in linkage disequilibrium with another 
dysfunctional variant. 
Mus81 is an endonuclease with a potential role in resolving Holliday junctions. The 
protein has a VERK motif that is conserved in the XPF family of nucleases and has 
helix-hairpin-helix DNA binding domains at the N- and C-termini that are also 
thought to be conserved (Chen et al., 2001). Mus81 interacts with the fork-head 
associated (FHA) domain of Chk2 and this interaction may require phosphorylation 
of Mus81 (Chen et al., 2001). These sites of interaction and potential 
phosphorylation are not yet determined for Mus8 1. 
Several polymorphic sites of Mus8l were identified in colorectal tumours but the 
majority of these did not lead to amino acid substitutions in the protein. 
The majority of the detected polymorphisms were in Hardy-Weinberg equilibrium 
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within the tumour population. However, the genotype distributions for the A840G 
polymorphic site were statistically significantly different from those expected under 
Hardy-Weinberg equilibrium. This difference could be due to the strong association 
between this and the other 7 loci studied as the linkage disequilibrium may cause 
some bias and result in a deviation from Hardy-Weinberg at certain loci. 
The frequency of the synonymous polymorphisms in a normal population was not 
determined since they were unlikely to affect protein function and therefore unlikely 
to be associated with colorectal cancer. 
Two non-synonymous polymorphisms were identified in sequencing of Mus8l. The 
first of these was a C-G polymorphism in exon 6 of the gene that led to substitution 
of proline 105 for arginine (P105R). The second was a C-T polymorphic site in 
exon 9 that led to alteration of threonine 224 to methionine (T224M). Comparison 
of genotype frequency distributions between a normal blood donor control and a 
colorectal cancer population showed no statistically significant differences between 
the two, suggesting the non-synonymous polymorphisms were not associated with 
colorectal cancer. However, the colorectal cancer population had again been 
compared to an unmatched blood donor control sample. Both the cancer and control 
populations had been collected from the South Yorkshire area but they were not 
sex-matched and the control population was likely to have a younger average age 
than the cancer population. 
Therefore, to further study whether the polymorphisms observed were tumour- 
specific, corresponding normal and tumour DNA from the same patient was 
amplified for SSCP-PCR analysis of each of the polymorphisms detected in Mus81. 
This investigation showed that the normal and tumour DNA gave rise to the same 
pattern on SSCP further suggesting that the sequence changes are not tumour- 
specific. 
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The two non-synonymous polymorphisms of Mus8l could have some effect on 
protein function as substitution of the small proline residue for a hydrophilic, 
positively charged arginine may have a significant effect on protein structure or 
function, as may replacing a hydrophilic threonine with the hydrophobic, sulphur- 
containing amino acid methionine. Furthermore, threonine 224 could potentially be 
a phosphorylation site in the Mus81 protein. However, this is unlikely since, similar 
to proline 105, the Thr224 residue is not absolutely conserved through eukaryotic 
species (Chen et al., 2001). Additionally, neither the Thr224 nor the Pro105 
residues lie in the conserved VERK or helix-hairpin-helix domains (Chen et al., 
2001) suggesting that these variants do not directly alter the functional domains of 
the protein. Therefore, it is perhaps unsurprising that these polymorphisms are not 
associated with colorectal cancer. This investigation has shown that, although 
variants of Mus8l exist in the population, these variants do not appear to be 
associated with an increased risk of colorectal cancer development. 
MMR-deficient tumours are more likely to accumulate mutations in critical genes 
that have repetitive sequences. This is seen for MMR-deficient sporadic colorectal 
tumours that acquire mutations in the repetitive elements of genes such as TGFßRII 
and BAX (Chung, 2000). 
Since the original mutation screen of the candidate genes in this study did not reveal 
any tumour specific changes it was hypothesised that mutations in these genes 
might be more common in MMR-deficient tumours. Sequence alterations may be 
seen more frequently in the mononucleotide runs of these genes and notably a 
frameshift mutation of an XRCC2 Tg run was found to be associated with MMR- 
deficient uterine cancer cells (Mohindra et al., 2002, Mohindra et al., 2003). This 
heterozygous frameshift mutation leads to the introduction of a premature stop 
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codon and generates a truncated protein. Cells expressing this variant protein 
become more sensitive to thymidine- and MMC-induced DNA damage than cells 
expressing the wild type protein (Mohindra et al., 2002). However, a screen for this 
mutation in MSI'' colorectal cancer samples did not provide any evidence for its 
association with MMR-deficient colorectal tumours. Analysis of the A7 and T7 
tracts of XRCC2 also failed to reveal any tumour-specific frameshift mutations of 
these runs. Therefore, although the XRCC2 T8 run might be important in 
development of a rare subset of MMR-deficient uterine tumours, results obtained 
here suggest that mutations in the mononucleotide runs of XRCC2 do not play a role 
in MMR-deficient colorectal tumour development. 
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4.1 Introduction 
The central hypothesis for this research was that the homologous recombination (HR) 
repair pathway is defective specifically in MMR-deficient tumour cells. Previous 
studies revealed that MMR-deficient cells display thymidine sensitivity and an HR 
repair deficiency (Mohindra et al., 2002). Thymidine treatment slows DNA synthesis 
and may create substrates at the replication fork that must be resolved by 
recombination and indeed it was shown that the HR pathway alone was required for 
cell survival following thymidine treatment (Lundin et al., 2002). Increasing evidence 
suggests that HR is involved in repair of collapsed or impaired DNA replication forks 
(Henry-Mowatt et al., 2003, Flores-Rozas and Kolodner, 2000) similar to those that 
might be created by thymidine treatment. 
Together, these data suggest that loss of HR repair and thymidine sensitivity are a 
result of events downstream of MMR loss. Initial analysis of three candidate HR 
genes, XRCC2, XRCC3 and Mus8l, in a collection of primary colorectal tumours 
failed to reveal any tumour-specific mutations. Therefore, further candidate genes 
involved in recombination repair and maintenance of replication fork integrity were 
identified for screening. 
The MRE11 complex consists of MRE11, NBS1 and Rad50 and this complex is a 
potential key organiser of double-strand break (DSB) repair (Paull and Gellert, 1999). 
It has been proposed that the MRE11 complex might be a sensor of S-phase DNA 
damage or an effector of the DNA damage-dependent S-phase checkpoint, or may 
fulfil both these roles (Petrini and Stracker, 2003). 
The MRE11 complex has been shown to be associated with several other proteins 
with roles in recognition of abnormal DNA structures or damaged DNA in the 
BRCA1-associated genome surveillance complex (BASC) (Wang, 2000). It has 
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further been suggested that interference with the functions of BASC may be a central 
event in tumorigenesis (Wang, 2000). 
The MREI 1 complex is known to be active during S-phase in unstressed cells and the 
complex associates with chromatin in a replication-dependent manner (Mirzoeva and 
Petrini, 2003). Depletion of MRE1 I from Xenopus extracts leads to the accumulation 
of DSBs during genomic DNA replication (Costanzo, 2001). Therefore, an additional 
potential role for the MRE11 complex is in surveillance of the genome during the 
normal cell cycle to preserve genomic integrity. 
The components of the MRE11 complex are obviously important and as such, 
mutations in these genes might increase genetic instability and predispose to 
malignancy. Loss of MMR increases the chance of further mutations in genes 
involved in fundamental cellular processes and therefore mutations of the MRE11 
complex are more likely in MMR-deficient cells. 
4.2 Aims and Objectives 
Acquired mutations in MREI1, NBSI or Rad5O may affect MRE11 complex 
formation or function and therefore lead to a decreased repair capacity or surveillance 
ability and an increased chance of malignancy. The aim of this study was to screen 
several MMR-deficient tumour cell lines and MSI+ primary colorectal cancers for 
mutations of the MRE11 complex. Mutations that were found to be significantly 
associated with colorectal cancer would be further investigated to determine the 
phenotypic effects of the mutation. 
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4.3 Analysis of MREll, NBS1 and RadSO in Cell Lines 
RNA extracted from one MMR-proficient and five MMR-deficient cell lines was 
analysed for mutations in the MRE11, NBS1 and Rad5O genes. 
The full-length cDNA of each gene was amplified in overlapping fragments (MRE11 
fragments 1-3, NBSI fragments 1-4, Rad5O fragments 1-6) and these cDNA sequences 
were analysed for base changes. None of the cell lines tested; the MMR-deficient 
colon cancer cell lines HCT116 and DLD-1, MMR-deficient endometrial cancer lines 
SK-UT-1,2774 and HEC-1-A, and the MMR-proficient colon cancer cell line SW480, 
showed any mutation in the coding sequence of any of the tested genes. 
4.4 Analysis of MRE11, NBS1 and RadSO in MSI+ Colorectal Tumours 
It is well established that the mononucleotide runs of genes, especially runs with 6 or 
more nucleotides, are targets for mutation in MSI+ tumours (Toft and Arends, 1998, 
Chung, 2000, Bhattacharyya et al., 1994). All mononucleotide runs (N>6) of MREJ1, 
NBSI and Rad5O were amplified from 20 MSI+ colorectal tumours and amplification 
products were subject to direct sequencing (Table 4.4.1). Sequence analysis suggested 
that some cancer samples had heterozygous mutations in the coding A8 and A9 runs of 
RadSO and in an exonic A7 and an intronic A7 run of MRE11(Figure 4.4.1). 
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Table 4.4.1. Summary of mutation screening using direct sequencing of 
mononucleotide runs of the MREI 1 complex genes in MSI-L and MSI-H colorectal 
cancer samples. 
RadSOle, 53tß-541 0/5 (0.0) 0/13 (0.0) 
Rad50 A6 1717-1722 0/6 (0.0) 0/14(0.0) 
Rad50 : &v 2157-2165 1/6(16.7) 4/13(30.7) 
Rad 50 As 2794-2801 0/6(0.0) 1/14(7.1) 
. ABSI A0 
242-247 0/6 (0.0) 0/14 (0.0) 
. \'BSI A, 
1390-1396 0/5 (0.0) 0/13 (0.0) 
. ''BSI A, 
1645-1651 0/6 (0.0) 0/14 (0.0) 
. VBSI . 
1953-1958 0/5 (0.0) 0/13 (0.0) 
31REII A6 596-601 0/5 (0.0) 0/14 (0.0) 
. ºfREII 
T, 1209-1214 0/6 (0.0) 0/13 (0.0) 
31RE11 . 1235-1240 0/6 (0.0) 0/13 (0.0) 
31REII A7(jn, ronic) Intron 11 0/6 (0.0) 2/13 (15.4) 
. 11REII. 
1458-1463 0/5 (0.0) 0/13 (0.0) 
. 11REII 
A7(coding) 1550-1556 0/5 (0.0) 1/13 (7.7) 
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Figure 4.4.1. Direct sequencing of mononucleotide runs in MRE11 and Rad5O reveals 
possible heterozygous mutations (shown by blue arrows). The stutter bands on the gel 
are characteristic of frameshift mutations. (A) Several samples have potential 
mutations in Rad5O Aq. (B) One sample appears to have a frameshift mutation in 
Rad5O A. (C) One sample shows a potential heterozygous mutation in an intronic A7 
run of AMRE11. (D) One MSI+ colorectal cancer sample may have a mutation in the 
coding AIREII A7 run. 
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There is, however, a possibility that heterozygous mutations introduced to repetitive 
elements are an artefact of PCR and sequencing procedures. Therefore, samples that 
appeared to have mutations from direct sequencing were re-analysed. The run was 
amplified with the more accurate AccuPrime Taq polymerase and PCR products were 
cloned into a pDrive vector. Six clones were chosen for sequencing and where >_ 50% 
(but <100%) of the clones had taken up a mutant allele the sample was classified as 
having a heterozygous mutation. Cloning analysis confirmed the presence of a 
heterozygous mutation in Rad5O A9 in one MSI-H colorectal cancer sample (Figure 
4.4.2). However, less than 50% of clones (1 out of 6 clones) from samples suspected 
of having a mutation in either MREI1 run or the Rad5O A8 run carried a mutant allele 
(Figure 4.4.2) indicating that the mutation may have been an artefact. Alternatively, if 
these mutations are present in the tumour but not represented in 100% of tumour cells 
this could account for the low frequency of clones observed. However, a mutation that 
drives tumour development is likely to be present in the majority of tumour cells and 
therefore it was assumed that these mutations were not the primary determinants of 
cancer. Overall, this cloning analysis showed that mutations in MREJI and Rad5O 
mononucleotide runs were not as frequent or predominant as predicted by direct 
sequencing of PCR products (Table 4.4.2). 
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Table 4.4.2. Summary of mutations seen in MSI-L and MSI-H colorectal cancer 
samples in mononucleotide runs of the MREII complex after cloning of PCR 
products. 
Rad50 Ao O6 (0.0) 1/13 (7.7) 
Rad50 : fix 0/6(0.0) 0/14 (0.0) 
31REll A7(intronie) 0/6 (0.0) 0/13 (0.0) 
. t1REl1 A7(coding) 
0/5 (0.0) 0/13 (0.0) 
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Figure 4.4.2. Sequencing of cloned samples. (A) Over 50% of clones from one sample 
show a mutation in Rad50 A9 confirming the presence of a heterozygous mutation in 
this sample. (B) Less than 50% of clones from one sample show a mutation in Rad5O 
A. (C) The majority of clones have taken up a wild-type allele for the coding MREII 
A7. (D) Only one clone out of 6 carries a mutant allele for the intronic MREI1 A7. 
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4.5 Analysis of the Intron 4 Tu Tract of MREI1 in MSI+ Colorectal Tumours 
A mutation of the MREJI gene was recently reported in MSI+ colon cancer cell lines 
(Giannini, 2002). This mutation is a -1 or -2 frameshift in a run of 11 thymine residues 
in intron 4 of MREI J and results in altered splicing and generation of truncated 
MRE11 products (Giannini, 2002). The alternative splicing was reported to create a 
variant called 484de188 that skipped exon 5 (88bp) and rejoined exon 4 to exon 6 out- 
of-frame. This variant was predicted to code for a truncated protein containing the first 
105aa (of 708aa), a further 9aa then a stop codon (Giannini, 2002). 
To determine whether this mutation was present in the collection of MSI+ colorectal 
tumours under investigation, primers were designed to amplify the tract in intron 4. 
The T11 run was analysed in 6 MSI-L, 14 MSI-H, 4 MSS tumours and corresponding 
normal DNA from 4 MSI-H tumours. These results showed that a heterozygous 
frameshift mutation in MREl J T11 was present in the majority of MSI+ tumours, but 
was not seen in MSS tumours or in normal tissue (Table 4.5.1). 
To confirm that the high mutation frequency in MSI+ tumours was not a sequencing or 
PCR artefact, samples were once again amplified with an accurate Taq polymerase 
and PCR products were cloned to a pDrive vector. Assessment of clone data showed 
that direct sequencing had slightly over-estimated mutation frequency (Table 4.5.1). 
However, the frameshift mutation of MREI1 intron 4 T1 1 was present in >85% MSI-H 
colorectal tumours (Figure 4.5.1). 
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Table 4.5.1. Comparison of MREN Ti 1 mutation frequency seen after direct 
sequencing of PCR products and sequencing of cloned PCR products. 
of P('R products 
Sequencing of 0/6 (0.0) 12/14 (85.7) 0/2 (0.0) 0/2 (0.0) 
cloned products 
Figure 4.5.1. Sequencing of . tIRE11 TI, intronic mononucleotide run in colorectal 
cancer samples. (A) Direct sequencing suggests that heterozygous mutations are 
present at a high frequency in MSI' samples. (B) Sequencing of clones from one 
sample shows 50'o of clones carry a mutant allele confirming this sample has a 
heterozygous frameshift mutation. 
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4.6 Creating Nlutant 11RE11 Expression Constructs 
a) AnzplifIcation of MRE11 from Cell Lines 
A 5' fragment of. 11RE11 was amplified from total cDNA of one MMR-proficient and 
4 MMR-deficient cell lines and amplification products were run on an agarose gel 
(Figure 4.6.1). This suggested that two MMR-deficient cells lines, HCT116 and 
SIVV48, carried an MRE11 mutant product that was approximately 88bp smaller than 
the wild type. In both cell lines, the mutant cDNA appeared to be present at a lower 
level compared to the wild-type MRE11. This was consistent with the results from the 
original report identifying this mutation where the smaller PCR product had been 
named 484de188 (Giannini, 2002). Sequencing confirmed that these two cell lines 
contained a frarneshift mutation in the intronic Ti i tract of MREI1. 
Figure 4.0. l. Amplification of MRE/I fragment-1 in cell lines HCTI 16 (1), SW480 
(2), SW48 (3). HEC-1-A (4) and DLD-l (5). HCT116 and SW48 show a smaller 
amplification product along with the wild type suggesting the presence of a mutation 
in AfRF_11. 
Wild-type MRI 
4S4dcTFS \IR1 
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b) Isolation of Reported Mutant MREJ 1 Variant 
A construct expressing MRE11 484de188 was required to assess the phenotypic 
consequences of this mutation. Attempts were made to isolate this variant from 
HCT116 and SW48. Although RT-PCR results suggested that a mutant MRE1 1 
product was being produced in both cell lines, at least at the RNA level, a 
corresponding cDNA could not be directly isolated. A 5' RT-PCR product of MRE11 
from HCT116 was run on a high percentage agarose gel to give better separation of 
products and clearly showed the presence of a variant that corresponds to 484de188 
(Figure 4.6.2A). A further variant that was 300-350bp smaller than the wild-type 
MRE11 also appeared to be amplified in the RT-PCR reaction at lower levels (Figure 
4.6.2A). 
It was noted that when full length MRE11 was amplified from HCT116 several 
smaller atypical MRE11 products were also detected, and these were not seen when 
MRE11 was amplified from SW480 (Figure 4.6.2B). These smaller products might 
represent other alternative splice variants arising due to the mutation of MRE11 Ti 1 in 
HCT116. The mutant 484de188 product could not be detected on this agarose gel 
because the wild-type product is 2127bp and the difference between a 2127bp and 
2039bp product is difficult to see on a standard agarose gel. 
The reported mutant 484de188 MREll allele was re-created by designing primers to 
the specific region required (ex2-4) and a stop codon was added to the end of the 
primer. Amplification of HCT116 cDNA using these primers provided the desired 
mutant AMRE11 product, which was named 314de188. This name reflected the fact that 
the sequence runs from the ATG through to the end of exon 4 (314bp) and misses the 
88bp of exon 5. MRE11 314de188 was cloned into the pIRESparo3 expression vector by 
blunt-end ligation and clones carrying the correct product in the correct orientation 
were isolated (Figure 4.6.3). 
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Figure 4.6.2. (A) AIREI1 products amplified from HCT116. The two main products 
are the wild type (WT) MREJI and the reported 484de188 mutant MREI1. When 
excess PCR product is loaded onto the gel, a further band is apparent. (B) Smaller 
anomalous PCR products are apparent when full length MREII is amplified from 
HCTI 16 but not from SW480. 
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Figure 4.6.3. PCR-engineered MREII 314de188. Primers were designed to amplify 
from the : CTG stars codon in exon 2, through exon 4 and to a stop codon added to the 
end of the prinmer. 
Exon 2 
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c) Isolation of Other MREll Splice Variants 
Whilst attempting to isolate MRE11 484de188 cDNA several other interesting splice 
variants were obtained from HM 16. 
One of these splice variants, named 314del92, lost exon 5 and the last 4 bases of exon 
4 (92nt) and also lacked exons 7-10. Exon 4 rejoined out-of-frame to exon 6 creating 
a premature stop codon and this variant was predicted to code for a truncated protein 
containing the first 103aa (of 708aa) of the wild-type protein, then 10aa, then a stop 
codon. This truncated protein of 113aa was almost identical to the 114aa protein 
coded for by 314de188 (Figure 4.6.4). MRE11 314de192 and the engineered 314de188 
code for similar proteins that lack the last two of four conserved motifs in the nuclease 
domain of MRE11 and miss the C-terminal DNA binding domains (Figure 4.6.5). 
These variants were chosen for further study because of their similarity to the reported 
MRE11 mutant 484de188. 
A second interesting MREll splice variant, named 314de1345 was revealed during the 
cloning process. This variant skipped exons 5-7 (345nt) so that exons 4 and 8 re- 
joined in-frame and was predicted to code for a 593aa (out of 708aa) protein (Figure 
4.6.4). This mutation eliminates the third of four conserved phosphoesterase motifs 
from the protein that are necessary for nuclease activity of MRE11 and some of the 
surrounding amino acids (Figure 4.6.5 and Appendix V). MRE11 314de1345 was 
chosen for further study because it codes for a protein that is similar in size to the 
wild-type protein but specifically lacks one functional motif. 
The mutant MRE11 alleles were blunt-end ligated into the pIRESparo3 vector and 
clones carrying the correct sequences in the correct orientation were obtained (Figure 
4.6.6). 
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Figure 4.6.4. Alternatively spliced alleles of MRE11. (A) The wild-type splicing 
pattern gives rise to a 708aa protein. (B) Loss of 1-2 thymines from the intronic T11 
tract can promote skipping of exon 5 and generation of a truncated protein as reported 
by Giannini et al. (C) Splicing pattern seen in 314de1345 allele isolated from HCT1 16. 
(D) Splicing pattern seen in 314de192 isolated from HCT116, similar to reported 
mutant it codes for a truncated protein. 
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Figure 4.6.5. The protein product of MREI I has four motifs (M1-M4) in a conserved 
nuclease domain. The first three are common to many phosphoesterases and the fourth 
is common to some nucleases. (A) AIREI1 314del345 codes for a protein that lacks 
the third phosphoesterase motif and some surrounding amino acids. (B) MREII 
314dcl88 and 3l4del92 code for similar truncated proteins that lack two motifs of the 
nucleasc domain and all of the C-terminus of the protein. 
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Figure 4.6.6. Sequence analysis of 314de1345 and 314de192. (A) 314de192 skips the 
last 4 bases of exon 4, all exon 5 and rejoins to exon 6. (B) 314de1345 skips exons 5-7 
and rejoins exon 4 to exon 8. 
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4.7 Mutant MRE11 Expression in MMR-proficient Cells 
For expression of the MRE11 variants in cultured cells, 314de188,314de192 and 
314de1345 were transfected to SW480/SN3 using lipofectamine treatment. 
SW480/SN3 is a MMR-proficient tumour cell line that carries the SCneo 
recombination reporter (Appendix IV) (Mohindra et al., 2002). 
No cells stably expressing 314de188 or 314de192 were isolated, even after transfection 
of 106 cells but two independent clones (SM1.3 and SM1.6) stably expressing 
314de1345 were isolated. Expression of MRE11 314de1345 was confirmed in SM1.3 
and SM1.6 by RT-PCR and Western blot analysis (Figure 4.7.1A and B). Western 
blots were carried out using a second independent MRE11 antibody to confirm 
consistent expression of a correctly sized novel MRE11 variant corresponding to 
mutant 314de1345 (Figure 4.7.1 Q. 
To determine whether the mutant 314de1345 MRE11 isolated as a transcript from 
HCT116 was expressed endogenously in the cell a further Western blot was carried 
out to probe HCT116 cell lysate with MRE11 antibody (Figure 4.7.1D). This blot had 
to be over-exposed to detect not only the wild-type MRE11 but also minor products 
that were difficult to visualise. This analysis revealed relatively low-level expression 
of the full-length wild-type MREI1 protein in HCT116, consistent with an earlier 
report (Giannini et al., 2002). Examination of the Western blot also showed an 
MRE11 protein that corresponded to the mutant 314del345. Extensive analysis failed 
to reveal a peptide that corresponded to the previously reported MRE11 variant coding 
for a truncated protein of 114aa (Giannini et al., 2002). This suggests that the 
314de1345 variant is in fact expressed in the HCT116 cell line but a peptide 
corresponding to the 314de188 variant is not, or is turned over very rapidly. The 
314de1345 MREI 1 variant was never observed in SW480/SN3 cells. 
149 
Chapter 4: Analysis of the MREI I Complex 
Figure 4.7.1. Expression of MREI 1314de1345 in the transfected colon cancer cell line 
S\V480 SN3 and endogenous expression in HCT116. (A) RT-PCR showing 
expression of the mutant AMRE11 allele in transfected cells. Reactions were carried out 
with (+) and without (-) RT to control for contaminating genomic DNA. (B) and (C) 
Western blot analysis with independent MREII antibodies showing consistent 
expression of 314de1345 in transfected cells. (D) Western blot analysis showing 
endogenous expression of MREII 314de1345 from HCT116. This blot was over- 
exposed to detect variant MREI I products that were difficult to visualise. 
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4.8 Phenotypic Consequences of MREll Mutation 
To determine the phenotypic effects of mutant MRE11 expression several functional 
studies were carried out on two independent isolates carrying 314de1345, SM1.3 and 
SM 1.6. 
To establish whether the expression of mutant MRE11 or presence of puromycin (the 
selective agent for pIRESParo3 expression vector) affected cell growth a growth assay 
was carried out (Figure 4.8.1). This showed that the transfected lines did grow slightly 
slower than the SW480/SN3 parental cell line, although the presence of puromycin 
did not seem to exacerbate this. Therefore, expression of a mutant MRE11 appears to 
affect cellular growth rates. 
The response of cells expressing mutant MRE11 to various toxic agents was compared 
to the response of the parental SW480/SN3 cells and to HCT116, the cell line from 
which that the mutant MREII was isolated. Experiments were carried out to 
determine whether the expression of a mutant MRE11 could affect sensitivity of 
MMR-proficient cells to thymidine (Figure 4.8.2), ionising radiation (IR) (Figure 
4.8.3), camptothecin (CPT) (Figure 4.8.4), mitomycin C (MMC) (Figure 4.8.5) and 
hyroxyurea (HU) (Figure 4.8.6). 
This analysis showed that cells expressing mutant MRE11 314de1345 were 
dramatically more sensitive to thymidine relative to the parental SW480/SN3, even at 
the lowest doses (Students t-test at 0.25mM thymidine SW480/SN3 vs SMI. 3 
p=2.5x10'3 and SW480/SN3 vs SM1.6 p=3.6x10'7). 
Expression of mutant MREI 1 also caused cells to become significantly more sensitive 
to CPT at doses over 5nM (SW480/SN3 vs SM1.3 p=0.004, SW480/SN3 vs SM1.6 
p=0.001, by the t-test). 
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The effect of mutant MRE11 expression on IR sensitivity was more complex. The 
SMI. 3 and SMI. 6 cells showed a significant increase in IR sensitivity relative to 
parental cells only at higher doses (p=0.042 at 8Gy by the t-test). 
Both control cell lines (SW480/SN3 and HCT116) showed a similar response to 
MMC exposure, and cells expressing 314de1345 were only significantly more 
sensitive than parental cells to MMC at 60nM MMC (SW480/SN3 vs SM1.3 p=6x10'5 
and SW480/SN3 vs SM. 16 p=8.4x10'5, by the t-test). 
HCT116 cells were more resistant to HU treatment relative to parental SW480/SN3 
cells. Introduction of a mutant MRE11 into the parental SW480/SN3 cell line caused a 
slight but significant increase in HU sensitivity (SW480/SN3 vs SM1.3 p=0.018 and 
SW480/SN3 vs SM. 16 p=0.03 at 50µM HU, by the t-test). 
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Figure 4.8.1. Growth assay comparing the growth rate of the parental SW480/SN3 
with the transfected cell lines, in the presence or absence of puromycin. 
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Figure 4.8.2. Expression of hMREII 314de1345 in the colon cancer cell line 
SW480/SN3 sensitises cells to thymidine. Lines show an average of three independent 
colony-forming assays, error bars represent standard deviations. 
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Figure 4.8.3. Cells expressing MRE11 314de13454 are sensitive to ionising radiation 
(IR) only at higher doses. Shown is an average of three independent colony-forming 
assays, error bars represent standard deviations. 
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Figure 4.8.4. Sensitivity of SM1.3 and SM1.6 cells, expressing MRE11 314de1345, to 
camptothecin (CPT). Colony forming assays were performed independently three 
times. Error bars represent standard deviations. 
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Figure 4.8.5. Introduction of mutant MRE11 314de1345 to SW480/SN3 does not 
significantly alter response to mitomycin C (MMC), except at 60nM MMC. Shown is 
an average of three independent assays, error bars represent standard deviations. 
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Figure 4.8.6. Mutant MREI 1 expression slightly increases sensitivity to HU, relative 
to the parental cell line. Shown is an average of three independent colony-forming 
assays, error bars represent standard deviations. 
1 
0.1 
c 0 
U 
12 0.01 
C 
Cl) 0.001 
0.0001 
- - SW480/SN3 
-a- HCT-116 
-o- SM1.3 
--o- SM1.6 
0 100 200 300 400 500 
Hydroxyurea [uM] 
158 
Chapter 4: Analysis of the MRE11 Complex 
4.9 Activation and Expression of MRE11 and NBS1 
It had previously been determined that HCT116 was defective in the phosphorylation 
of MRE1I following treatment with either thymidine or IR (E. Bolderson, personal 
communication). To establish whether this response was due to expression of a mutant 
MRE1I Western blots were carried out. Cell free extracts were prepared from 
SW480/SN3, SM1.3, SM1.6 and HCT116 cells treated with thymidine, IR and HU 
and analysed by Western blotting using antibodies against MRE11, NBS1 and the 
ATM-phosphorylated form of NBS1 (Phospho-Ser343 NBS1). Thymidine treatment 
of the parental SW480/SN3 cell line induced a shift in the electrophoretic mobility of 
the full length MRE11, similar to the phosphorylation dependent band shift found 
following treatment with IR or HU (Figure 4.9.1 and (Dong, 1999). In contrast, 
SM1.3, SM1.6 and HCT116 did not show such activated forms of MRE11. 
Phosphorylation of NBS1 could be detected in all the cells tested following treatment 
with thymidine, HU or IR. 
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Figure 4. x). 1. Cells expressing 314dcl345 activate NBSI but not MRE11 following 
treatment with 10mM thymidine (TdR), 2mM HU or IOGy IR. The mobility shifts 
characteristic of MRE11 phosphorylation (*) are evident in treated SW480/SN3 but 
not SM 1.3. SM 1.6 or HCT116 cells. Actin loading controls are also presented. 
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4.10 Activation and Expression of Chkl and Chk2 
To disco\ er whether cells expressing a mutant MREI 1 were capable of activating 
Chk2 and Chk 1 following DNA damage Western blots were carried out using 
antibodies against the ATM-phosphorylated form of Chk2 and the ATR- 
phosphorylated form of Chkl. The parental cell line and cells expressing MREII 
314dc1345 did phosphorylate Chkl and Chk2 as a consequence of DNA damage 
(Figure 4.10.1). Chk 1 phosphorylation was apparent after DNA damage in lysates 
prepared from HCT 1 16 but Chk2 signalling was strongest following IR treatment in 
these cells (Figure 4.10.1). 
Figure 4.10.1. Cells were treated with 2mM HU, 10mM thymidine or IOGy IR before 
protein was harvested and analysed by Western blot using antibodies against the 
ATM-phosphorylated form of Chk2 (P-Thr68-Chk2) and the ATR-phosphorylated 
form of Chkl (P-Ser345-Chk1). 
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4.11 Double-Strand Break Induced Recombination 
It has previously been shown that MMR-deficient cell lines are defective in 
homologous recombination repair following a single site-specific double-strand break 
(Mohindra et al., 2002). To determine whether a mutant MRE11 could contribute to 
this phenotype a recombination assay was carried out. Recombination was measured 
using the SCneo recombination reporter which measures homology-based 
recombination events between two defective neomycin resistance genes (Appendix IV 
and (Johnson et al., 1999). A site-specific DSB was introduced by transient 
transfection of an I-SceI expression construct into cells carrying a single copy of 
SCneo and cells were plated on G418 to select for neo+ recombinants. 
The frequency of neo+ recombinants in the parental SW480/SN3 and the SM1.3 and 
SMI. 6 cells increased 87- to 110-fold whereas HCT116 cells showed no significant 
increase in neo+ recombinants following a site-specific DSB (Figure 4.11.1). 
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Figure 4.11.1. Parental SW480/SN3 cells and cell expressing MRE11 314de1345 
induce homology-directed repair following a site-specific DSB. MMR-deficient 
HCT116 cells fail to induce HR following a site-specific DSB. 
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4.12 Thymidine-Induced Recombination 
Previous work has shown that cells defective in HR repair become sensitive to 
thymidine and that thymidine is a potent inducer of HR (Lundin et al., 2002). These 
observations indicate that thymidine induces the accumulation of DNA lesions and 
that cell survival depends on the resolution of these lesions by HR. Given the 
increased thymidine sensitivity of cells expressing mutant MRE11 314de1345 it was 
important to establish whether this response was caused by an inability to repair 
thymidine-induced DNA damage. 
Replica cultures of 1000 cells were plated for SW480/SN3, SM1.3, SM1.6 and 
HCT116. These cultures were allowed to grow out to lx106 cells before being treated 
for 24 hours with increasing concentrations of thymidine. Treated cultures were left 
for two days to allow recovery before plating on G418 to select for neo+ 
recombinants. 
This analysis showed that thymidine treatment increased the frequency of neo+ 
recombinants up to 12-fold in SW480/SN3 cells in a dose-dependent manner (Figure 
4.12.1). SMI. 3 and SMI. 6 cells expressing a mutant MRE11, and the MMR-deficient 
HCTI 16 cells, showed no increase in the frequency of neo+ recombinants after 
thymidine treatment (Figure 4.12.1). Comparison of the responses using regression 
analysis showed that the SW480/SN3 cell line had a significantly increased 
recombination frequency in response to thymidine compared to the SM1.3 and SM1.6 
cell lines (likelihood ratio test p=0.0025). 
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Figure 4.12.1. Thymidine induces recombination in SW480/SN3 but fails to 
significantly induce recombination in SM1.3, SM1.6 or HCT116 cells. 
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4.13 Camptothecin-Induced Recombination 
Cells expressing a mutant MRE11 may not be able to tolerate the level of damage 
induced by thymidine treatment. Alternatively, it is possible that thymidine treatment 
creates a specific recombinogenic lesion that requires MRE11 to resolve it. To 
distinguish between these possibilities HR events following CPT treatment were 
measured. This analysis showed that cells expressing MRE11 314del345 remained 
proficient in homology-directed repair following CPT treatment (Figure 4.13.1). A 
similar stimulation of HR following CPT treatment was seen in the parental 
SW480/SN3 cells (A. Mohindra, personal communication). 
These results were very interesting in that a considerable induction (100-fold) in HR 
was seen in SM1.3 and SM1.6 cells after treatment with 7.5nM CPT. Such a large 
induction following treatment with relatively low doses suggests altered kinetics in 
HR activation following CPT treatment. The nature of this phenomenon is beyond the 
scope of this thesis but certainly merits further investigation in the future. 
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Figure 4.13.1. Camptothecin treatment induces recombination in cells expressing 
mutant MRE 11 314de1345. 
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4.14 Pulsed-Field Gel Electrophoresis 
Pulse-field gel electrophoresis (PFGE) was used to determine whether thymidine 
treatment induced DNA DSBs in SW480/SN3, SM1.3, SM1.6 and HCT116 cells. 
Cultures of each cell line were treated with HU, CPT, thymidine, and IR and 
harvested for analysis (Figure 4.14.1). 
PFGE showed that thymidine did not induce detectable DSBs in any of the cell types. 
DSBs were evident in all cell types following treatment with CPT and IR, although 
CPT treatment did appear to induce less DSBs in HCT116 cells. Some lower 
molecular weight DNA, which may represent cells undergoing apoptosis, was 
observed following HU and thymidine treatment in most cell types. 
This investigation confirmed that thymidine treatment does not generate the same 
level of DNA double-strand breaks as CPT or IR treatment. 
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Figure 4.14.1. Pulse-field gel electrophoresis shows damaged DNA in all cells 
following treatment with CPT or IR. Thymidine and HU do not introduce the same 
level of double-strand breaks. 
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4.15 Transfection of MRE11314de1345 to MRC5VA 
The cellular background of the parental SW480/SN3 tumour cell line may have 
contributed to the phenotypic response of SM1.3 and SM1.6 cells in this investigation. 
The effects observed thus far have been attributed to the presence of MRE11 
314de1345. To determine whether they were solely due to the mutant MRE11 and not 
intensified by the inherent nature of the SW480/SN3 tumour cells the mutant MRE11 
construct was introduced into a second cell line, MRC5VA. This is an immortalised 
normal lung fibroblast cell line. 
Expression of 314de1345 in two transfected MRC5VA clones (MM1.2 and MM1.3) 
was confirmed by RT-PCR and Western blot (Figure 4.15.1). This analysis showed 
that the MRC5VA and SW480/SN3 clones did not express comparable levels of the 
mutant MRE11 protein, with expression of the 314de1345 variant being much reduced 
in transfected MRC5VA cells. Time limitations of this project meant it was not 
possible to screen further transfectants to establish clones expressing comparable 
levels of mutant MRE11. However, this is a priority for future experiments. 
The thymidine sensitivity of MM 1.2 and MM 1.3 was compared to the thymidine 
sensitivity of the MRC5VA parental cell line (Figure 4.15.2). MRC5VA cells 
expressing mutant MRE11 were slightly but not significantly more sensitive to 
thymidine than the parental cell line (MRC5VA vs MM1.2 p=0.49, MRC5VA vs 
MMI. 3 p=0.27 at 2mM thymidine with the Students t-test). 
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Figure 4.15.1. Expression of MRE11 314de1345 in the immortalised normal lung 
fibroblast cell line MRC5VA. (A) RT-PCR showing expression of the mutant A4REI 1 
allele in two transfected clones. RT-PCR analysis reactions were run with (+) and 
without (-) RT to ensure that the truncated product was not caused by genomic DNA 
contamination. (B) Western blot analysis showing expression of MRE11 from 
SW480/SN3 (1), SM 1.3 (2), SM 1.6 (3), MM 1.2 (4), MM 1.3 (5) and M RC5VA (6). 
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Figure 4.15.2. Thymidine sensitivity of the MRC5VA parental cell line does not differ 
significantly from sensitivity of MRC5VA cells transfected with mutant 314de1345 
MRE11 (MM1.2 and MM1.3). 
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4.16 Transient expression of 314de188 and 314de1345 
Cells that stably express mutant MRE11 314de188 could not be established. One 
potential reason for this is that 314de188 codes for a severely truncated protein that 
causes cell death. To test this possibility cells were transiently co-transfected with a 
GFP-tagged vector and MRE1 1 314de188, MRE11 314de1345 or empty pIRESparo3 
vector. Cells that expressed GFP were presumed to also be expressing the second 
construct. Apoptosis events following the transfection were measured using Hoechst 
33342 staining. The level of apoptosis in cells expressing empty pIRESparo3 vector was 
taken as the background apoptotic level following transfection and apoptosis induced 
by the introduction of a mutant MRE11 was compared to this (Figure 4.16.1). 
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Figure 4.16.1. Hoechst 33342 staining of cells 24 hours after transfection with a 
mutant MRE I1 allele or empty pIRESparo3 vector. Data shows percentages of 
apoptotic cells exhibiting condensed nuclear morphology. Averages (columns) and 
standard deviations (bars) of 2 trials are shown. 
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4.17 Discussion 
The MRE11 complex (composed of MRE11, NBS1 and Rad50) plays a key role in 
DNA replication and the cellular response to DNA damage (D'Amours, 2002, 
Mirzoeva and Petrini, 2003). The complex has potential roles in homologous 
recombination (HR) repair of DNA double-strand breaks and non-homologous end- 
joining (NHEJ). The MRE11 complex has been implicated in DNA damage 
recognition functions and signal transduction to activate ATM-dependent cell-cycle 
checkpoints (Stewart et al., 1999). The complex also has a potential role in 
maintaining genomic stability by preventing the accumulation of DNA double-strand 
breaks during genomic replication (Costanzo, 2001). 
Inherited mutations of MRE11 or NBSI result in chromosome instability disorders 
characterized by hypersensitivity to IR, immunodeficiency, and predisposition to the 
development of malignancies (Carney et al., 1998, Stewart et al., 1999, Varon et al., 
1998). The precise roles of MRE11 and NBS1 in these responses has been difficult to 
establish because null mutations of these genes are lethal (Yamaguchi-Iwai, 1999, Zhu 
et al., 2001). 
Since the MREI 1 complex has important roles in maintaining genomic integrity it was 
hypothesised that the MREI l, NBSJ and Rad5O genes were potential targets for 
mutation in the development of cancer. Given that loss of MMR increases overall 
genomic instability and promotes further mutations in other key repair proteins, 
mutations in MREll, NBSI and Rad5O became even more probable in MMR-deficient 
tumour cells. 
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a) Mutation of the MREll Complex is Frequent in MSr Cancers 
Previously, mutations and polymorphisms in the coding sequence of MREII and 
NBS1 have been observed in primary tumours and cell lines (Fukuda, 2001, Tessitore 
et al., 2003). However, analysis of the colon and endometrial cancer cell lines 
available for this study revealed no mutations in the coding sequence of any of the 
candidate genes. 
A further investigation of primary colorectal tumours revealed heterozygous 
frameshift mutations in mononucleotide runs of the Rad5O and MREII genes. 
Analysis showed that the Rad5O A9 coding mononucleotide run was mutated in 7.7% 
of MSI+ CRC samples whereas previous studies have reported the mutation frequency 
of Rad5O A9 in MSI{' colorectal tumours to be 28-33% (Kim et al., 2001, Duval and 
Hamelin, 2002). Although the observed incidence of Rad5O A9 mutations is much 
lower than previous reports the extensive cloning analysis in this study suggests that 
the mutation frequency obtained for this population is accurate. The inter- 
experimental variation could be due to population differences, such as age, ethnicity 
or sex. An alternative explanation for the difference is that not all tumour cells 
examined in this study express the mutant allele. If this were the case then this 
frameshift mutation would not be expected to play a primary role in tumour 
development since mutations that predispose to malignancy are likely to be present in 
the majority of tumour cells. 
However, a frameshift in the A9 tract of RadSO would truncate the protein from 
1312aa to 734aa. The functional consequences of this truncated Rad50 have yet to be 
established. Future studies to examine the phenotypic consequences of this mutation 
will be important in determining the impact of Rad50 alteration on cancer 
development. 
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A recent study reported a -1/-2 frameshift mutation in the T11 polypyrimidine tract in 
MREI1 intron 4 (Giannini, 2002). T9 and/or Tlo alleles were seen in 93% of MMR- 
deficient primary colorectal cancers and all MMR-deficient cancer cell lines studied 
but were not detected in MMR-proficient cancer cell lines or primary tumours 
(Giannini, 2002). This mutation has also been observed in 12% of MMR-defective 
acute leukaemia (Casorelli et al., 2003). 
Extensive cloning and sequencing analysis of 20 MSI+ colorectal tumours estimated 
that this mutation occurred in >85% of MSI-H colorectal tumours. The frameshift 
mutation was not seen in non-cancer (normal) tissue surrounding the MSI+ cancers or 
in MSS tumours suggesting that the MRE11 mutation is associated with a MMR- 
deficiency. Interestingly, the mutation was not seen in any MSI-L tumours and this is 
consistent with other studies that have reported that MSI-H tumours have distinct 
clinicopathological and molecular characteristics from MSI-L and MSS tumours 
(Duval and Hamelin, 2002, Halford et al., 2002). 
Polypyrimidine tracts are important cis-acting signal sequences directing intron 
removal. Tracts with 11 continuous uridines are the strongest tracts and decreasing 
numbers of uridines in the tract can alter 3' splice site selection and reduce efficiency 
of splicing (Coolidge et al., 1997). The mutation in the T11 run of MREJI intron 4 
shortens the polypyrimidine tract, reduces its strength as a signal sequence and so 
reduces but not abolish the correct splicing process. Cells with the MRE11 T11 
frameshift mutation produce a mixture of wild type and mutant MRE1 1 products. 
It was reported that in >50% of MMR-deficient colorectal cancer samples with the 
mutation in MRE11 T11 the wild-type allele was under-represented compared with the 
mutant alleles, suggesting a homozygous change (Giannini, 2002). However, the 
homozygous nature of the mutation was not confirmed and no homozygous mutations 
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were seen in this current study. However, since the MRE11 mutation reduces but does 
not completely abolish the correct splicing process a combination of wild-type and 
variant transcription products are generated both when the mutation is heterozygous 
and homozygous. 
To investigate the phenotypic consequences of the mutation in MRE11 a cDNA copy 
of the principal reported mutant product, 484de188 was required. Expression of the 
484de188 cDNA could be confirmed in HCT116 and SW48 but a cDNA copy of the 
MRE11 variant could not be isolated directly from these cell lines. The 484de188 
MREI1 variant cDNA or peptide was not isolated in the study that originally 
identified this variant either (Giannini et al., 2002). It is possible that the transcript 
does not exist in the cell for an extensive enough time to allow isolation and it was 
noted that nonsense mediated decay was taking place to degrade the aberrant 484de188 
transcript (Giannini et al., 2002). MRE11 Western blots on protein extracts from 
HCT116 showed no peptide corresponding to 484de188, suggesting that translation of 
the aberrant transcript does not take place in this cell line or that turnover of this small 
product is rapid. If this mutant MRE11 protein is not stably produced then the 
significance of the 484de188 variant in the cell is questionable. 
During analysis of cloned MRE11 products from HCT116, several other alternative 
mutant MREII alleles were detected. It was hypothesised that these variants were 
created by alternative splicing promoted by the mutation in the TI I tract of MRE11. 
Cells that stably expressed the isolated MRE11 truncating variants 314de188 and 
314de192 could not be obtained. Analysis revealed that transfection of 314de188 to 
cultured cells caused twice as much apoptosis as uptake of either empty vector or 
MRE11 314del345. This result is consistent with the idea that severely truncated 
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mutant MRE11 transcripts cause cell death upon their expression in the cell and it is 
known that null mutants of MRE11 are lethal (Yamaguchi-Iwai, 1999). This also 
raises the possibility that shorter aberrant transcripts that might be present in HCT116 
are transient, as is the case for 484de188 (Giannini, 2002), to prevent induction of 
apoptosis. 
b) MRE11314de1345 Affects Response to DNA -damaging Agents 
Functional studies to investigate the phenotypic effects of a mutant lacking the third 
phosphoesterase motif, 314de1345, provided insights into the consequences of 
compromising wild-type functioning of MRE11. 
One proposed role for the MRE11 complex is to prevent the accumulation of DNA 
DSBs at replication forks (Costanzo, 2001, Mirzoeva and Petrini, 2003). Treatment of 
cells with camptothecin induces replication fork-associated DNA DSBs in the S-phase 
of the cell cycle (Arnaudeau et al., 2001, Furuta et al., 2003). Since only S-phase cells 
are susceptible to CPT-induced DNA damage and in wild-type S-phase cells MRE11 
is associated with the replication fork (Maser, 2001) accumulation of DSBs in these 
cells could be prevented. In contrast, expression of a mutant MRE 11 conferred CPT 
sensitivity, possibly by reducing surveillance ability or efficiency at the replication 
fork thereby allowing accumulation of CPT-induced DSBs and causing cell death. 
Cells from A-TLD patients expressing a severely truncated form of MRE11 show 
extreme sensitivity to IR, whereas cells from patients with a point mutation close to 
the third phosphoesterase motif do not show acute IR sensitivity (Stewart et al., 1999). 
Similarly, yeast mutants carrying a point mutation in motif III of the ScMrell 
nuclease domain do not show a dramatically increased sensitivity to IR (Bressan et al., 
1998). These results suggest that MRE11 mutations that decrease the efficiency of but 
do not abolish MRE11 function might not lead to severe IR sensitivity. The IR 
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sensitivity of cells expressing MRE11 314del345 was only significantly increased 
relative to parental cells at doses greater than 8Gy IR. This may reflect an inability to 
cope with increasing levels of IR-induced damage due to reduced MRE11 nuclease 
activity. 
Expression of MRE11 314del345 led to a slightly but significantly increased 
sensitivity to HU relative to the parental cell line. HU inhibits the ribonucleotide 
reductase enzyme and depletes cells of all dNTPs required for DNA synthesis. This 
suspends DNA replication by limiting the dNTP pools and leads to stalling of the 
replication fork (Lopes 01). HU is known to trigger phosphorylation of NBS1 in an 
ATM-independent manner (Wu et al., 2000) but the role of MRE11 in this response is 
unknown. Potentially, MRE11 314de1345 could impair MRE11 complex formation or 
de-regulate NBS1 phosphorylation so that the response to HU is altered. Alternatively, 
the presence of a mutant MRE11 may force the cell to use a second, less efficient 
pathway to process the HU-induced damage and this might be reflected as an increase 
in sensitivity to HU. 
Sensitivity to MMC was not dramatically affected by expression of 314de1345, 
suggesting that the mutant MRE11 does not significantly impair the response to 
MMC-induced damage. MMC-induced interstrand cross-links are usually resolved by 
sister chromatid exchanges mediated by HR (Hoeijmakers, 2001, Sonoda et al., 2001) 
and MMC sensitivity is more frequently associated with defects in HR genes that have 
a direct role in the resolution of cross-links, such as the Rad51 paralogs (Takata et al., 
2001). It is possible that the endogenous wild-type MRE11 in the transfected cells has 
sufficient activity to process the damage caused MMC. 
Together, these results support a role for MRE11 in the DNA damage response 
triggered by impaired DNA replication forks or DSBs in the cell. 
180 
Chapter 4: Analysis of the MREI I Complex 
c) MREII 314de1345 Affects Phosphorylation Events Following DNA Damage 
The MRE11 314de1345 variant appears to block phosphorylation of the wild-type 
protein upon DNA damage to prevent MRE11 activation. The phosphorylation of 
MRE11 is likely to increase its nuclease activity (Costanzo et al., 2001) and therefore 
loss of this post-translational modification may compromise repair functions of the 
MRE11 complex. Phosphorylation of MRE11 in response to DNA damage precedes 
foci formation (Dong et al., 1999) and therefore may play a role in targeting the 
MRE11 complex to sites of repair. However, the exact role of MRE11 modification 
has yet to be established and further studies are required to determine the biochemical 
consequences of defective MRE11 phosphorylation. Whether MRE11 
phosphorylation is required for all downstream functions of the MRE11 complex also 
merits investigation. 
Examination of cell-free extracts from HCT116 suggested that this cell line expressed 
MRE11 314de1345 endogenously. This result indicates that the 314de1345 variant may 
exist in cells carrying a frameshift mutation in the intronic T11 tract of MRE1I and 
may well be exerting an effect in vivo. 
Further analysis showed that all cell lines remained proficient in ATM-dependent 
NBSI phosphorylation induced by DNA-damage, showing that the mutant MRE11 
did not interfere with NBS1 signalling. 
Cells expressing mutant 314de1345 remained proficient in DNA damage-induced 
phosphorylation of the Chk2 and Chkl kinases. Furthermore, phosphorylation events 
in cells expressing 314de1345 did not appear to be up-regulated compared to those in 
SW480/SN3 cells suggesting that there was no attempt to compensate for a defective 
MREl1 pathway by up-regulating other branches of the DNA damage-dependent S- 
phase checkpoint response. Defects in the ATM-Chk2-Cdc25A branch of the pathway 
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do not affect the ATM-NBSI-MRE11 branch (Falck, 2002), and the results obtained 
here show that the reverse is also true. 
One observation made during analysis of Chk2 phosphorylation conflicted with a 
previous report. It was suggested that the MMR-deficient cell line HCT116 fails to 
undergo ATM-mediated Chk2 phosphorylation following IR and that Chk2 
phosphorylation depends on MMR (Brown et al., 2003). This does not agree with data 
obtained here where Chk2 phosphorylation was seen following IR treatment in 
HCT116 cells. There are several possible explanations as to why there are differences 
between the two studies. Firstly, this study uses 10Gy IR to induce damage whereas 
Brown et al use 5Gy. It is possible that there is a threshold switch within the cell to 
activate certain response pathways above specific levels of damage. Secondly, the 
stage of the cell-cycle at which IR-induced damage occurs may affect the checkpoint 
pathway that is activated (Xu et al., 2002). Lastly, these cells are in dynamic cultures 
where various events take place over time that may affect cellular outcomes. 
It was noted however, that two other impartial researchers, one in the same laboratory, 
the second in an independent laboratory obtained equivalent data showing 
phosphorylation of Chk2 from HCT116 after IR-induced damage (E. Bolderson and J. 
Dziegielewski, personal communication). 
d) MREI J is Essential for HR Repair of Thymidine-impaired Replication Forks 
Depletion of dCTP pools through the allosteric regulation of ribonucleotide reductase 
following thymidine treatment slows but does not arrest DNA replication fork 
progression and cells accumulate in S-phase (Bjursell and Reichard, 1973). The 
disruption of DNA replication caused by the dCTP depletion appears to generate 
substrates for recombination that must be resolved by HR for cell survival (Lundin et 
al., 2002). Expression of MRE11 314de1345 dramatically increased cellular sensitivity 
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to thymidine, possibly by disrupting the HR repair response to thymidine-induced 
damage. In support of this hypothesis, cells expressing the variant MRE11 were 
proficient in HR following a site-specific DSB but failed to induce HR following 
thymidine treatment. Thymidine has previously been shown to be a potent inducer of 
HR in hamster cells (Lundin et al., 2002) and results obtained from the SW480/SN3 
parental cell line indicate that it also induces HR in human cells. It was initially 
proposed that thymidine did not activate HR in transfected cell lines because cells 
with a mutant MREII would be overwhelmed by the level of damage. However, 
further experiments revealed that cells expressing 314de1345 could activate HR 
following CPT treatment. This suggested that it was not that cells with a mutant 
MRE11 failed to cope with the level of damage as both CPT and thymidine have the 
potential to act at every replication fork in the cell. 
This raised the interesting possibility that a specific lesion is created at the replication 
fork by thymidine treatment. Results from PFGE experiments imply that thymidine 
does create a different lesion to CPT as CPT treatment creates detectable levels of 
DSBs, whereas treatment with thymidine does not. This research shows for the first 
time that HR-mediated rescue of thymidine-impaired replication forks requires a 
functional MRE11 and supports increasing evidence for a role of MRE11 in 
maintaining the integrity of DNA replication forks (Yamaguchi-Iwai et al., 1999, 
Costanzo et al., 2001, Mirzoeva and Petrini, 2003). 
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e) Putative Requirement for Threshold Levels of Mutant MRE11 
Expression of MRE11 314del345 in MRC5VA cells did not give as dramatic 
phenotypic consequences as when expressed in SW480/SN3 cells. 
If the mutant MRE11 is interfering with wild-type MRE11 activation, as was 
suggested by the lack of phosphorylation of wild-type MRE11 protein following DNA 
damage in SW480/SN3 transfected cells, then it would make sense that a threshold 
level of mutant protein would be necessary to alter MRE11 responses. It follows then, 
that the mutant 314de1345 MRE11 transfected to MRC5VA cells fails to introduce a 
significant detrimental phenotype because there is insufficient mutant MRE11 
expression. A normal cell line expressing comparable levels of mutant MRE11 to the 
SW480/SN3 transfectants needs to be created for future studies to establish the impact 
of cellular background on mutant MRE 11 phenotype. 
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5.1 Discussion 
The primary focus of this research was to undertake a systematic study of mutations 
and polymorphisms in candidate genes with roles in homologous recombination 
(HR) repair and cell-cycle checkpoints. The frequency of such mutations and 
polymorphisms has been determined in MMR-deficient cancer cell lines and 
primary colorectal tumours and the validity of these mutation frequencies confirmed 
by extensive cloning analysis. The phenotypic consequences of a common MRE11 
mutation have been comprehensively investigated and a role for MRE11 in repair of 
impaired DNA replication forks has been proposed. 
5.2 Alteration of HR Genes in Colorectal Cancer 
This investigation found little evidence to support the hypothesis that mutations in 
XRCC2, XRCC3 or Mus8l are associated with colorectal cancer. Mutations of these 
genes are likely to have severe consequences for the cell and therefore may not be 
tolerated. Some polymorphisms of these genes are present in the cancer population, 
although results from this study suggest that they are not associated with a 
significantly increased risk of colorectal cancer development. A mutation ofXRCC2 
has been found in rare cases of uterine cancers (Mohindra et al., 2003) and a subtle 
acting polymorphism of XRCC2 has been shown to be associated with a subset of 
breast cancers (Rafli et al., 2002). A common polymorphic variant of XRCC3, 
T241M has been reported to be associated with increased risk of malignant 
melanoma, bladder cancer and breast cancer (Winsey et al., 2000, Matullo et al., 
2001, Rafii et al., 2003). However, there is conflicting evidence regarding the 
XRCC3 findings and the originally observed association was not detected in other 
bladder cancer or malignant melanoma populations (Duan et al., 2002, Stern et al., 
2002). 
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Whereas the majority of previous studies have associated the 241Met XRCC3 
variant with increased cancer risk, a recent study found a weak association between 
the 241Thr variant and colorectal cancer (Mort et al., 2003). Therefore, there is still 
debate as to whether this polymorphism of XRCC3 increases cancer risk and no 
conclusive evidence has been gathered to show that XRCC2, XRCC3 and Mus8l are 
involved in colorectal cancer development. Studies designed to detect associations 
between DNA repair gene polymorphisms and cancer susceptibility may have 
differing results because of insufficient sample sizes or population differences. 
While this study does not exclude the possibility that HR gene polymorphisms may 
make minor contributions to colorectal cancer predisposition an exhaustive study 
would be required to examine the relationship of polymorphisms in these genes 
with colorectal cancer. Extensive genotyping followed by comparison of genotype 
distributions of a larger colorectal cancer population and a large matched normal 
population would provide a more accurate insight into the role of XRCC2, XRCC3 
and Mus8l gene polymorphisms in colorectal cancer. Such analysis was beyond the 
scope of this research since the primary focus was to determine whether somatic 
mutations of candidate HR genes are present in colorectal cancers and to establish 
the phenotypic consequences of such mutations. 
5.3 Essential Cellular Roles of MRE11 
This research revealed that a high proportion of MSI-H colorectal tumours have a 
mutation in the intronic Tl I run of MREI 1 that leads to the creation of several MRE11 
splice variants. Comprehensive investigation of the phenotypic consequences one of 
these variants, 314de1345, suggested an essential role for MRE11 in the HR repair- 
mediated rescue of DNA replication forks arrested by thymidine. 
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The exact nature of this role is not yet clear as the lesion created by thymidine 
treatment is not known. It has been proposed that impairment of replication fork 
progression by thymidine treatment causes the replication fork to regress leading to a 
four-way junction known as a `chicken foot' (Lundin et al., 2002). These structures 
can be resolved into Holliday junctions that then act as substrates for recombination. 
A role for MRE11 in maintaining DNA replication fork integrity has previously been 
suggested. Chicken DT40 cells depleted of MRE11 die with chromosomal breaks 
(Yamaguchi-Iwai et al., 1999) and MRE11 is required to prevent the accumulation of 
DSBs at DNA-replication forks in cell-free extracts prepared from Xenopus eggs 
(Costanzo et al., 2001). The MREI l complex is known to be associated with PCNA at 
replication forks throughout S-phase (Mirzoeva and Petrini, 2003) and a proposed 
function for the MRE11 complex is in resolution of damaged or stalled replication 
forks (Maser et al., 2001). Therefore, it has been hypothesised that the MRE11 
complex may associate with and resolve unusual structures formed during DNA 
replication (Xiao and Weaver, 1997). 
This research supports a model in which the MRE11 branch of the ATM-mediated S- 
phase response is required for thymidine-induced HR. The MREI1 mutant studied 
here blocks activation of wild type MRE11 and prevents thymidine-induced HR. 
These data, together with the fact that A-TLD cells show radio-resistant DNA 
synthesis (Stewart et al., 1999), suggests that a fully activated MRE11 is critical for 
both damage-dependent activation of the S-phase checkpoint and HR-mediated rescue 
of DNA replication forks impaired by thymidine (Figure 5.3.1). 
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Figure 5.3.1 Model predicting an essential role for the MREI 1 complex in activating 
the S-phase checkpoint response and homologous recombination (HR) following 
exposure to thymidine. 
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5.4 Disruption of MRE11 Motif III 
Although, MRE11 314de1345 appears to function in a dominant-negative manner the 
mechanism by which it exerts its effect is still unclear. The protein encoded by 
MRE11 314de1345 has amino acids 106-219, including the third phosphoesterase 
motif, deleted. The function of this region of the protein has been investigated to some 
extent in model systems. 
An investigation of Pyrococcus furiosus MRE11 revealed seven conserved residues 
that tightly coordinated two Mn2+ ions (Hopfner et al., 2001). The Mn2+ binding is 
required for 3'-5' exonuclease activity of the protein (Trujillo et al., 1998). Two of the 
conserved, coordinating amino acids in the human MRE11 protein (Asn128 and 
His217) are missing from 314de1345. Therefore expression of 314de1345 may 
destabilise metal ion binding and lead to a decreased exonuclease activity that may be 
necessary for HR functions. Disruption of metal ion binding may also have a global 
effect on MREl1 structure leading to impairment of molecular interactions at distal 
sites (Stewart et al., 1999). 
Mutations of the conserved phosphoesterase motifs of MREI1 were created in S. 
cerevisia (Bressan et al., 1998). Ablation of one of the critical residues of motif III did 
not affect spontaneous mitotic HR, IR-directed DSB repair or the MRE11-Rad50 
interaction in yeast cells (Bressan et al., 1998) suggesting that motif III is not crucial 
for these functions. However, the study in yeast mutated only one residue whereas 
314del345 has a complete deletion of motif III and therefore expression of this mutant 
may have a more detrimental effect on the cell. 
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A potential Chk2 phosphorylation site on MREI 1 was identified between amino acids 
152-163 (Seo et al., 2003). This region is deleted in 314de1345 but the significance of 
this is unknown as the phosphorylation of MRE11 by Chk2 has not been proven in 
vivo. 
One A-TLD family carries an MRE1 1 mutation in close proximity to motif III leading 
to N117S (Stewart et al., 1999). This mutation weakens or alters NBS1 binding such 
that MRE11 does not undergo nuclear localisation (Stewart et al., 1999). MRE11 
amino acids 1-319 are required for interaction with NBS1 (Desai-Mehta et al., 2001) 
and since 314del345 misses amino acids 106-219 it is likely that NBS1 binding is 
disrupted in cells expressing this mutant. Indeed, further biochemical analysis is 
needed to assess whether 314de1345 affects MRE11 complex formation. It will also be 
important to determine whether expression of 314de1345 impairs nuclear foci 
formation or the hypothesised DNA damage sensor function of the MRE11 complex. 
It has been proposed that association of the MRE11 complex with chromatin during S- 
phase may allow the complex to function as a sensor of DNA damage that detects 
chromatin changes induced by a DSB (Petrini and Stracker, 2003). Chromatin 
association of the MRE11 complex requires sequences in the N-terminus of NBS1 
(Zhao et al., 2002) and therefore MRE11 must maintain the interaction with NBS1 to 
become chromatin bound. If the mutant 314del345 disrupts NBS 1 binding, as 
suggested above, MRE11 may not become targeted to chromatin. However, 
biochemical evidence to support the proposed sensor function of the MRE11 complex 
has yet to be established and the requirement for MI E11 and its nuclease activity in 
this suggested role needs to be examined. 
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Future studies should also include investigation into whether this variant affects cell- 
cycle checkpoint functions as well as repair. The loss of S-phase checkpoint activation 
in HCT116 was presumed not to stem from abrogation of the ATM-NBS1 pathway 
but to be a consequence of MMR-deficiency in these cells (Brown et al., 2003). 
However, if MRE11 314de1345 is expressed in HCT116, as is suggested by this 
research, then the ATM/NBS1 pathway is defective and this could potentially be the 
source of the S-phase checkpoint defects seen in HCT116. 
Nevertheless, if the 314de1345 mutant affected all roles of MRE11, a more severe or 
lethal phenotype might be expected. The variant MRE11 may actually decrease the 
efficiency of MRE11 functioning by interfering with the endogenous wild type 
protein. 
5.5 The MRE11 Complex in MSI+ Cancer 
This investigation also revealed a frameshift mutation of an A9 run of Rad5O in a 
subset of MSI+ colorectal tumours. This mutation has previously been detected in 
other MSI+ colorectal tumours and in MMR-deficient gastric cancers (Kim et al., 
2001, Duval and Hamelin, 2002). This frameshift mutation is predicted to truncate the 
Rad50 protein and, although the phenotypic consequences of such a truncation are not 
yet known, this is an interesting result supporting the hypothesis that all components 
of the MREI I complex are downstream mutational targets in MSI+ cells. 
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5.6 Conclusions 
Derivation of hypomorphic alleles, as used in this study, may help address functional 
issues such as whether the MRE11 complex is the primary sensor of DNA damage. 
It will be interesting in the future to examine the biochemical effects of this mutation 
to give additional insight into the role of MRE11. Further elucidation of MREII 
complex functions promotes understanding of the DNA damage response and the 
coordination of the checkpoint responses and DNA repair. As the functions of the 
MRE11 complex become more apparent it might be possible to predict the response of 
tumours that carry mutations in MRE11, NBS1 or Rad50. The DNA damage response 
pathway that includes the MRE11 complex appears to be disrupted in >85% of MSI' 
colorectal tumours. Since disruption of this pathway increases sensitivity to certain 
therapeutic agents these finding have important implications for novel treatment 
strategies directed specifically against this subset of tumours. 
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Appendix I 
Maps of Cloning Vectors 
Jvnrr 
xcnKM TI, ýcr, ýý7r k-c 
I"I, 
1" 
®Q 
pcDNA3. I/ 
V5-His-TOPO 
5523 bp 
Neu I. 
ii 
GAT ATCTG113000TahCTAriCGCTTAAGIiCfTGTTAaCCGGTCGTACG- 
ý,,., MCS Nhe I AB II 
40*1 
91: loll, fcoRV fco47III AgeI 
plRESpuro3 
5.1 kb UP IRIS TCT1; CGGATTGGAATTC. GGATCCG11GG, rY; I; ATAGATAACT13 ATCCA-3TGTGCTG-3 
on asp¬I -Tsw -IT- amH I otI BstX I 
EcoR I 
poh A 
Puro' 
Xba I 
way... $phl 
hN 
SwBI 
Sam" 
, 
Oý FmRI 
pDrive Cloning Vector 
3.85 kb uu Acts 
m mil 
MNA 
AW v5pI 
Xhal 
EMnl 
t`a r bolas 
sa+ 
Nall 
SP6 prnnodr 
211 
Appendix II 
PCR Primers and PCR Conditions 
BAT25 F: TCGCCTCCAAGAATGTAAGT -90 
R: TCTGCATTTTAACTATGGCTC 
BAT26 F: TGACTACTTTTGACTTCAGCC 80-100 
R: AACCATTCAACATT ITFAACCC 
MFD15 F: ACTCACTCTAGTGATAAATCG -150 
R: AGCAGATAAGACAGTATTACTAGTT 
APC F: ACTCACTCTAGTGATAAATCG 96-122 
R: AGCAGATAAGACAGTATTACTAGTT 
D2S123 F: AAACAGGATGCCTGCCTTTA 197-227 
R: GGACTTTCCACCTATGGGAC 
BAT40 F: ATTAACTTCCTACACCACAAC 80-100 
R: GTAGAGCAAGACCACCTTG 
DIOS197 F: ACCACTGCACTTCAGGTGAC 161-173 
R: GTGATACTGTCCTCAGGTCTCC 
D18S69 F: CTGTTTCTCTGACTCTGACC 110 
R: GACTTTCTAAGTTCTTGCCAG 
D18S58 F: GCT000GGCTGGTTTT 144-160 
R: GCAGGAAATCGCAGGAACTT 
MYCL1 F: TGGCGAGACTCCATCAAAG 140-209 
R: CTTTITAAGCTGC AACAATTC 
XRCC2 Exl F: GTTGGTGGCGGGAAAGTT 118 
R: TCTCCCTCACTCCCAACC 
XRCC2 Ex2 F: TTACAGACTTTCGGAAAATG 304 
R: TGTGTCTCATTTTCCAATTG 
XRCC2 Ex3-1 F: GAGCTACTGCATTTTGACTG 228 
R: CTTTGGGATAGTCTGTGCTC 
XRCC2 Ex3-2 F: TGATATGCTCCGGCTAGTT 242 
R: AGTTCACACTTTCTCCTCCA 
XRCC2 Ex3-3 F: GGATAGCCTGTCAGCTTTT1T 251 
R: G CCATGCCTTACAGAGATAA 
XRCC2 Ex3-4 F: TGCCTCTCGACGACTGTGTG 247 
R: CGTAGTACCCTGCAAAAGAC 
XRCC2 Tg F: TGATATGCTCCGGCTAGTT 179 
R: TCAAAAGGCAGAGAGATGG 
XRCC2 A71T7 F: GATTCTCAAAGCAGCAACCAA 144 
R: CGTAGTACCCTGCAAAAGAC 
XRCC3 Ex3 F: TGGGAAGTTATTCATCCTGGT 200 
R: GGTAGGCAAAGGAAGGAAGG 
XRCC3 Ex4 F: GCACCTTTTGTCACTGTGTTG 270 
R: GGGACCATGATGCTGGAG 
XRCC3 Ex5 F: TGACACTAT000TGCCCTIT 267 
R: GCCCAGACCCCACGGAAG 
XRCC3 Ex6 F: GTTAGAAATGGCGGGAGACA 268 
R: GGCTTCT000ACACTCAC 
XRCC3 Ex7 F: GACAGTCCAAACGGGGTCT 312 
R: AGCAACCCTGCCTTGGTG 
XRCC3 Ex8 F: GCTGACCTGGACTGTGCTCT 193 
R: CAGAACCTGAGAAACAGGAA 
54 
51 
52 
54 
59 
58 
62 
57 
52 
50 
53 
50 
54 
52 
54 
57 
53 
57 
56 
54 
54 
54 
54 
58 
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XRCC3 Ex9 F: TGCCTGCTTCCTGTTTCTC 275 52 
R: TCTCAGGCAGGGCTGTTGT 
Mus8l Exl F: TCGAATCCCGACTCCAGAAC 247 54 
R: CCAGCAGCTTTT000ATC 
Mus81 Ex2 F: AAGCTGCTGGCCAGGTCAG 252 57 
R: AGGAGAGTACGGAGGCTCC 
Mus8l Ex3 F: GGTTGCAT000AGATCCT 206 53 
R: CATACTCCCGCACTCCCA 
Mus81 Ex4 F: GGACTTATTCAAAGATGACTG 263 55 
R: CAGGTGGCTGGGATAATCTT 
Mus8l Ex5 F: AAGATTATCCCAGCCACCTG 277 54 
R: GTACCACCACAAGTCCATG 
Mus81 Ex6 F: CATGGACTTGTGGTGGTAC 209 54 
R: TGGGTGACTCTAAGGCCCT 
Mus81 Ex7 F: GCCTGCCAGGAATGAGTGA 259 54 
R: GCTTTGGCCTCATTTCCCA 
Mus8l Ex8 F: CGGGTGGCATGGGTGTGG 243 58 
R: CCTAGATCAGAGCAGGGCA 
Mus81 Ex9 F: AGATGATCAGAGGAGGCTGG 259 56 
R: CGTTAGCTTGCGATCCCCT 
Mus81 ExIO F: AGGTGAAGGGCCGTGGAC 254 56 
R: 000TGGATTGCTCTGGGC 
Mus8l Exil F: TTGAGTGTGACATCATGGAT 260 52 
R: TAGACCATGAACCATGGAC 
Mus81 Ex12 F: GGTCCATGGTTCATGGTCTA 220 54 
R: GCCCAGGCAAGGTGAATTC 
Mus81 Ex13 F: TTCGAGCTCCAGCCTGGC 260 55 
R: TTCTCGCACCGACTGGGC 
Mus81 Ex14 F: CTGTCTCTGCCTAGCTTCT 257 53 
R: CCTCCACGAAGCATGGATT 
Mus81 Ex15 F: CCACTCTTCCAT000ATGCT 212 57 
R: CCTCCAGGTTCCGTCTCTTG 
Mus81 Ex16 F: GGAACCTGGAGGGAGTGG 203 55 
R: GGCTGGCTAGCCTGGGTT 
MREII Aaflts%) F: CCATTCCAGATGAAAGGCTCT 153 57 
R: CCTCAGCACTTGGCTCAAAC 
MRE11An235V F: CAGTGTTCTTCGCTITAGCC 244 57 
Tantizo9»A7(intron) R: AAGAGAATTATTCCCACTGTCA 
MRE11 A6(nt14) F: GGAGAAAGATGCCATTGAGG 103 56 
R: CTCATCGATTTTGTCTTCGAG 
MREII A,, coJ, ng) F: GGAATAGGCAACATGTTTGTGA 205 
58 
R: TCCCCTAGACCTCTGGACTG 
NBSI Aanuu) F: TCAAACAGATGAAATCCCTGTA 120 54 
R: GTAATACCATCCCCCGACTT 
1BSI A7(nt390) F: 000AAACTATCAGCTTTCACC 236 58 
R: CTGCAGCAGCAGAAGCATAC 
N'BS1 A7(nbs) F: CTGCCAGTAAATCTCATGCTG 118 57 
R: AACTCTGGTTTTGTGTCCTTG 
%BSI Amn, 19S3) F: CCTATCCATCTTAA000CATTT 222 57 
R: TTTC AAACACTG ACCTCTTGTG 
Rad50 Ta,, 1 ) F: CAG7TCTCTTGGGG' TTCCA 192 55 
R: TCCAAATTGCAAACACAGTTC 
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Rad50 A6(nil -1-) F: AGGCACAGTGATGAATTAACCT 125 57 
R: TACTTCAATTTGGCAAGTCTGT 
Rad-'; O Ag(A, Z1s7) F: CTGCGACTTGCTCCAGATAA 210 58 
R: ACAGGGCATACCAGCTCAGA 
Rad50 A8(ii12794) F: AGAGCAGGTAAG000TTTGG 177 57 
R: AGTGTCCGACGTGGTGCTAT 
11REII Fragl F: CCCAGAGGAGCTTGACTGACC 768 57 
R: TGTTCATGGCCCCAGATAAC 
NI RE 11 Fragt F: TTCCAGAACAAT1 TTGGATGA 797 53 
R: TTCGAGGGCATCAATATGAC 
NI RE I1 Frag3 F: GGAGAAAGATGCCATTGAGG 780 55 
R: ATTTTCCTGTATCTTGCATGT 
\BSI Fragl F: GTCTAGCAG000CGGTTAC 768 56 
R: GTTITCTTTCCTGCCGTCCT 
NBS1 Fragt F: TA000ACCTCTTGATGAACC 763 58 
R: CTGCTGAGAAGCCCTATCT 
NBSI Frag3 F: 000AAACI'ATCAGCTTTCACC 624 58 
R: GCTGACCATAGTGAGTCTTCC 
\BSI Frag4 F: CAAGAAAATGAAATTGGGAAGA 482 55 
R: TGTTGGCCTGAAGTAGATGC 
Rad50 Fragl F: CCTTGCTTCGGCCTCAGTTA 740 55 
R: CGAATCTCACAAGC TMCC 
Rad50 Fragt F: CGTCAGACACAAGGTCAGAAA 747 57 
R: CTCAATTCTTC TTCCCAGTCCA 
Rad50 Frag3 F: GAATGACTTTGCAGAAAAAGAG 760 57 
R: CTGGGAGTAAACTGCTGTGG 
Rad50 Frag4 F: GCCAGGATTTTGAAAGTGATT 763 54 
R: CTCCTCCAGTTGCTGACGAC 
Rad50 Frag5 F: CCAGCAGGAACAGATTCAAC 739 55 
R: CTCAGCATCCCGAAATTGTG 
Rad50 Frag6 F: GCGACAGAAAGG"I'TATGAAGA 739 55 
R: GAGGACCTACATTTCTATGGC 
MREII T1, F: AATATTTTGGAGGAGAATCT 122 51 
R: AATTGAAATGTTGAGGTT 
MM RE I 1314de188 F: CCCAGAGGAGCTTGACTGACC 345 54 
R: ('TACTTACTAAAACC AA AGTT 
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Appendix III 
SSCP Conditions 
\R('('2 Exl 12 2500 
XR('('2 Ex2 12 4000 
\R('('2 Ex3-1 10 3500 
\R('('2 Ex3-2 10 3500 
\R('('2 Ex3-3 10 4000 
\R('('2 Ex3-4 10 3500 
XRCC3 Ex3 12 3000 
\R('('3 Ex4 12 4500 
XR('('3 Ex5 12 3500 
\R('('3 Ex6 12 5000 
XR('('3 Ex7 12 6000 
\R('('3 Ex8 10 3500 
XR('('3 Ex9 10 4500 
Mus81 Exl 12 4500 
NIUS81 Ex2 12 4000 
NIUS81 Ex3 10 3500 
M1us81 Ex4 10 4000 
NIUS81 Ex5 12 3500 
NIUS81 Ex6 10 3000 
Mus81 Ex7 12 4000 
t1us81 Ex8 12 4000 
Mus8l Ex() 12 4500 
Mus81 Ex10 12 4500 
NIUS81 Exll 12 4000 
Mus81 Ex12 10 3500 
\1u%81 Ex13 10 3500 
NIUS81 Ex14 10 3500 
NIUS81 Ex15 10 3000 
Mus81 Ex16 12 3000 
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Appendix IV 
Recombination Reporter Constructs 
SCneo Recombination Reporter 
no probe 
h' MI II  
hyg 'iai 
Mal r Mrd II 
d. O Ch 
Induction' of a DSB 
Intrachromatid 
Sister chromatid pairing 
pairing 
x 
Short tract gene 1 
Gene conversion COfly lion Long tract gene conversion 
or sister chromatid exchange 
R neo 
p('\1V'3xnls-l-Seel 
I Cý1ý' ; H, ý 1-Seel I poly-A SV40ori 
HA = epitope tag poly-A = human growth hormone polyadenylation site 
NLS = nuclear localisation signal SV40ori = SV40 origin for replication of plasmid COSI cells 
l-Sccl = endonuclease CMV = human cytomegalovirus promoter/enhancer 
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Appendix V 
MRE11 Protein Alignments 
The amino acids lost in 314de1345 MRE 11 are shown in blue, highly conserved motifs of the nuclease 
domain of the protein are shown in red. 
Human 
S. ccrc%isia 
Mouse 
Rat 
Chicken 
Xcnopus 
Silkworm 
Ncurospora 
Fungus 
consensus 
I ----------------- \\, 
---------------- ý15 
1 --------------- %III-A I)I - 
I MPRSGKVYYAHELL\ 
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Appendix VI 
Cancer Sample Details 
Sample Sex Age T N Dukes' MS1 
1 f 76 3 0 b MSS 
2 f 83 4 1 c MSS 
3 m 72 3 1 c MSS 
4 f 87 3 0 b MSS 
5 m 61 3 1 c MSS 
6 m 87 3 0 b MSS 
7 f 91 2 0 a MSI-L 
8 m 54 2 0 a MSS 
9 m 73 4 2 c MSS 
10 m 62 4 2 c MSS 
11 f 68 3 2 c MSS 
12 m 65 3 2 c MSS 
13 m 60 2 0 a MSS 
14 m 77 3 0 b MSS 
15 f 40 3 2 c MSS 
16 f 65 3 1 c MSS 
17 f 46 3 0 b MSS 
18 f 93 3 0 b MSS 
19 m 78 3 0 b MSS 
20 f 84 3 1 c MSS 
21 m 63 3 0 b MSS 
22 m 71 3 0 b MSS 
23 f 61 3 2 c MSS 
24 f 31 3 0 b MSS 
25 m 57 4 2 c MSS 
26 m 94 3 2 c MSS 
27 m 86 3 1 c MSS 
28 f 93 4 1 c MSS 
29 m 50 3 1 c MSS 
30 m 70 3 0 b MSS 
31 m 51 4 1 c MSS 
32 m 41 3 1 c MSS 
33 m 57 3 1 c MSS 
34 m 38 3 0 b MSS 
35 m 56 2 0 b MSS 
36 f 79 3 1 c MSS 
37 f 54 4 1 c MSS 
38 m 79 4 0 b MSS 
39 f 78 4 0 b MSS 
40 m 52 3 0 b MSI-L 
41 f 88 3 0 b MSS 
42 m 90 3 0 b MSI-H 
43 f 76 3 0 b MSI-H 
44 f 79 3 1 c MSS 
45 f 66 4 1 c MSS 
46 f 58 3 2 c MSS 
47 m 71 4 2 c MSS 
48 f 51 3 0 b MSS 
49 m 53 4 0 b MSS 
50 f 76 4 2 c MSS 
51 m 90 3 1 c MSS 
52 f 40 2 1 c MSS 
53 m 79 3 2 c MSS 
54 m 62 3 2 c MSS 
55 m 73 3 0 b MSS 
220 
S le Sex Age T N 
Dukes' 
amp 
56 66 3 2 c 
MSS 
57 m 84 3 0 
b MSS 
58 f 68 3 0 b 
MSI-H 
59 m 72 3 2 c 
MSI-L 
60 f 62 3 0 b 
MSS 
61 m 79 3 2 c 
MSS 
62 m 67 3 1 c 
MSS 
63 f 79 3 2 c 
MSS 
64 f 86 4 1 c 
MSS 
65 m 81 3 0 b 
MSS 
66 f 72 2 0 b 
MSS 
67 m 60 3 2 c 
MSS 
68 f 69 3 0 b MSI-H 
69 m 68 3 0 b 
MSS 
70 m 68 3 0 b 
MSS 
71 f 78 4 0 b MSS 
72 m 78 3 2 c 
MSS 
73 m 72 2 0 b 
MSS 
74 m 86 4 2 c 
MSS 
75 m 74 2 0 b 
MSS 
76 f 72 4 0 b MSS 
77 f 84 3 1 c 
MSS 
78 m 69 3 2 c 
MSS 
79 m 67 3 1 c 
MSS 
80 m 61 3 1 c 
MSS 
81 f 59 4 1 c MSS 
82 m 66 2 0 a 
MSS 
83 m 73 4 0 b 
MSS 
94 f 66 3 0 b 
MSS 
85 m 84 3 0 b 
MSS 
86 m 63 3 2 c 
MSS 
87 m 54 3 2 c 
MSS 
88 f 91 2 2 c 
MSS 
89 m 63 3 0 
b MSS 
90 m 29 2 0 
b MSS 
91 f 73 4 2 c 
MSS 
92 m 73 2 1 c 
MSS 
MSS 
93 f 76 2 1 
0 
c 
b MSS 94 m 64 2 0 b MSS 95 f 79 2 
0 b MSS 96 f 79 3 
0 b MSS 97 f 69 3 
1 c MSS 98 nm 67 3 
1 c MSS 99 m 60 3 
0 b MSS 100 f 85 3 
0 b MSS 101 f 65 3 
0 b MSS 102 m 68 3 
2 c MSS 103 m 58 3 
1 c MSS 104 f 58 2 
0 a MSS 105 f 89 2 2 c MSS 106 m 85 2 2 c MSS 107 unknown 82 4 0 b MSI-H 108 unknown 56 3 MSS 
109 unknown 73 3 1 0 
c 
b MSI-H 
110 m 
f 
80 
53 
2 
3 0 b MSI-H 111 
112 unknown 75 2 0 a 
MSS 
113 unknown 71 4 1 c MSI-L 
114 unknown 62 3 0 b 
MSI-H 
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115 m 70 3 1 c MSS 
116 m 42 3 0 b MSI-L 
117 unknown 82 3 0 b MSI-H 
118 unknown 66 3 1 c MSI-H 
119 unknown 50 3 2 c MSS 
120 unknown 90 3 0 b MSS 
121 unknown 66 3 2 c MSS 
122 unknown 39 3 1 c MSS 
123 unknown 59 2 0 b MSS 
124 unknown 68 3 0 b MSI-H 
125 unknown 57 3 1 c MSI-H 
126 unknown 66 3 1 c MSI-L 
127 unknown 78 3 1 c MSS 
128 unknown 81 4 2 c MSI-H 
129 unknown 74 3 0 b MSS 
131 unknown 61 3 2 c MSS 
132 unknown 82 2 0 b MSS 
134 unknown 68 3 0 b MSI-H 
136 unknown 69 4 2 c MSS 
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Appcndix VII 
Suppliers AJdresscs 
Allgene, 
Blenheim Road, Epsom, Surrey, KT19 9AP 
American Type Culture Collection (ATCC) 
P. O. Box 1549, Manassas, VA 20108 USA 
Amersham Pharmacia Biotech UK Limited. 
Amcrsham Place, Little Chalfont, Buckinghamshire, HP7 9NA 
Ananchcm, Ltd, 
Anachem House, Charles Street, Luton, Bedfordshire, LU2 OEB 
Becton Dickinson, 
Bet%vccn Twons Road, Cowley, Oxford, OX4 3LY 
Bethyl Laboratories Inc, 
25043 Vest FM 1097, Montgomery, TX 77356 
Bennet Scientific Ltd., 
I Tenterk Close, Bleadon, Weston-supe-Mare, Somerset, BS24 OPJ 
Bibby Stcrilin Ltd, 
Tilling Drive, Staffordshire, ST15 OSA 
ßioline Ltd. 
16 The Edge Business Centre, Humber Road, London NW2 6EW 
Bio-Rad Laboratories Ltd. 
Bio-Rad house, Maylands Avenue, Hemel Hemstead, Herts, HP2 7TP 
Britannia Pharmaceuticals, 
41-51 Brighton Road, Redhil1, Surrey, RH 1 6YS 
Calbiochcm, 
10394 Pacific Center Court, San Diego, California 92121 USA 
Cambrcx Bioscience Inc. (formerly BioWhittaker), 
8830 Biggs Ford Road, Walkersville, MD 21793-0127, USA 
Cancer Research UK, 
P. O. Box 123, Lincoln's Inn Fields, London WC2A 3PX 
Professor Carl Smythe, 
Centre for Developmental Genetics, University of Sheffield, Firth Court, Sheffield. 
Cell Signaling Technology, Inc. 
166B Cummings Center, Beverly, MA 01915 
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CIS Biointernational, 
RN306-91400 Saday, BP32, F-91132, Gif/Yvette, Cedex, France. 
Continental Lab Products (CLP), 
5648 Copley Drive, San Diego, CA 92111, USA 
Corning Inc., 
HP-AB-03, Corning, NY 14831, USA 
Denver Instrument Company, 
1855 Blake Street, Suite 201, Denver, CO 80202, USA 
Epicentre, 
726 Post Road, Madison, WI 53713, USA 
Eppendorf AG, 
Barkhausenweg 1,22331 Hamberg, Germany. 
Eurogentec, 
Parc scientifique du Sart Tilman, 4102 Seraing, Belgium 
Gene Codes Corporation, 
640 Avis Drive, Ann Arbor, MI 48108, USA 
Gilson Medical Electronics, 
BP45, F95400, Villiers-le-Bel, France. 
Grant Instruments (Cambridge) Ltd, 
Shepreth, Cambridge, SG8 6GB 
Greiner Labs, 
Maybach Strasse 2, Postfach 1162, D-7M3, Frickenhausen, Germany. 
GRI Ltd, 
Gene House, Queensborough Lane, Rayne, Braintree, Essex, CM77 6TZ 
Harvard Apparatus Inc., 
Fircroft Way, Edenbridge, Kent, TN8 6HE 
Hirschmann Laboratory, 
D-72606, Nuertingen, Germany. 
ILFORD Imaging UK Limited 
Town Lane, Mobberley, Knutsford, Cheshire WA 16 7JL 
International Equipment Company, 
300 Second Avenue, Needham Heights, MA 02494, USA 
Invitrogen Life Technologies, 
3 Fountain Drive, Inchinnan Business Park, Paisley, UK. 
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Kodak Scientific Imaging Systems, 
LabTech International, 1 Acorn House, The Broyle, Rigmer, East Sussex, BN8 5NW 
MediCell International Ltd., 
239 Liverpool Road, London, NI 1LX 
Mettler-Toledo Ltd, 
64 Boston Road, Beaumont Leys, Leicester, LE4 lAW 
MWG-Biotech AG, 
Anzinger Strasse 7, D-85560, Edersberg, Germany. 
Nalgene, 
Unit I a, Thorn Business Park, Hereford, HR2 6JT 
New England Biolabs, Inc. (NEB), 
32 Tozer Road, Beverly, MA 01915-5599 
Nikon, 
Nikon House, 380 Richmond Rd, Kingston-Upon Thames, Surrey, KT2 5PR 
Oncogene Research Products, 
10394 Pacific Center Court, San Diego, California 92121 USA 
Perbio, 
Knutpunkten 34, SE-252 78 Helsingborg, Sweden 
Philip Harris Scientific, 
Lynn Lane, Shenstone, Lichfield, Stafford. 
Promega UK, 
Delta House, Chilworth Science Park, Southampton SO16 7NS 
QIAGEN Ltd. 
Boundary Court, Gatwick Road, Crawley, West Sussex, RH 10 9AX 
Roche, 
F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland 
Sanyo Gallenkamp, 
Monarch Way, Belton Park, Loughborough, LE11 5XG 
Sanyo Scientific, 
1062 Thorndale Avenue, Bensenville, IL 60106, USA 
Scaleman, 
10 Peabody Street, Bradford, MA 01835, USA 
Scientific Industries, 
70 Orville Drive, Bohemia, NY 11716, USA 
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Scotsman Ice System Ltd, 
20010 Bettonlino di Pogliano, Milan, Italy. 
Sigma-Aldrich Company Ltd., 
Fancy Road, Poole, Dorset, BH12 4QH 
SLS Ltd., 
Wilford Industrial Estate, Nottingham, NG 11 7EP 
Starstedt Ltd., 
68 Boston Road, Beaumont Leys, Leicester, LE4 1AW 
Stata Corporation, 
702 University Drive East, College Station, TX 77840, USA 
Stratagene, 
11011 N. Torrey Pines Road, La Jolla, CA 92037 
Stuart Scientific, 
21 Holmethorpe Avenue, Redhill, Surrey, RH1 2NB 
Thermo Forma Scientific, 
401 Millcreek Road, PO Box 649, Marietta, OH 45750, USA 
UVP Inc, 
Upland, CA, USA 
Volac International Ltd., 
Orwell, Royston, Herts, SG8 5QZ 
VWR International Ltd., 
Merck House, Poole, Dorset, BH15 1TD 
Whatmann Biometra, 
Rudolf-Wissel-Strasse 30,37079, Gottingen 
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